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SORCS2 and SORLA are members of the Vps10p-domain receptor family, which 
comprises five multifunctional neuronal receptors. All family members are involved in 
intracellular sorting and trafficking of various neurotrophic factors and their precursor 
forms, as well transmembrane receptors and synaptic proteins. This gene family has 
been implicated in a broad range of cellular processes, including neuronal health, 
differentiation and synaptic plasticity. Importantly for this thesis, SORLA and SORCS2 
have been shown to play a role (SORLA in vivo and in vitro; SORCS2 in vitro) in the 
processing of the amyloid precursor protein (APP) and thus amyloid β (Aβ) 
production. Genetic and functional studies provide further evidence for the 
involvement of both receptors, alongside other family members, in cognition and 
various brain disorders.  
DNA damage and compromised DNA repair have been implicated in brain aging, 
psychiatric and neurodegenerative disorders. Recently, a specific type of DNA 
damage- DNA double- stranded break (DSB) formation, has been implicated in both 
Alzheimer’s disease (AD) and physiological brain activity, i.e. learning and memory 
processes. In mice, exploration of a novel environment led to a transient increase in 
DSB formation in the dentate gyrus (an area of the brain important for learning and 
memory). The breaks were repaired within 24 hours. Subsequently, it was shown that 
these breaks are generated by Topoisomerase II β (TopoIIβ) and are required for the 
expression of early-response genes. In mice, pathological Aβ levels were associated 
with increased neuronal DSB formation and repair deficits. The effect of Aβ on DSB 
formation and repair was attributed to aberrant network activity and dysregulated 
NMDA receptor signalling. Given the link between sortilins and neuropsychiatric 
illness, as well as their role in APP processing and, recently, NMDA receptor 
trafficking (SorCS2), my project aimed to address the relationship between the two 
genes and DSB formation.  
I examined levels of DNA DSBs in WT and Sorcs2-/- mice before and after exploration 
of a novel environment. Following exploratory activity, WT mice showed increased 
numbers of DSBs, which were repaired within 24 hours. Meanwhile, I detected 
elevated levels of DSBs at baseline in the dentate gyrus of Sorcs2-/- mice. Moreover, 
compared to the corresponding WT mice, the Sorcs2-/- mice exhibited an altered 
response to the novel environment, as they failed to acquire new breaks. To explore 
ii 
 
possible mechanisms that could explain this phenotype, I knocked out SORCS2 in 
the human dopaminergic neuronal cell line LUHMES using CRISPR/Cas9 genome 
editing. I did not observe any difference in the extent of DSB formation in untreated 
SORCS2 knockout (KO) clones, compared to WT controls grown simultaneously. 
However, SORCS2 KO neurons showed elevated levels of DSBs following treatment 
with etoposide- a compound that prevents the re-ligation of TopoIIβ-induced DSBs. 
In addition, knocking out SORCS2 was also associated with reduced neuronal 
viability.  
I next explored possible mechanisms underlying the observed increase in etoposide 
induced DSBs in the SORCS2 KO clones. In line with previous work, treatment with 
NMDA led to a significant increase in the number of DSBs in WT LUHMES neurons. 
I did not, however, observe any difference in the extent of DSB formation in NMDA-
treated SORCS2 KO clones compared to WT controls. This experiment was 
performed on a small number of WT and KO clones and the results may thus reflect 
lack of power to detect a difference. However, if this lack of difference was confirmed 
in subsequent experiments, this would suggest that the increase in etoposide-induced 
DSBs in the SORCS2 KO clones is unlikely to be due to dysregulated NMDA 
signalling. Meanwhile, I was unable to measure Aβ42 levels reliably in LUHMES. Thus, 
the possible role of Aβ in the increased DSB formation observed in etoposide-treated 
SORCS2 KO clones cannot be excluded.  
Surprisingly, mouse primary hippocampal neurons derived from Sorcs2-/- pups did not 
show any difference in DSB levels with or without treatment with etoposide. However, 
this experiment was performed on a limited number of hippocampal cultures and thus 
the results obtained may not reflect a true lack of difference. The possible discrepancy 
between the results in the etoposide-treated primary hippocampal and LUHMES 
dopaminergic neurons, but more importantly the role of SorCS2 in dopaminergic 
signalling, led me to investigate whether knocking out SORCS2 alters extracellular 
dopamine levels, as a potential mechanism underlying the increased DSB formation. 
ELISA analysis showed no difference in dopamine release between SORCS2 KO and 
WT LUHMES neurons. 
Due to technical difficulties and time constraints, I was unable to assess the levels of 
DSB formation in Sorl1-/- mice or primary hippocampal neurons derived from them. 
Obtaining SORL1 KO LUHMES cell lines using CRISPR/Cas9 genome editing also 
proved to be challenging. However, I generated mutant cell lines carrying the rare 
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SORL1 missense mutation, G508S, which is associated with early onset AD. Despite 
being located at a splice site, introducing the G508S mutation in LUHMES did not 
affect splicing. However, it led to reduced SORL1 mRNA, but not protein, levels.  
In conclusion, the work completed in this project constitutes the first evidence for a 
potential role of the sortilins in DSB formation. Future work investigating this link 
further might provide us with valuable knowledge on the cellular mechanisms 




Breaks in the DNA of nerve cells, or neurons, occur in the healthy brain and are 
normally repaired. However, if they are not repaired, these breaks can impair neuronal 
function and lead to premature neuronal death. Neuronal death is often seen in brain 
disorders, such as dementia, but its cause is unknown. The sortilins are an important 
family of five molecules (encoded by five genes) that help neurons function correctly 
and remain healthy. Mutations, or mistakes, in the sortilin genes have been 
discovered in a number of brain conditions. The aim of my project was to examine the 
link between two of the sortilin family members, SORLA and SORCS2, and the 
formation of DNA breaks in neurons. My experiments showed more DNA breaks in 
the brains of mice in which the SORCS2 molecule was missing. I also saw more 
breaks in human neurons that I grew in a dish after I had deleted SORCS2. Apart 
from having more breaks in their DNA, these neurons were also less healthy 
compared to neurons that had SORCS2. I was less successful in studying the link 
between SORLA and DNA breaks. However, I made neurons that have mutations in 
SORLA and can be used to study this in the future. Understanding how neuronal DNA 
breaks can be avoided may help us to treat brain disorders better.
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1.1. The Vps10p-domain receptor family 
The Vps10p-domain receptor family, also known as the sortilins, constitutes a family 
of five multifunctional, type I transmembrane receptors- Sortilin in humans or sortilin 
in mice (encoded by the gene SORT1 or Sort1, respectively), SORLA/SorLA 
(encoded by SORL1/Sorl1) and SORCS1-3/SorCS1-3 (encoded by SORCS1-
3/Sorcs1-3). The receptor family is expressed predominantly in the nervous system 
(both developing and adult), in a dynamic, region- and cell-type specific manner. 
Collectively, these proteins exert diverse cellular functions, including anterograde and 
retrograde intracellular protein sorting and trafficking, as well as signal transduction 
in response to various pro- and mature neurotrophic factors. As a result, genetic 
variation within this receptor family has been associated with a broad range of 
diseases- from cardiovascular to psychiatric and neurodegenerative disorders. The 
role of SORLA and SORCS2 in the aetiology of neurodegenerative disorders 
constitutes the main focus of this thesis.  
 
1.1.1. Structural features of the Vps10p-domain receptor family 
As suggested by its name, the hallmark of the sortilin receptor family is the shared 
Vps10p-domain. Named after the yeast vacuolar protein sorting 10 protein (Vps10p), 
this is a luminal domain that is unique to the family. In yeast, Vps10p is a type I 
receptor with a large extracellular N-terminal domain and a short cytosolic tail, 
involved in the sorting of proteins to vacuoles (the yeast equivalent of lysosomes)1.  
It is considered that in mammals, the sortilins have evolved as a result of increasing 
cellular complexity2 (Figure 1.1.). The Vps10p domain has been shown to harbour 
binding sites for a large number of ligands, including neurotrophic factors and their 
precursors, such as GDNF (glial cell line-derived neurotrophic factor) in the case of 
SorLA3, pro- and mature NGF (nerve growth factor) and pro- and mature BDNF (brain-
derived neurotrophic factor) in the case of SorCS24,5,6. The role of these interactions 
in terms of neuronal viability and function is further discussed in the following sections.  
Sortilin, which is also known as neurotensin receptor-3 (NT3), constitutes the 
prototype of the receptor family. The extracellular domain of sortilin consists of the 
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Vps10p domain, followed by a transmembrane α- helix and a short cytosolic tail2. In 
contrast, SORLA has a much more complex extracellular domain with modules not 
present in the rest of the family members and providing additional ligand-binding sites. 
For example, SORLA is the only member of the receptor family shown to bind to the 
amyloid precursor protein (APP), which it does via its complement-type repeat (CR) 
domain7. The exact role of the six-bladed β-propeller or the six fibronectin type-III 
repeats is less known, but based on ontology with other proteins they might play a 
role in ligand release in endocytic departments or other protein-protein interactions, 
respectively8. SORCS1-3 constitute a subfamily of homologues in which SORCS1 
and SORCS3 share nearly 70% amino acid sequence identity, while SORCS2 exerts 
much lower sequence homology (45- 47 %) with the highest conservation found in 
the Vps10p domain and the lowest in the cytoplasmic tail. In the SORCS subfamily, 
the Vps10p domain is followed by a polycystic kidney disease (PKD) and a leucine-
rich domain2. The exact role of the PKD domain is still unknown, but based on other 
proteins that share this domain, it might be involved in protein-protein interaction. 
While the luminal domain enables the sortilins to recognise and interact with a large 
number of ligands, their cytosolic tails and the recognition motifs for various adaptor 
proteins within them determine their role as sorting receptors (see below).  
 
Figure 1.1. Structural organisations of the Vps10p-domain receptor family from yeast 
(VPS10P) and humans (SORLA, sortilin, SORCS1, -2, -3). A characteristic feature of the 
family is the presence of a Vps10p domain, followed by a transmembrane domain and a 
cytosolic tail. Additional domains are present in different members of the family. They are 
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mostly involved in protein-protein interactions and include leucine-rich domains (SORCS1-3), 
complement-type repeats, epidermal growth factor-type repeats, fibronectin-type III domains 
and β-propeller (SORLA). The illustration is adapted from Andersen et al. (2016)9. 
 
1.1.2. Processing and intracellular transport of the Vps10p-
domain family 
Another feature common to all members of the family is the presence of short (44-100 
amino acid) propeptide at their N-terminal domain, which is proteolytically removed 
during the receptor’s passage through the trans-Golgi network (TGN)2 or at the cell 
surface8. In the case of SorLA and sortilin, but not SorCS1-3, this leads to receptor 
activation, allowing the binding of ligands to the Vps10p-domain2. The presence of an 
N-terminal propeptide has also been implicated in the processing and correct folding 
of newly synthesised receptors, acting as a chaperon in the endoplasmic reticulum 
(ER) for all family members except for SorCS22.  
SORLA is mainly found intracellularly, with the small proportion expressed at the cell 
surface being rapidly internalised. The trafficking of SORLA between different cellular 
compartments (e.g. endosomes, lysosomes and TGN), as well as its recycling from 
the cell surface is mediated by adaptor complexes, which bind specific motifs within 
the cytoplasmic tail10 (Figure 1.2.A). For example, SORLA internalisation at the cell 
surface occurs via clathrin-mediated endocytosis, which is dependent on the 
interaction of the receptor cytosolic tail with the clathrin adaptor protein (AP2). Once 
internalised, the receptor is sorted back to the TGN, where it shuttles continuously to 
and from endosomes. The retrograde movement of SORLA from endosomes to the 
TGN has been shown to be guided by the binding of PACS1 (phosphofurin acidic 
cluster sorting protein 1) and AP1 to the same acidic cluster in the receptor tail as 
AP2, as well as by the interaction of the multimeric adaptor complex retromer with 
another part of the cytosolic tail, known as the FANSHY motif11,12. Meanwhile, the 
receptor sorting from the TGN to endosomes depends on AP1, as well as GGA1 and 
GGA2- two monomeric clathrin adaptors that recognise a distinct sequence within the 
receptor’s tail11,13. The ability to shuttle its cargo proteins between the TGN and 
endosomes constitutes one of SORLA major roles in neurons as described further in 
the following sections. Additionally, it has been demonstrated that this receptor might 
also be involved in the sorting of proteins from endosomes to both the cell surface 
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and lysosomes via its interaction with SN27 and GGA3, respectively14,15. In contrast, 
SorCS2 is expressed mainly at the cell surface and has been shown to contain motifs 
that enable its endocytosis10.  
If not internalised, all five receptors can be subjected to processing by α-secretases 
(ADAM10 or -17) at the cell surface, leading to shedding of their ectodomains in the 
extracellular space. Subsequently, what remains of the receptor is further processed 
by γ-secretases, releasing the receptor cytoplasmic tail16,17 (Figure 1.2.B). The exact 
role of these processes and the resulting in free ectodomain and cytosolic tail remains 
largely unknown. However, in the case of SORLA it has been shown that once 
released, the receptor cytosolic tail is transported to the nucleus, where it can 
influence gene transcription17. 
 
Figure 1.2. SORLA intracellular trafficking pathways and processing. [A] SORLA is synthesised 
as an inactive pro-receptor (pro-SORLA). Following proteolytic cleavage of the pro-peptide 
and maturation of the receptor in the TGN, SORLA is transported through the constitutive 
secretory pathway to the cell surface. This relies on the interaction of SORLA with the adaptor 
protein SNX27. At the cell surface, the majority of SORLA molecules undergo clathrin-
mediated endocytosis facilitated by AP2. Once internalised, SORLA is constantly being 
recycled between the TGN and endosomal compartments. The retrograde SORLA movement 
from endosomes to the TGN requires SORLA interaction with the retromer complex, PACS1 
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and AP1. Meanwhile, the anterograde sorting between TGN and endosomes relies on SORLA 
interaction with GGA1 and GGA2. SORLA sorting from endosomes to lysosomal 
compartments is aided by the adaptor protein GGA3. [B] A figure showing the site of (1) 
proteolytic processing of pro-SORLA in the TGN, leading to the release of its pro-peptide and 
maturation of the receptor; (2) ectodomain shedding mediated by α-secretases at the cell 
surface and (3) release of the cytoplasmic tail following γ-secretase cleavage. [Created with 
BioRender] 
 
1.1.3. Expression profile of the Vps10p-domain receptor family in 
the nervous system 
In mice, all members of the sortilin receptor family are predominantly expressed in 
both the adult and developing nervous system in a dynamic and sometimes transient 
manner. However, members of the family have also been found in other tissues, 
including lung, liver, kidney and testis1. During embryonic development (E11.5), 
SorLA has been detected primarily in the cerebral cortex18, while SorCS2 has been 
observed in a number of regions, including the dopaminergic midbrain nuclei and the 
dorsal thalamus19. In adult mouse and rat brains, Sorl1 is expressed predominantly in 
the cortex, hippocampus and the cerebellum18. Meanwhile, in the mature mouse 
brain, Sorcs2 has been detected in the olfactory bulb, cerebellum, amygdala, 
hippocampus and parts of the thalamus and midbrain20. While the expression patterns 
of Sorl1and Sort1 mostly overlap, the Sorcs genes are expressed in a more restricted 
and complementary to each other manner20. For example, Sorcs1 and Sorcs3 are 
found primarily in the CA1 area of the hippocampus, and Sorcs2 has been detected 
mainly in the CA2and dentate gyrus21, but also in the CA1 region5. Moreover, it has 
been previously suggested that apart from being developmentally regulated, the 
expression of Sorcs1 and Sorcs3, but not Sorcs2, can also be induced by neuronal 
activity20. However, a more recent paper have reported increased SORCS2 levels in 
the CA2 region of the hippocampus of epilepsy patients, as well as in mice upon 
induction of status epilepticus using chemoconvulsant agents22. Furthermore, in vitro 
experiments have shown SORCS2 upregulation in an alcohol withdrawal paradigm23. 
Both epilepsy and alcohol withdrawal involve neuronal hyperexcitation.  
The sortilins have been detected in defined cell populations and subcellular 
compartments, suggesting that they might serve distinct neuronal functions. For 
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example, in the adult rat brain Sorl1 mRNA was abundant in pyramidal neurons of the 
frontal cortex and the CA1-3 region of the hippocampus, as well as in granule cells in 
the dentate gyrus and Purkinje cells in the cerebellum18. Meanwhile, Sorcs2 was  
found in neurons in layer 5 of the cerebral cortex, pyramidal neurons of CA2 and the 
dentate gyrus and a subgroup of Purkinje cells in the cerebellum in the mature mouse 
brain24. At the subcellular level, SORLA has been detected mainly in the cell body, 
but also in dendrites, axons and axonal terminals25,26. Only a small proportion of these 
receptors (<10%) is expressed at the plasma membrane, where they are quickly 
internalised (see section 1.1.2.). In contrast, SorCS2 has been mainly found at the 
neuronal cell surface27, and more specifically at post-synaptic densities co-localising 
with PSD-95 but not with the presynaptic marker synaptophysin5.  
 
1.1.4. Cellular roles of the Vps10p-domain receptor family in the 
central nervous system 
The sortilins have been associated with a great number of binding partners, ranging 
from transmembrane receptors to soluble proteins. These interacting proteins 
implicate the family in multiple physiological processes related to neuronal survival, 
differentiation and plasticity. 
1.1.4.1. The role of the Vps10p-domain receptor family in growth factor 
signalling  
Initially, the sortilins were identified as sorting receptors involved in neurotrophic and 
pro-neurotrophic growth factor signalling. The neurotrophins (NTs) comprise a family 
of growth factors, including NGF, BDNF, NT3 and NT4/5, which are produced by 
neurons and activated glia cells, and are required for neuronal cell survival, growth, 
differentiation and synaptic potentiation. The trophic function of NTs is mediated by 
direct interaction with two receptor classes- the tropomyosin-related kinase receptors 
TrkA, -B and -C and the p75 neurotrophin receptor (p75NTR). Co-expression with 
p75NTR strengthens Trk receptor affinity and specificity for the corresponding NTs. In 
contrast to the trophic role of NTs, their precursor forms (pro-NTs) have been 
implicated in synaptic depression, neuronal apoptosis during development, aging and 
neurodegeneration signalling. They also act via p75NTR, but independently of Trk 
receptors28.  
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Sortilin was the first member of the family to be characterised as a receptor for both 
pro- and mature NTs. It was shown to be involved in neuronal cell death by forming a 
ternary receptor complex with p75NTR and pro-NGF29. Subsequent studies in Sort1-/- 
mice, and neuronal cultures derived from them, further confirmed the role of sortilin in 
apoptotic signalling30. Additionally, sortilin has also been shown to interact directly 
with Trk receptors in hippocampal, cortical and a subtype of sensory neurons. Further 
experiments performed in neuronal cultures and Sort1-/- mice showed that sortilin is 
involved in neurotrophin signalling by facilitating anterograte axonal trafficking and 
synaptic localisation of Trk receptors31. It has also been implicated in BDNF secretion 
from neurons and neurosecretory cells by directly binding BDNF and mediating its 
intracellular trafficking to secretory granules32. 
SORLA constitutes the second member of the family to be functionally characterised. 
As discussed above in section 1.1.2., it interacts with many adaptor proteins involved 
in TGN-endosome/lysosome sorting, which enables this receptor to continuously 
shuttle between the plasma membrane, endosomes and the Golgi apparatus. The 
role of SorLA in neuronal trafficking processes was first suggested by its interaction 
with both GDNF and the GDNF receptors, GFRα1 (GDNF family receptor α 1) and 
RET (Rearranged During Transfection) receptor tyrosine kinase3. GDNF interacts 
initially with GFRα1 forming a tetrameric complex, which then binds to the RET 
receptor and activates multiple downstream signalling pathways, including ERK 
(extracellular regulated kinase) and Akt. The association of SorLA with the 
GDNF/GFRα1 complex leads to GDNF being targeted for lysosomal degradation, and 
GFRα1 being internalised from the cell surface to endosomal compartments. 
Moreover, SorLA also mediates the internalisation and intracellular sorting of the RET 
receptor to endosomes, when expressed together with GFRα13. Given the importance 
of GDNF in the development of the dopaminergic system and the role of SorLA in the 
intracellular sorting of the GDNF/GFRα1/RET complex, it is not surprising that 
blocking the receptor activity potentiates the neurotrophic effects of GDNF in terms of 
cell survival, proliferation and neurite outgrowth both in SH-SY5Y cells and in primary 
dopaminergic neurons3. Additionally, knocking out Sorl1 in mice leads to increased 
GDNF levels and altered dopaminergic connectivity in the striatum and midbrain3.  
SORLA has also been implicated in TrkB-dependent BDNF signal transduction33. 
Treatment of Sorl1-/- primary neuronal cultures with BDNF led to activation of its 
receptor TrkB, and the downstream signalling pathways ERK and Akt. However, the 
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strength of the induction, as assessed by the levels of TrkB, ERK and Akt 
phosphorylation, was much less pronounced compared to that of treated wild type 
(WT) neurons33. Subsequent experiments showed that SORLA interacts with TrkB 
and is required for both its anterograde and retrograde transport to and from the post-
synaptic density33. Interestingly, BDNF itself has been previously identified as a major 
inducer of Sorl1 expression, potentially leading to further potentiation of the trophic 
signals34.   
Similarly to sortilin, SorCS2 interacts with both pro-NGF and p75NTR4. Moreover, 
SorCS2, but not sortilin, has been shown to be mediate pro-NGF-induced growth cone 
collapse in embryonic (E15) neuronal cultures grown for three days in vitro (DIV3) in 
the presence of p75NTR. Further experiments demonstrated that this process required 
both the displacement of Trio (a scaffold protein localised at actin-rich neuronal 
protrusions) from the SorCS2/p75NTR receptor complex upon pro-NGF binding, as well 
as the dissociation of fascin (an actin filament stabilising protein) from the growth 
cone4. A subsequent study published in 2014 confirmed the interaction between 
SorCS2 and p75NTR,  both in HEK cells and brain homogenates derived from eight 
week-old mice6. Moreover, the association of these two receptors was required for 
the efficient binding of both pro-BDNF and pro-NGF. As previously demonstrated by 
Deinhardt et al. (2011)4, SorCS2 co-localised with p75NTR in filopodia-rich protrusions 
and was required for proNT-induced collapse of growth cones. Neonatal cerebellar 
granule cells (CGN) derived from Sorcs2-/- mice failed to respond to pro-BDNF as they 
showed marked neurite extension compared to WT neurons, seven days post-
treatment6. Similarly, pro-BDNF failed to induce growth cone collapse in dopaminergic 
neurons of midbrain explants derived from Sorcs2-/- mice (E14.5). In adult Sorcs2-/- 
mice, this led to increase innervation of the frontal cortex from the ventral tegmental 
area (VTA), suggesting that SorCS2 plays an important role in the development and 
maturation of the dopaminergic system through its interaction with p75NTR and pro-
BDNF6.  
A subsequent paper showed that the interaction of SorCS2 with p75NTR and pro-BDNF 
is also required for the induction of NMDA receptor (NMDAR)-dependent long-term 
depression (LTD) in the hippocampus. Hippocampal slices derived from Sorcs2-/- mice 
were unresponsive to low-frequency stimulation (LFS) LTD protocols5. However, this 
was not the result of developmental deficits due to failure in growth cone collapse as 
first SorCS2 was not detected in the developing hippocampus, and second basic 
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synaptic properties were not altered in the knockout mice. Moreover, overexpression 
of Sorcs2 in the knockout mice restored LTD, while blocking the interaction between 
SorCS2 and p75NTR in WT animals had the opposite effect5. Additionally, knocking out 
Sorcs2 was also associated with impaired response to high frequency stimulation 
(HFS), known to induce NMDAR-dependent long-term potentiation (LTP). As before, 
lentiviral expression of Sorcs2 in the knockout mice rescued the phenotype, while 
blocking SorCS2 in WT mice abolished LTP. Interestingly, high concentrations of 
BDNF were also sufficient to restore LTP in the Sorcs2-/- hippocampal slices5. Binding 
of BDNF to the TrkB receptor is required for the induction of the early phase of LTP, 
while the interaction of pro-BDNF with p75NTR results in LTD. Subsequent experiments 
showed that SorCS2 interacts with TrkB at the cell surface of hippocampal neurons 
and is required for the correct targeting of the receptor to post-synaptic densities upon 
HFS5. The functional importance of the interaction between SorCS2 and TrkB was 
further confirmed by the inability of Sorcs2-/- primary neurons to respond to BDNF 
treatment as demonstrated by reduced neurite branching and dendrite complexity 
when compared to treated WT cultures5. These results suggested that the interaction 
of SorCS2 with TrkB is crucial for both BDNF-dependent synaptic plasticity and 
changes in neuronal morphology5. 
1.1.4.2. The role of the Vps10p-domain receptor family in cellular processes 
linked to neurodegeneration  
Both in vitro and in vivo functional studies (using transgenic mouse models) provide 
evidence for the involvement of the Vps10p-domain receptor family in 
neurodegeneration, and Alzheimer’s disease (AD) in particular. A characteristic 
signature of AD pathology constitutes the abnormal deposition of ‘senile plaques’ and 
‘neurofibrillary tangles’. While AD is recognised and confirmed as a diagnosis based 
on the presence of these two lesions, other neuropathological abnormalities have also 
been observed. Substantial synaptic loss, significant cerebral cortical and 
hippocampal atrophy, and symmetrical enlargement of the ventricles are also strong 
indications of AD pathology. Nonetheless, it is worth noting that AD often occurs in 
conjunction with other conditions (e.g. stroke and Parkinson’s disease), and when 
encountered in elderly, the distinction between neuropathological abnormalities 
occurring as a result of normal aging or dementia becomes difficult35.  
Hyper-phosphorylation of the microtubule-stabilising protein tau results in its 
intracellular deposition as ‘neurofibrillary tangles’. Meanwhile, abnormal APP 
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cleavage leads to the release of insoluble Aβ, which accumulates into extracellular 
‘senile plaques’35. Newly synthesized APP molecules follow the constitutive secretory 
pathway, being transported from the ER through the TGN to the plasma membrane. 
At the plasma membrane, APP is cleaved by α-secretase, releasing the soluble APP 
fragment sAPPα. The membrane-anchored C-terminal fragment of APP- CTFα is 
internalised and further processed into peptide P3 and APP intracellular domain 
(AICD) by γ-secretase inside the cell. This pathway is known as the non-
amyloidogenic processing pathway, as the α-secretase cleave site is within the Aβ 
peptide sequence, and thus Aβ oligos are not produced. In contrast, in the 
amyloidogenic processing pathway, unprocessed APP molecules are internalised and 
transported to late endosomal-lysosomal compartments, or retrogradely to the TGN. 
In these compartments, APP is cleaved first by β-secretase, which results in the 
formation of sAPPβ and the membrane-bound C terminal APP fragment- CTFβ. The 
latter is further processed by γ-secretases, leading to the formation of Aβ peptides of 
mainly 40 to 42 amino acids, and AICD36 (Figure 1.3.A).  
Functional studies have implicated SORLA in the trafficking and processing of APP, 
and thus Aβ accumulation. Evidence for the direct interaction between APP and 
SORLA was first published by Andersen et al. (2005)37 who showed that SORLA can 
bind all human APP isoforms, forming a 1:1 stoichiometric complex. In the same 
study, lack of SORLA in SH-SY5Y and CHO cells that over-expressed APP, led to 
APP localisation mainly to the ER. Meanwhile, introducing the full length SORL1 
transcript in the same cell lines confined APP to vesicular (endosomes) and 
perinuclear (cis-Golgi) regions. The observed intracellular APP accumulation was 
accompanied by a reduction in the amount of its processing products Aβ, sAPPα and 
sAPPβ. In contrast, overexpression of a mutant form of SORLA that lacked the 
cytosolic domain resulted in co-localisation of APP and SORLA at the cell surface37. 
These and other studies have suggested a role of SORLA as a sorting receptor for 
APP, which prevents its entry into amyloidogenic and non- amyloidogenic pathways 
by confining the transmembrane protein to the TGN and/or recycling it between 
endocytic and secretory compartments. Overexpressing SORL1 in CHO and SH-
SY5Y cells prevented APP exit from the TGN, but had no effect on its trafficking from 
the ER to the Golgi compartments or from the cell surface to perinuclear regions11. 
This effect seemed to be dependent on SORLA interaction with the adaptor proteins 
PACS1 and GGA1/2. As before, introducing SORLA mutants lacking the entire 
cytosolic tail or carrying mutations within the PACS1 binding site led to the 
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mislocalisation SORLA and APP at the cell surface, accompanied by an increase in 
Aβ40 and Aβ42 levels. Meanwhile, disruption of the GGA1/2 binding sequence led to 
the accumulation of SORLA and APP in recycling endosomes, suggesting faulty 
transport to the cell surface11. In addition to mediating APP transport through the TGN, 
SORLA was also shown to influence APP processing and Aβ production by directly 
interacting with β- secretase in the Golgi network and thus inhibiting its access to 
APP38.  
In addition, further overexpression studies in HEK293 cells, followed by 
immunofluorescence on rat and human brain sections, showed considerable co-
localization of SORLA and APP within early endosomal compartments39. Subsequent 
studies confirmed that the ability of SORLA to prevent APP processing depends on 
the receptor shuttling between endosome and the TGN. In a more recent study, 
overexpressing a mutant version of SORLA carrying a disrupted PACS1 binding site 
led to both the receptor and APP accumulation in endosomes40 as opposed to the 
previously reported mistrafficking to the cell surface11. As expected, APP 
mislocalisation was paralleled with an increase in both amyloidogenic and non-
amyloidogenic processing40. Similarly, introducing a version of SORLA, where the 
FANSHY motif has been mutated, increased APP trafficking to endosomal 
compartments and enhanced its amyloidogenic processing12. In a subsequent paper, 
Dumanis et al. (2015) replicated these observations in vivo. Deleting the retromer 
binding site in Sorl1 resulted in the receptor depletion from the TGN and accumulation 
in early endosomes. Meanwhile, crossing this mouse line with the 5xFAD model of 
AD, which carries a total of five mutations in the human APP and presenilin-1 (PSEN1) 
transgenes, resulted in increased APP proteolytic processing, suggesting that 
retrograde sorting leads to the sequestration of SORLA and APP in the TGN and is 
required for the protection against APP amyloidogenic and non-amyloidogenic 
processing15.  
In mice, overexpression of human SORL1 cDNA significantly reduced the amount of 
murine Aβ, but not sAPPα41. A similar decrease in human Aβ, but not sAPP species, 
was detected when human SORL1 was expressed in PDAPP mice (an AD mouse 
model in which an incomplete version of the APP gene, carrying an AD-associated 
mutation, is expressed)41. The observed effect of SORLA on Aβ catabolism was 
shown to be the result of a direct binding of Aβ to SORLA Vps10p domain. In vitro 
experiments in SH-SY5Y cells in which WT human APP transgene was stably 
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expressed in the presence or absence of SORLA showed that the association 
between Aβ and SORLA led to increased lysosomal targeting and degradation of the 
Aβ peptides41. A subsequent study in the same cell line demonstrated that the 
anterograde transport of the SORLA/Aβ complex to lysosomes was mediated by the 
receptor interaction with the adaptor proteins GGA1 and GGA215. The possible ways 
in which SORLA can influence APP processing and Aβ accumulation are summarised 
and illustrated in Figure 1.3.B.  
Sorl1-/- mice have increased levels of Aβ, and crossing SorLA deficient mice with 
different AD mouse models promotes APP amyloidogenic processing even 
further42,43. In addition to the example of the double-transgenic 5xFAD mouse model 
described above, loss of SorLA in APP/PS1 mice (a mouse model of AD expressing 
the human APP and PSEN1 genes bearing AD autosomal dominant mutations) 
accelerated the observed Aβ pathology, as well as the disease onset. Further 
experiments suggested that this was the result of increased APP amyloidogenic 
processing rather than reduced Aβ clearance42. Crossing Sorl1-/- mice with another 
mouse model of AD- AD10, in which NGF neutralisation by peripheral antibodies is 
associated with neurodegeneration and Aβ accumulation results in from the 
processing of endogenous APP, was also associated with exacerbated early Aβ 
pathology. Intriguingly, it also led to decreased levels of cholinergic 
neurodegeneration and tau hyperphosphorylation, suggesting that SorLA might be 
involved in various other aspects of AD-related phenotypes43.  
It is worth noting that while the above studies have provided valuable information 
about the mechanisms in which SORLA regulates APP processing, there are several 
issues surrounding the use of overexpression systems, including cytotoxicity. 
Moreover, the overexpression of some proteins could promote promiscuous protein-
protein interactions and the abnormal modulation/activation of intracellular 
pathways188. Thus, results obtained from overexpression studies should be treated 
with caution, and distinction between the role of the protein of interest and the effects 
of the overexpression itself should be considered wherever possible. 
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Figure 1.3. APP processing and the role of SORLA in this process. [A] APP processing 
pathways. In the non-amyloidogenic processing pathway, APP is initially cleaved by α-
secretases at the cell surface, leading to the release of the soluble fragment sAPPα and the 
generation of the membrane-bound fragment CTFα. The latter is internalised and further 
processed into peptide P3 and AICD by γ-secretases. Alternatively, APP can be processed 
via the amyloidogenic pathway. Following internalisation, APP is first cleaved by β-secretases 
at the amino terminal end of Aβ, generating sAPPβ and CTFβ. The consequent cleavage of 
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CTFβ by γ-secretases at the Aβ carboxy terminal generates Aβ and AICD. [B] SORLA role in 
APP sorting and processing. SORLA interacts and retains APP within the TGN, hindering APP 
entry into amyloidogenic and non-amyloidogenic processing pathways. SORLA might also 
interact with APP at the cell surface, and in endosomes, following protein internalisation. 
Through its interaction with the retromer complex and PACS1, SORLA sorts APP from 
endosomal compartments to the TGN, and is recycled back through its interaction with GGA1 
and GGA2. SORLA also binds Aβ directly, leading to the fragment sorting to lysosomes. This 
process is mediated by the interaction of SORLA with GGA1 and GGA2. [Created with 
BioRender]. 
  
In addition to its binding to APP and Aβ, SORLA has been implicated in the aetiology 
of AD through its interaction with the apolipoprotein E (APOE). APOE is a 
glycoprotein, mediating the transport and delivery of cholesterol and other lipids. It 
constitutes the major genetic risk factor for developing both EOAD and LOAD. In 
humans, there are three APOE alleles: ε3 constitutes the common variant, while ε4 
increases and ε2 decreases the risk of AD44. In vitro, SORLA has been shown to bind 
to the APOE isoforms with differing affinity- the highest affinity was detected upon 
binding to ε4, followed by ε3 and finally ε2. This difference in binding corresponded to 
isoform-dependent cellular uptake of both APOE and APOE-Aβ complexes in the 
presence of SORLA (the highest uptake was observed in presence of the ε4 allele, 
followed by ε3 and ε2)45.   
Members of the SORCS subfamily have also been associated with APP processing 
and thus potentially with AD. Overexpression of all members of the family in HEK293 
cells led to a significant decrease in the levels of APP processing mediated by γ-
secretase. Meanwhile, knocking down SORCS2, SORCS3 and SORT1 had the 
opposite effect on γ-secretase activity46. Similarly, overexpression of both SORCS1 
and APP in HEK293 was associated with decreased secretion of Aβ40 and Aβ42, as 
well as sAPPα47. Meanwhile, knocking down SORCS1 with shRNAs had the opposite 
effect in terms of APP processing. Immunoprecipitation experiments in HEK293 cells, 
supported by confocal analysis in SH-SY5Y cells, showed an interaction between 
SORCS1 and APP47.  
Sortilin has also been shown to interact with both APP and APOE. However, unlike 
SORLA, crossing sortilin knockout mice with commonly used AD mouse models 
(namely, PDAPP and 5xFAD mice) did not alter murine or human APP and sAPP 
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levels, but only increased Aβ production. In vitro experiments attributed the observed 
increase in Aβ levels to impaired cellular uptake of APOE. Thus, sortilin was identified 
as a major cell surface receptor for APOE, mediating the endocytosis and subsequent 
degradation of Aβ bound to APOE48. With respect to APP, sortilin has been shown to 
associate with the transmembrane receptor in neuronal processes. Additionally, 
sortilin deficiency did not affect APP intracellular distribution, but led to decreased 
sAPPα extracellular levels49. 
Apart from AD, almost all members of the sortilin family, except for SORCS1, have 
also been associated with the neurobiology of other neurodegenerative conditions. 
For example, functional studies have linked both SorLA and SorCS2 to Huntington’s 
disease (HD). The striatum constitutes the most affected part of the brain in HD, and 
reduced BDNF levels in this area have been detected in HD patients, as well as in a 
mouse model of HD- the HD82 mice50. In the latter, the decrease in BDNF levels 
coincided with decrease Sorl1 expression34. Based on this observation, as well as on 
the role of SorLA in the trafficking of the BDNF receptor TrkB, Rohe et al. (2013)33 
hypothesised that loss of SorLA would lead to potentiation of the BDNF-dependent 
neurodegenerative phenotype observed in the HD82 mice. Indeed, crossing Sorl1-/- 
and HD82 mice accelerated the onset of the motor deficits normally observed in these 
mice. In the double transgenic mice, hind limb clasping and compromised rotarod 
performance appeared at around ten weeks of age in contrast to the HD82 mice, 
which normally displayed these phenotypes between 16-22 weeks of age33. Similarly, 
SorCS2 deficiency both accelerated the onset and exacerbated the disease motor 
phenotype in another mouse of model of HD- the zQ175 mice51. NMDARs have been 
shown to play an important role in the regulation of striatum-mediated motor functions. 
Moreover, both reduced function and genetic variations in the NR2 receptor subunits 
have been observed in HD patients, with the latter being also linked to the age of 
onset of motor deficits51. In agreement with this, Ma et al. (2017)51 reported decreased 
cell surface expression of the NMDAR subunit NR2A in the medium spiny neurons 
(MSNs) in the striatum of zQ175 mice. Subsequent experiments in WT and Sorcs2-/- 
mice identified SorCS2 as NR2A binding partner, which together with VPS35 (a 
component of the retromer complex) mediates the receptor subunit trafficking to 
dendrites of the MSNs in the striatum51. Additionally, reduced SorCS2 levels were 
observed in zQ175 mice, as well as in another HD mouse line- R6/2. The decrease 
was restricted to the striatum and became more pronounced with age. Additionally, 
SorCS2 was found to interact selectively with the mutant but not the WT form of the 
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huntington protein prior to the disease onset. As a result, SorCS2 mislocalisation from 
somato-dendritic compartments to perinuclear regions was observed in both human 
and mouse HD brain section, potentially interfering with the correct trafficking of the 
NMDAR subunit NR2A51. Meanwhile, sortilin has been functionally linked to 
Parkinson’s disease52 and FTD53.  
1.1.4.3. The role of the Vps10p-domain receptor family in cognition and 
neuropsychiatric disorders 
Most of the evidence supporting a role of the receptor family in cognition and 
neuropsychiatric disorders comes from analysis of knockout mice. As described in the 
sections above, in vivo studies have implicated all family members in cellular 
processes related to synaptic plasticity, and SorLA and SorCS2 have also been 
shown to be crucial for the development of the dopaminergic system. In addition, 
recent studies have identified a role of SorCS2 in cellular stress response pathways. 
All of these processes have been implicated in the aetiology of various 
neuropsychiatric disorder. 
Sorl1-/- mice display impaired object recognition memory from an early age (three 
months) as they do not distinguish between familiar and new objects. These mice 
have also shown impaired spatial learning memory in the Morris water maze43. Both 
deficits in object recognition and spatial memory were attributed to the observed 
increased Aβ plaque deposition43. In addition to the memory deficits reported by 
Capsoni et al. (2013)43, Sorl1-/- mice display behavioural traits resembling symptoms 
of ADHD, such as reduced anxiety levels, hyperactivity and altered response to 
psychostimulants. It has been suggested that these phenotypes are the result of the 
decreased nigrostriatal wiring due to the increased GDNF levels observed in these 
mice as described in section 1.1.4.13. 
Meanwhile, as described above, Sorcs2-/- mice showed abolished NMDA-dependent 
LTP and LTD as a result of altered TrkB receptor trafficking and BDNF signalling5. 
Behaviourally, these deficits translated into long-term, but not short-term, memory 
impairments after a weak electrical shock in an inhibitory avoidance test. Barnes test 
revealed impaired spatial memory in these mice5. Additionally, Sorcs2-/- mice exhibit 
ADHD-like behaviours, including hyperactivity, reduced anxiety and increased risk 
taking in an open field test, as well as dampened response to amphetamines5,6. Lack 
of SorCS2 was also associated with phenotypes reminiscent of affective disorders 
and schizophrenia (e.g. depression-like response to both tail suspension (TST) and 
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forced swim tests (FST), and deficits in sensorimotor gating)5. According to Glerup et 
al. (2014, 2016)5,6 these behavioural traits could be explained by dopaminergic 
hyperinnervation of the frontal cortex and the impaired hippocampal plasticity in 
response to pro- and mature BDNF found in the Sorcs2-/- mice. 
More recently, SORCS2 has been linked to cellular pathways involved in neuronal 
protection against oxidative stress. Increased SORCS2 expression levels were 
detected in the CA2 region of the hippocampus of human epileptic brains, as we as 
in a mouse model of chronic epilepsy- the PTZ (pentylenetetrazol)-kindled mice. 
Moreover, this increase was particularly apparent in healthy neurons within this 
area22. Meanwhile, when subjected to the PTZ kindling paradigm, Sorcs2-/- mice 
displayed an overall comparable phenotype to the one observed in WT, except for a 
significant increase in the mortality rate during the course of the experiment. The latter 
was accompanied by a significant increase in the number of neurons positive for the 
oxidative stress marker 8-hydroxy-2’-deoxyguanosine (8-OHdG) in the hippocampus 
of Sorcs2-/- mice.. This observation, combined with the increased response to oxidative 
stress detected in primary hippocampal neurons from these mice, suggested that 
SORCS2 plays a role in the cell defence against oxidative stress22. Subsequent 
experiments showed that SorCS2 is required for the synthesis of the reactive oxygen 
species (ROS) scavenger- glutathione, through its interaction with the glutamine and 
cysteine transporter EEAT3 (excitatory amino acid transporter 3). In primary neurons, 
loss of SorCS2 led to the missorting of EEAT3 from the cell surface and early 
endosomes to lysosomes, ultimately leading to reduced levels of the transporter and 
thus altered response to oxidative stress22. In addition to its role in oxidative stress 
response, SORCS2 has been linked to the cell response to alcohol and stress 
hormones23,54. SorCS2 deficiency was also linked to reduced alcohol seeking and 
withdrawal symptoms in vivo. Sorcs2-/- mice showed abolished alcohol-induced place 
preference, which was not the result of impaired contextual memory, and was 
accompanied by reduced alcohol consumption and lack of alcohol withdrawal 
symptoms54. In addition, in vitro studies in SH-SY5Y cells showed increased SORCS2 
expression upon alcohol exposure and withdrawal, as well as following glucocorticoid 
application23.  
The other members of the receptor family have also been functionally implicated in 
both cognition and neuropsychiatric disorders. For example, Sort1-/- mice displayed 
memory deficits similar to the ones reported for Sorl1-/- mice, but at a later 
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developmental stage55. Knocking out SORT1 was also associated with reduced 
immobility time in FST and TST, thought to be a depression resistant phenotype. 
Further investigation linked the observed phenotype to reduced TREK-1 cell surface 
levels and increased BDNF content and TrkB expression. In addition to the anti-
depressant phenotype, Sort1-/- mice also displayed anxiety-like behaviour as it has 
been assessed in an open plus maze and marble burying test56. Meanwhile, unlike 
Sorcs2-/- mice, Sorcs3-/- mice showed normal hippocampal LTP but impaired NMDA-
and mGluR-dependent LTD, as well as intact acquisition memory, but accelerated 
extinction of short-term memory in an inhibitory avoidance test. SorCS3-deficient 
animals also showed deficits in spatial learning and memory, as well as reduced basal 
synaptic transmission and short-term synaptic plasticity in the hippocampus, 
potentially as a result of altered AMPA receptor turnover at the post-synaptic 
density57. Lack of SorCS3 was also associated with rapid fear memory extinction in 
an inhibitor avoidance test, implicating this receptor in aversive memory formation and 
retrieval58. 
 
1.1.5. Genetic and expression studies provide further evidence 
for the role of the Vps10p-domain receptor family in 
cognition and disease 
As discussed in the previous section, all members of the Vps10p-domain receptor 
family act as binding partners for various pro- and mature neurotrophic factors and 
synaptic proteins, and knockout mice for these genes recapitulate phenotypes 
reminiscent of various brain disorders. Thus, in keeping with these functional studies, 
genetic and expression analyses have provided further evidence for the involvement 
of the gene family in cognition, learning and memory, as well as neurodegenerative 
and psychiatric conditions.  
1.1.5.1. Genetic and expression studies implicate the Vps10p-domain 
receptor family in cognition and neurodegenerative disorders, AD in 
particular 
A recent genome-wide association study (GWAS), performed on 1.1 million 
individuals from a European ancestry, linked SORL1 (and SORCS3) to cognition59. It 
identified SNPs (single nucleotide polymorphisms) within these genes as genome-
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wide significant hits for cognitive educational attainment, mathematical ability and 
highest math class every taken59- traits previously shown to correlate with general 
cognitive performance and to a lesser extend with learning abilities60,61. Meanwhile, 
SORSC2 shows only suggestive association with cognition at the genome- wide 
level62. The genome-wide significant (p≤5x10-8) and suggestive (5x10-8< p ≤1x10-5) 
associations between the sortilins, cognition and cognitive processes are summarised 
in Table 1.1.  
In terms of association of the gene family with neurodegenerative conditions, SORL1 
constitutes the only member that has been linked to AD at a genome-wide level. 
SORL1 was first identified as an AD risk gene in a study conducted by Rogaeva et al. 
(2007)63, who tested several SNPs within the VPS family, including VPS35 and 
VPS26A, for association with AD. Six SNPs clustered within two haplotype blocks at 
the 5’ and the 3’ end of SORL1 showed nominal association with AD in both the 
discovery and replication data set (p<5x10-8). Moreover, the SNPs located at the 5’ 
block possessed both risk and protective haplotype. The variants identified were non-
coding and thus likely to exert their effects via altering SORL1 transcription and 
translation63. Following from this observation, a more recent study linked the presence 
of a protective haplotype within the 5’ block with increased SORL1 expression and 
consequently reduced Aβ production in iPSC-derived neurons in response to BDNF 
treatment64.  
Subsequent meta-analyses on larger datasets confirmed the association between the 
SNPs within the two haplotype blocks and AD risk, but also identified additional 
variants within distinct linkage disequilibrium blocks, conferring the risk of developing 
AD65,66. Interestingly, an additional SNP- rs689021, located within the 5’ haplotype 
block, was shown to be protective against AD within the Caucasian population65. Age, 
sex, ethnic origin and APOE status had no effect on the identified associations63,65–67. 
Additional GWASs further confirmed the association of SORL1 variants with late-
onset AD (LOAD)68,69,70. The most recent genome-wide meta-analysis study, 
combining individuals from three independent cohorts, identified the SORL1 locus as 
genome-wide significantly associated with LOAD status (p=5.57x10-11), but not with 
family history of AD (p=2.81x10-6). Conducting a meta-analysis on the LOAD and AD-
by-proxy (family history of AD) GWASs, where a total of 383,378 controls were 
compared to 71,880 cases, confirmed the association of the SORL1 locus with 
LOAD70. In addition, Marioni et al. (2018)71 reported a genome-wide significant 
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association between variants within SORL1 and familial history of AD. Polymorphisms 
in SORL1 have also been associated with progression from mild cognitive impairment 
(MCI) to AD72. 
Rare SORL1 coding variants, including missense, splice site and nonsense 
mutations, have also been linked to both familial and sporadic AD, as well as early 
and late onset forms of the disease41,73–82. In 2012, Pottier et al.73 reported two 
missense and five nonsense mutations in SORL1, present in autosomal dominant 
early-onset AD (EOAD) patients, but not in ethnically matched controls. Further 
investigation revealed allele-specific reduction in SORL1 expression in peripheral 
blood cells from a patient carrying the p.Cys1478* mutation. In silico analysis of the 
identified missense mutations showed that they were likely to exert damaging effect, 
being located within domains known to bind APP and Aβ (e.g. Asn1358Ser mutation 
within the CR domain and p.Gly511Arg within the Vps10p domain)73. In line with these 
predictions, an independent study in which a mutant version of SORL1 carrying the 
p.Gly511Arg variant was overexpressed in SH-SY5Y cells showed reduced Aβ 
binding to the receptor Vps10p domain, followed by decreased lysosomal 
degradation41. Subsequently, a whole exome sequencing (WES) study, performed by 
Verheijen et al. (2016)77 on larger cohort of 1255 EOAD cases and 1938 age- and 
origin- matched controls, identified a significant enrichment of rare missense variants 
within SORL1 in patients versus controls. 48% of the rare variants identified were 
unique to the patient group, and amongst these 80% were predicted to be 
pathological. Moreover, eight of them- six frameshift variants (p.Thr659Serfs*30, 
p.Cys752Serfs*21, p.Tyr350fs*, p.Gly447Argfs*22, p.Cys1103Valfs*4, p.Val1747fs*) 
and two nonsense mutations (p.Arg416* and p.Arg1442*), introduced a premature 
stop codon. Introducing a premature stop codon is predicted to lead to 
haploinsufficiency due to non-sense mediated decay (NMD). This was confirmed for 
one mutation- p.Gly447Argfs*22, which was associated with decrease SORL1 
expression levels in lymphoblast cells, derived from the patient carrier. Treating these 
cells with cycloheximide increased SORL1 mRNA levels, suggesting that the 
observed decrease was due to NMD. None of the identified low-frequency to common 
variants showed a statistical association with EOAD in this sample set77. Similarly, 
another WES study identified enrichment of rare damaging missense SORL1 
mutations in EOAD patients, especially in those with family history of the disease80. 
Following up on the results from the study conducted by Verheijen et al. (2016)77, 
Holstege et al. (2017)82 added 640 AD cases (including 320 EOAD case) and 1268 
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controls from the Netherlands, and classified the rare variants identified based on the 
predicted severity of effect. The association between a given variant and the risk of 
AD correlated with frequency, as extremely rare variants increased the AD risk by 12-
fold in this sample set. Meanwhile, common variants were not associated with AD, 
even if they were predicted to be highly damaging82.  
In addition, Vardarajan et al. (2015)75 reported the presence of rare, coding mutations 
in SORL1, which were predicted to be damaging and segregating with LOAD. The 
effect of three of the identified mutations was functionally assessed in HEK293 cells 
by overexpressing mutated version of the SORL1 gene. Introducing the p.Gly270Lys 
and Thr947Met mutations led to an increased secretion of Aβ40 and Aβ42, while 
overexpressing the Ala528Thr variant increased Aβ42, but not Aβ40, levels. All three 
mutations were associated with elevated sAPPα and sAPPβ production, as well as 
weakened SORLA binding to APP. However, only the Thr947Met variant influenced 
SORLA cell surface levels, suggesting that the other two mutants might affect APP 
processing by disrupting its interaction with SORLA at the cell surface75. Interestingly, 
all three variants were located within close proximity to SNPs initially identified by 
Rogaeva et al. (2007)63. Similarly, Cuccaro et al. (2016)76 and Gomez-Tortoza et al. 
(2018)81 found additional rare variants segregating with both LOAD and EOAD. In 
keeping with the findings published by Vardarajan et al. (2015)75, functional analysis 
of the novel SORL1 variants identified by Cuccaro et al.76 (p.Thr588Ile and 
pThr2134Met) confirmed their impact on APP trafficking and Aβ production.  
In summary, the studies described above have identified rare coding variants, 
scattered throughout the different domains of SORLA and predicted or functionally 
validated to have negative consequence in terms of SORLA’s role in APP trafficking 
and processing into Aβ. However, these studies applied diverse strategies in terms of 
patient inclusion criteria, variant identification and assessment. In order to overcome 
these limitations, a meta-analysis study published this year combined and reanalysed 
the data from five non-overlapping WES studies74. The variants were filtered 
according to their allele frequency and predicted damaging effect. Protein truncating 
variants conferred the highest AD risk, and missense mutation classified as damaging 
by three independent tools (SIFT, Mutation Taster and Polyphen2) were associated 
with AD at an exome-wide significant level, independent of their allele frequency. 
These associations were stronger when assessed only for EOAD cases (as opposed 
to a combined sample of EOAD and LOAD). Variants located within the Vps10p 
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domain, CR domain or fibronectin type III domain showed stronger association with 
AD risk compared to mutations located in other domains74. 
SORCS2 does not show association with AD, but shows suggestive association 
(5x10-8< p ≤1x10-5) with hippocampal sclerosis, an AD neuropathological feature83. 
With regard to the rest of the family members, SORCS3 has shown suggestive 
association with LOAD risk in a family-based GWAS meta-analysis84, and a non-
coding SORT1 variant has been linked to decreased risk of developing AD85. In 
addition to AD, rare variants in SORT1 and SORCS3 have been associated with 
frontotemporal dementia (FTD)86 and multiple sclerosis87, respectively. Genome-wide 
significant (p≤5x10-8) and suggestive (5x10-8< p ≤1x10-5) associations linking 
members of the Sortilin family to neurodegeneration are summarised in Table 1.1. 
In terms of expression, reduced SORLA protein levels have been detected in post-
mortem brain tissue derived from AD patients39,88. Reduced SORL1 mRNA levels 
have also been found in brain areas of cognitively intact individuals that show early 
signs of AD-related neuropathology89. Additionally, two variants in LD, located within 
SORL1 3’ end, were significantly associated with reduced mRNA and protein levels 
in AD patient brain speciments90. SORL1 risk variants have also been shown to 
reduce SORL1 expression during childhood and early adolescence, as well as to 
predict endophenotypes of AD (e.g. decreased white matter fractional anisotropy and 
increased amyloid pathology in post-mortem brain) in individuals who were dementia-
free at the time of the study91. Reduced SORCS1 expression was also detected in the 
amygdala, but not the cerebellum (a brain region spared in AD) of AD patients47.  
 
 
Table 1.1. GWAS data linking the sortilins to cognition and neurodegeneration. The columns show a given family member, the trait with which it has been 
associated, the identified SNPs and their significance at the genome-wide level. The far-right column provides a reference to the respective study.  
Gene Trait SNP p-value PUBMED ID 
SORL1 Alzheimer’s disease in APOE e4-carriers rs11218343 9x10-6 (suggestive) 25778476 

















Educational attainment (self-reported) rs12146618 3x10-9 30038396 





Mathematical ability (self-reported) rs1448133 4x10-9 30038396 
Non-word reading (dyslexia) rs556349 2x10-6 (suggestive) 30741946 
Word reading (dyslexia) rs556349 6x10-6 (suggestive) 30741946 
SORT1  Cognitive ability rs11102974 1x10-9 29186694 
SORCS1 - - - - 
SORCS2 General cognitive ability rs192716625 7x10-6 (suggestive) 29844566 




Gene Trait SNP p-value PUBMED ID 
SORCS3 Alzheimer’s disease and age of onset rs117792039 2x10-7 (suggestive) 26830138 
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1.1.5.2. Genetic studies implicate the Vps10p-domain receptor family in 
psychiatric disorders 
SORL1, SORCS2 and SORCS3 have been genetically associated with risk taking 
behaviours. A GWAS on over one million individuals from UK Biobank, identified a 
SNP within SORCS2 as a genome-wide significant hit for general risk-taking 
behaviour, and SNPs in SORL1- for alcohol consumption and smoking status92. 
Interestingly, these risky behaviours correlated genetically with traits like neuroticism, 
extraversion and openness to new experience, as well as with psychiatric phenotypes 
such as ADHD, bipolar disorder and schizophrenia92. Additionally, a recent GWAS 
identified SORCS2 as a genome-wide significant hit for alcohol withdrawal severity. 
Moreover, the risk haplotype was mapped to a regulatory region, known to be 
specifically active in the hippocampus and modulated by stress hormones23. Similarly, 
two independent studies identified SORCS3 as a GWAS hit for both smoking status93 
and initiation94.  
SNPs within SORCS2 have been also associated at a suggestive level (5x10-8< 
p ≤1x10-7) with various psychiatric conditions and phenotypes, including anorexia 
nervosa95, attention deficit in ADHD96, long-term treatment outcome in bipolar disorder 
(BD)97 and neuroticism98. Additionally, one GWAS on pooled DNA from two 
independent case-control sample sets99 and two candidate gene studies100,101 further 
linked SORCS2 to the aetiology of BD. However, amongst all members of the receptor 
family, SORCS3 shows the strongest association with psychiatric illness, in particular 
depression and associated phenotypes102–105. The GWAS-based links between 









Table 1.2. GWAS data linking the sortilins to psychiatric disorders. The columns show a given family member, the trait with which it has been associated, 
the identified SNPs and their significance at the genome-wide level. The far-right column provides a reference to the respective study.  
  
Gene Trait SNP p-value PUBMED ID 






Mood disorder in prion disease rs11218343 9x10-6 (suggestive) 25897833 
















SORT1 - - - - 
SORCS1 Methadone dose in opioid dependence rs6584756 4x10-6 (suggestive) 28115739 
SORCS2 Anorexia nervosa rs13125782 9x10-7 (suggestive) 28494655 
Attention function in attention deficit hyperactive disorder rs4689642 4x10-7 (suggestive) 26174813 
 
 
Gene Trait SNP p-value PUBMED ID 
SORCS2 Depressive and manic episodes in bipolar disorder rs16840900 4x10-6 (suggestive) 26297903 
Neuroticism rs34369999 6x10-6 (suggestive) 27089181 
Risk taking behaviour rs3846425 1x10-8 30643258 
Response to antidepressants (symptom improvement) rs17382228 2x10-6 (suggestive) 29160301 
SORCS3 Attention deficit hyperactivity disorder rs11591402 3x10-9 30478444 
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1.2. DNA DSB formation and repair in 
neuropsychiatric disorders 
1.2.1. Maintenance of genome integrity in the nervous system 
As it is isolated from the environment, the central nervous system (CNS) is protected 
from the most common exogenous sources of DNA damage, such as. UV radiation 
and tobacco smoke. However, endogenous DNA damage occurs both during 
development and in the mature nervous system. During early development, and more 
specifically neurogenesis, the high replication rate of neuronal precursor cells results 
in replication-associated DNA damage. Meanwhile, in mature neurons, the extremely 
high energy demands, and metabolic activity associated with high transcriptional rates 
lead to the production of ROS. ROS, together with their reaction products, such as 
reactive nitrogen species and lipid peroxidation products, constitute the main source 
of DNA damage in the brain106. Recently, neuronal activity has been also linked to 
DNA damage107. The maintenance of cellular genome integrity is vital for long-lived 
cells, such as neurons with no or limited regeneration from precursor cells. 
Accumulation of excessive and/or unrepaired damage can lead to neuronal loss. 
In the nervous system, there are four main DNA damage response (DDR) pathways, 
each of which responds to a particular type of damage106 (Figure 1.4.). The base 
excision repair (BER) pathway detects and corrects base modification caused by the 
production of ROS. Meanwhile, the nucleotide excision repair (NER) mechanism is 
responsible for the repair of DNA lesions resulting in from the exposure to UV radiation 
or chemicals. Single-stranded DNA breaks (SSBs) can arise from damage of the DNA 
backbone caused by ROS, as well as intermediates of the BER pathway, and are 
repaired by the single strand break repair (SSBR) pathway. DNA double-stranded 
breaks (DSBs), the type of DNA lesions discussed in this thesis, can be repaired by 
either non-homologous end joining (NHEJ) or homologous recombination (HR). DSBs 
can be generated in various ways ranging from unrepaired SSBs and replication 
stress (i.e. exposure to ionizing radiation or chemotherapeutic agents)108. Unresolved, 
they are amongst the most dangerous DNA lesions, as they can cause large 
chromosome rearrangements leading to cell death or tumorigenesis. Thus, their 
repair is crucial for cell survival. The choice of the repair pathway depends on the 
presence of specific proteins and the cell cycle. For example, HR occurs only during 
the S- or G2-phase of the cells cycle as it requires the presence of a sister chromatid 
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serving as a template for error-free repair. Meanwhile, NHEJ, an error-prone process, 
involves processing and direct ligation of the damaged DNA ends, without the need 
for a repair template. Thus, NHEJ can take place at any stage of the cell cycle and is 
the only pathway responsible for the repair of DSBs in post-mitotic neurons.  
 
 
Figure 1.4. Types of DNA damage and the corresponding DNA repair pathways. Single base 
damage (e.g. abasic site or oxidised based) are generated by ROS, nitrogen species and other 
metabolic products. This type of DNA lesions is repaired by the BER (base excision repair) 
pathway. Modifications that destroy the double helix (e.g. bulky adducts and instrand 
crosslinks) are repaired by the NER (nucleotide excision repair) pathway. These lesions occur 
as a result of UV radiation, exposure to chemicals and ROS. SSBs (single-stranded DNA 
breaks) can be caused by ROS activity, ionizing radiation and chemotherapeutic reagents and 
are repaired by the SSBR (single-strand break repair) pathways. Meanwhile, DSBs (double-
stranded DNA breaks), caused by ionizing radiation, chemotherapeutic reagents, altered 
TopoII activity and neuronal activity, are repaired via the DSBR (double-strand break repair) 
pathways. [Created with BioRender]  
 
1.2.2. γH2A.X as a DSB marker in the CNS 
The hallmark of DSB formation is the phosphorylation of a major core histone H2A 
variant, H2A.X, on Ser139 (termed γH2A.X). Its role in DNA damage and DSB repair 
was first demonstrated by Rogakou et al. (1998)109, who showed that exposure to 
ionizing radiation led to rapid (as early as 10 min post-irradiation) phosphorylation of 
H2A.X both in vivo and in vitro. Subsequently, it was shown that H2A.X 
phosphorylation appeared as foci, and that their number corresponded directly to the 
number of DSBs110. The rapid induction of γH2A.X foci formation, together with the 
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1:1 ratio between the number of γH2A.X foci and DSBs has made antibodies against 
γH2A.X the ‘gold standard’ for detecting DSBs111. Subsequent work has shown that 
γH2A.X serves as a docking site for various DNA damage response factors, including 
the Mre11 complex, 53BP1 (p53-binding protein 1) and BRCA1112. Alongside 
providing a platform for the DDR machinery, there is evidence that γH2A.X also 
facilitates DNA repair by binding to the broken DNA ends and thus keeping them in 
close proximity113. Apart from radiation, phosphorylation of H2A.X can be induced by 
other genotoxic stressors, such as UV, hydroxyurea, topoisomerase inhibitors, 
environmental and chemical agents112.  
In the mouse brain, phosphorylation of H2A.X was detected throughout the entire 
rosto-caudal axis and in all stages of mouse development- prenatal, postnatal, adult 
and senescence111. In embryos, γH2A.X foci were present in brain areas known for 
their neurogenic capacity: the subgranular zone (SGZ), rostro migratory stream 
(RMS), olfactory bulb (OB) and third ventricle. In these areas γH2A.X foci were 
primarily found in proliferating cells. Meanwhile, in postnatal mice, the strongest 
γH2A.X signal was seen in the cerebellum, reaching its peak at P5-10. A clear 
reduction in the number of γH2A.X-positive nuclei was observed in adult and aged 
mice (two years). After P15, the γH2A.X signal intensity decreased in the cerebellum, 
while increasing in the cerebral cortex. Here, γH2A.X was primarily found in mature 
neurons and most likely as a result of the DNA damage response system activation 
rather than proliferation. In the hippocampus, γH2A.X foci were observed primarily in 
the SVZ of the dentate gyrus in mice aged between P10 and P60111.  
As reported in other tissues, ionizing radiation of embryonic mouse brain led to the 
rapid phosphorylation of H2A.X in both neurons and neuronal progenitor cells. 
Twenty-four hours later, the observed γH2A.X foci were completely abolished in 
neurons, but not in precursor cells, which displayed apoptotic features114. γH2A.X has 
also been shown to provide an early and sensitive marker of neuronal endangerment 
upon non-lethal insults115. In rat cortical neurons, γH2A.X was detected following non-
cytotoxic stimulation of the ionotropic glutamate receptors- NMDA and AMPA 
receptors115. The observed levels of γH2A.X induction were comparable to those 
detected after exposure to other conventional DNA damaging agents (e.g. ionizing 
radiation and hydrogen peroxide) and were shown to be at least partially dependent 
on ROS production. The majority of the detected γH2A.X foci (>50%) co-localised 
with the DSB repair protein Mre11, suggesting that at least a proportion were DNA 
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damage-dependent, as well as showing that the DNA repair pathway was activated. 
The authors of the paper suggested that the proportion of foci that failed to co-localise 
might have represented either transient co-localisation due to the rapid nature of the 
DNA damage detection and repair process or a DSB-independent function of γH2A.X 
(e.g. regulation of gene expression by modification the chromatin structure)115.  
A similar pattern of γH2A.X formation was also observed in vivo. In adult rats, 
recurrent individual seizures following injection with kainic acid (KA) led to a rapid 
(within 30 min) increase in the number of γH2A.X positive foci in multiple brain 
regions, including the hippocampus and the entorhinal cortex. Allowing the animals to 
enter status epilepticus resulted in higher γH2A.X levels after only five minutes 
exposure, with the highest levels reached after 120 minutes. This was the case in all 
brain areas examined, except for the dentate gyrus, which appeared to be resistant 
to seizure-induced DNA damage. Interestingly, the duration of both recurrent seizures 
and status epilepticus, required for γH2A.X induction, was insufficient to cause 
neuronal death116. 
 
1.2.3. DNA DSB formation- physiological function in the CNS and 
in neurodegenerative disorders 
In the developing brain, DNA DSB formation has been associated with DNA synthesis 
and proliferation of neural stem cells as shown by the co-localisation of γH2A.X with 
BrdU and a phosphorylated form of histone H3 (pHH3), respectively 111. In the adult 
brain, γH2A.X foci formation has been shown to be involved in the regulation of adult 
neurogenesis117. More recently, DNA DSB formation has been linked to physiological 
brain activity107 and activity-induced transcription of early- response genes118. 
Suberbielle et al. (2013)107 linked a natural behaviour, exploration of a novel 
environment, to increased DSB formation. Levels of DSB formation were measured 
as the number of neurons in various brain regions, linked to learning and memory 
including the dentate gyrus of WT mice, that were positive for γH2A.X107. Follow-up 
experiments showed that the increase in the number of γH2A.X-positive nuclei was 
the result of neuronal activity, and not stress-induced release of hormones (as 
adrenalectomy had no effect on the observed phenotype). Meanwhile, both exposure 
to visual stimuli and direct optogenetic stimulation led to elevated DSB formation in 
the visual cortex and the striatum on WT mice107. Subsequently, Madabhushi et al. 
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(2015)118 confirmed these observations both in vitro and in vivo. Pharmacological and 
electrophysiological stimulation of primary neurons and hippocampal slices, 
respectively, led to DSB formation accompanied by increased transcription of FOS 
and NPAS4118. Further ChIP-sequencing experiments, following neuronal stimulation 
with NMDA, showed that the γH2A.X signal occurred mostly at the promoters of early-
response genes, including Fos and Npas4118. Similarly to the treatment with NMDA, 
treatment of primary neurons with etoposide, but not other DSB-inducing agents (i.e. 
radiomimetic drugs and DDR inhibitors), resulted in increased expression of the same 
early-response genes. All together these results suggested that the increased 
expression of early-response genes depended on the formation of DSBs as a results 
of Topoisomerase II (TopoII) activity. ChiP-seq, knockdown and immunoprecipitation 
experiments confirmed the role of TopoIIβ in activity-induced DSB formation in 
neurons. Moreover, utilising the CRISPR/Cas9 genome editing technique, 
Madabhushi et al. showed that it was precisely the formation of DSBs that triggered 
the expression of the early-response genes118.  
In addition to the increased DSB formation in WT mice following exploration of a novel 
environment, Suberbielle et al. (2013)107 reported elevated baseline DSB levels in 
hAPP mice- a mouse model of AD, carrying a human APP (hAPP) transgene107. When 
subjected to the same exploratory task, these mice showed an increase in the number 
of neurons positive for γH2A.X comparable to the WT mice, but their capacity of 
repairing these DNA breaks was reduced. hAPP mice show aberrant network activity, 
and interventions that counteract this dysfunction (e.g. genetic ablation of tau or 
administration of anti-epileptic drugs) have been associated with improved synaptic 
and cognitive functions in these mice. Similarly, crossing hAPP mice with a line 
knockout for MAPT (which encodes tau) or treating them with levetiracetam (an anti-
epileptic drug) reduced the number of γH2A.X-positive neurons both at baseline and 
following recovery from the novel environment107. Incubating WT primary neurons with 
Aβ oligomers led to an increase both in the number of cells positive for γH2A.X and 
γH2A.X levels. In agreement with the observations from the hAPP mice, treating these 
cells with a sodium channel blocker (TTX) or with AMPAR or NMDAR antagonists 
abolished the Aβ-induced increase in DSB formation. Based on these results, 
Suberbielle et al. (2013)107 hypothesised that the effect of Aβ on DSB formation 
depended on neurotransmitter release as a results of action potential (AP) generation, 
as well as on the activation of NMDA receptors following AMPAR-mediated 
depolarisation of the synaptic membrane. Further experiments, involving culturing 
Chapter 1 Introduction  34 
neurons under conditions stimulating either NR2A- or NR2B-containing NMDARs, 
showed that the former is required for DSB repair, while the activity of the latter is 
necessary for DSB formation both in the presence and absence of Aβ oligos. While 
activation of NR2B-containing NMDARs is associated with increased production of 
ROS, treatment with the ROS-scavenger Euk-134 had no impact on γH2A.X foci 
formation under these conditions107.  
A follow-up study attributed the accumulation of DSBs in the neurons of hAPP mice 
to defective DNA repair machinery119. Reduced levels of the DSB repair factor BRCA1 
were detected in hAPP mice and were also seen in post-mortem brain tissue from AD 
patients. Knocking down BRCA1 led to increased formation and compromised repair 
of neuronal DSBs both in WT and hAPP transgenic mice. This was accompanied by 
learning and memory deficits, which were more pronounced in the hAPP mice. In WT 
mice, knock-down of BRCA1 was also associated with changes in neuronal 
morphology (e.g. smaller cell bodies and reduced dendritic branching) and function 
(e.g. altered AP frequency and LTP deficits). Meanwhile, increased neuronal activity 
following an exploratory activity (in vivo) or NMDA receptor stimulation (in vitro) 
induced BRCA1 expression. In vivo, this increase was less pronounced in the hAPP 
mice, potentially accounting for the compromised repair of activity-induced DSBs 
observed in them119. Additional post-mortem brain studies provide further evidence 
for the potential role of deficient DNA repair mechanisms in the accumulation of DNA 
damage observed in AD patients 120,121. 
 
1.2.4. DNA DSB formation in neuropsychiatric disorders, with 
focus on AD 
In contrast to the temporary acquisition of DNA DSB formation following neuronal 
activity, accumulation of this type of DNA lesion has been implicated in aging, 
neurodegenerative and neurological conditions, including AD, ataxia-telangiectasia, 
ataxia-telangiectasia-like disorder and Nijmegen breakage syndrome122,123. With 
respect to AD, initial post-mortem brain studies detected increased levels of DNA 
breaks (single- and double- stranded) in the hippocampus and the cerebral cortex of 
AD patients124,125. A more recent study reported increased expression of γH2A.X, 
parallel to that of a protein kinase (DNA-PK) involved in NHEJ, in both neurons and 
astrocytes of aging individuals126. These markers of DNA damage did not, however, 
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correlate with Aβ and tau pathology or Braak stage126. In contrast, further studies 
identified increased levels of DNA damage amongst a subset of early Braak stage 
individuals, who showed lower Mini-mental state examination (MMSE) scores than 
the rest127. Elevated γH2A.X and DNA-PK levels occurred independently of ApoE 
status, vascular pathology or accumulation of Aβ plaques, and were associated with 
increased activity of the senescence-associated protein β-galactosidase, but not with 
the further activation of senescence pathways127. These results suggested that the 
elevated levels of DDR contributed to neuronal dysfunction and cognitive decline 
independently of the development of AD pathology. A more recent paper provided 
further evidence supporting the notion that accumulation of DSBs in susceptible 
neurons and glia cells commences during early AD stages and persists throughout 
the disease progression. Using immunohistochemistry, Shanbhag et al. (2019)128 
detected an increased proportion of γH2A.X-positive neurons and astrocytes in the 
frontal cortex and the CA1 region of the hippocampus of both MCI and AD cases 
compared to cognitively healthy controls. 
Elevated levels of DNA damage have been also reported for a number of psychiatric 
disorders, including MDD, bipolar disorder and schizophrenia129. It is hypothesised 
that this is primarily the result of increased oxidative stress, as the DNA lesions 
detected were positive for 8-OHdG, which is one of the most widely used biomarkers 
of DNA damage due to oxidative stress129. Similarly, increased oxidative stress has 
been reported in post-mortem brains from MCI and AD patients, and elevated levels 
of 8-OHdG have been detected in brains from individuals with late-stage AD130. 
Usually, DNA lesions caused by oxidative stress are repaired by the BER or the NER 
pathways, as discussed in section 1.2.1. However, unrepaired these lesions can 
accumulate, forming oxidative clustered DNA lesions (OCDLs) and eventually leading 
to the formation of DSBs131. There is conflicting evidence of whether γH2A.X provides 
a reliable measure for oxidative stress-induced DNA damage. In vitro, treatment with 
hydrogen peroxide, a commonly used oxidative stress inducing reagent, led to an 
increase in the levels of γH2A.X staining132. However, this signal was distributed 
throughout the nucleus rather than appearing at distinct foci, as observed following 
ionizing radiation. Moreover, the detected γH2A.X staining did not always co-localise 
with 53BP1 or ATM (the main kinase that phosphorylates H2A.X in response to DSB 
formation) and knocking out XRCC4 (a major component of the NHEJ pathway) had 
no effect on γH2A.X elimination. Taken together, these results suggested that the 
observed induction in γH2A.X, as a result of increased oxidative stress, was not the 
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result of DSB formation132. In contrast, another study found that knocking out major 
components of the NHEJ and HR in vitro conferred susceptibility to low doses of 
hydrogen peroxide131.  This was accompanied by an increase in the formation of 
53BP1 foci, partially overlapping with γH2A.X signal, providing evidence that even low 
levels of oxidative stress can trigger the formation of DSBs131.   
 
1.3. LUHMES as a model system 
1.3.1. The LUHMES neuronal cell line 
The LUHMES (Lund Human Mesencephalic) cell line is a karyotypically normal 
human foetal mesencephalic cell line conditionally immortalised with the v-myc 
oncogene133. Proliferation of these neuronal precursor cells can be terminated by 
adding tetracyclin, thus halting v-myc expression. Subsequent addition of 
neurotrophic growth factors (e.g. GDNF) results in differentiation into post-mitotic 
dopaminergic neurons within five days. Five to six days after initiating differentiation, 
the expression of stem cell and neuronal precursor markers, such as SOX2 and 
PAX3, is significantly reduced, while that of neuronal markers, such as synaptophysin, 
synapsin and PSD-95, is strongly upregulated. While the expression of most neuronal 
markers peaks at day 6 and remains stable thereafter, the electrophysiological 
properties of differentiated LUHMES cells have been shown to progressively increase 
with the majority of cells generating spontaneous APs after 10-12 days of 
differentiation133. In addition to expressing pre- and post-synaptic, and dopaminergic 
markers, differentiated LUHMES cells have also been shown to express proteins 
relevant to AD, including APP, Aβ, sAPPβ, tau, p-tau and γ-secretase134. Members of 
the APP gene family, as well as genes involved in APP processing (e.g. α-, β- and γ-
secretases) and turnover (e.g. APOE and LRP1) were expressed in proliferating cells, 
with the expression of some of them increasing dramatically over the course of 
differentiation. At the protein level, a shift in the presence of immature to mature forms 
were observed for BACE and APP. Similarly, sAPPβ and Aβ secretion were 
upregulated upon differentiation, with the latter being triggered by GDNF and 
activation of its co-receptor RET134.   
1.3.2. Relevance of the dopaminergic system in respect to the 
biology of SORLA and SORCS2 
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As described above, LUHMES neurons are dopaminergic, and despite not being the 
most obvious choice of neuron type for studying processes related to learning and 
memory and Aβ pathologies, they were an appropriate model system for this study 
for the reasons described below. First, LUHMES constitute a human neuronal cell line 
that can be easily modified genetically135, which provides the advantage of studying 
human, rather than mouse primary neurons. Second, LUHMES cells can be rapidly 
differentiated into homogenous population of electrophysiologically active 
dopaminergic neurons within less than two weeks. This makes them a more cost and 
time effective in vitro system than iPSCs (induced pluripotent stem cells), which can 
take between 6-15 weeks until differentiated into neurons, depending on the protocol 
and the level of maturity required136. Moreover, both SorCS2 and SorLA have been 
shown to regulate differentiation and proliferation of dopaminergic neurons via 
regulation of BDNF and GDNF activity, respectively3,6.  
Additionally, with regards to AD, studies of both transgenic mouse models of AD and 
patients provide evidence for the involvement of dopaminergic neurons and brain 
circuits in the disease pathology. For example, in a cohort of healthy individuals and 
patients with MCI and AD, functional connectivity between the VTA and the 
hippocampus was correlated with hippocampal volume and memory performance137. 
Moreover, parkinsonism symptoms, such as bradykinesia, face masking, tremors, gait 
disturbances, are commonly seen in AD patients and are often attributed to 
dysfunction of the dopaminergic nigrostriatal pathways138. The presence of 
parkinsonian features and Lewy body pathology has been reported in individuals 
diagnosed with AD and carrying rare mutations in SORL176. Additionally, the AD 
mouse model APP/PS1 was shown to display dopaminergic pathology in the striatum 
and substantia nigra, which was closely associated with age-dependent amyloid 
deposition139. Recent analysis of another murine model of AD (Tg2576) showed 
significant, progressive loss of dopaminergic neurons in the VTA, prior to Aβ 
deposition140. Moreover, the accompanying reduction in dopaminergic innervation to 
the hippocampus was correlated with impairments in synaptic plasticity, memory 
performance and reward processing in these mice140.  
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1.3.3. Using CRISPR/Cas9 genome editing to introduce 
mutations in the LUHMES neuronal cell line 
CRISPR has recently become one of the most popular approaches for genome editing 
due to its simplicity, high specificity and efficiency compared to other editing 
technologies, such as zinc-finger nucleases and transcription activator-like effector 
nucleases141. Derived from the bacteria immune system, CRISPR comprises of two 
components- a ‘guide’ RNA (gRNA) and a non-specific endonuclease- Cas9, which 
is guided to the target DNA by the gRNA via Watson-Crick base pairing141. The target 
DNA can be any 20-nucleotide sequence, preceding a species-specific 3bp 5’ PAM 
sequence, which is necessary for target binding. The Cas9 protein and the gRNA form 
a riboprotein switching the Cas9 protein from an inactive to an active, DNA-binding 
conformation. The Cas9:gRNA complex then binds to any putative DNA sequence 
with a PAM site and if the gRNA and the target DNA match, the former will anneal to 
the later in a 3’ to 5’ direction. At this stage, the Cas9 protein undergoes a second 
conformational change which allows the endonuclease to cleave both strands of the 
target DNA. This results in the formation of a DSB that could be repaired either via 
NHEJ or HDR (homologous-directed repair). In post-mitotic cells, the NHEJ is the 
more active, but also error-prone repair mechanism141. Activation of this pathway can 
result in insertions, deletions or frameshift mutations at the DSB site, potentially 
leading to a gene knockout. While the NHEJ repair mechanism is used for disrupting 
the open reading frame of a gene, the HDR system can be implemented in generating 
specific nucleotide changes ranging from a single nucleotide substitution to large 
insertion. In order to do this, a DNA repair template containing the desired sequence 
must be delivered alongside the gRNA and the Cas9 protein. The repair template can 
take the form of a single- or double-stranded oligonucleotide, as well as a double-
stranded DNA plasmid141 (Figure 1.5).  
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Figure 1.5. Genome editing using CRISPR/Cas9. The first step is the formation of a 
riboprotein, following the gRNA association with the Cas9 protein. The Cas9:gRNA complex 
then bind to the target DNA, which results in the formation of a DSB that could be repaired 
either via NHEJ or HDR. Being error-prone, the NHEJ can lead to insertions, deletions or 
frameshift mutations at the DSB site, potentially generating a knockout. Meanwhile, the HDR 
system can be used to generate specific nucleotide changes by adding a DNA repair template 
containing the desired sequence. [Adapted after https://www.addgene.org/crispr/guide/]. 
 
One of the main considerations when designing CRISPR/Cas9-mediated genome 
editing experiments is ensuring the specificity of the system. This is mostly determined 
by how unique the gRNA target sequence is compared to the rest of the genome. 
Usually, a gRNA target sequence will show partial homology with additional sites, 
known as off- target sites, throughout the genome. The available online tools for gRNA 
design take this into account and can rank the gRNA target sequences for a given 
region of interest based on their predicted on- and off-target activity. The specificity of 
the system can be further increased by using modified versions of the Cas9 
endonuclease, such as the Cas9 nickase (Cas9n), which generates single strand 
nicks in the DNA. Thus, a double nickase is required for introducing a DNA DSBs at 
the target site, which increases the target specificity dramatically. More recently, high 
fidelity Cas9 systems have also been developed, in which mutagenesis has been 
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employed to minimize off-target activity by weakening the enzyme interaction with the 
DNA or increasing its proofreading and target discrimination activity.  
To date the CRISPR-Cas9 genome-editing system has been utilised in creating both 
in vivo and in vitro models for studying human disorders, including AD142. Moreover, 
this strategy has already been successfully implemented in LUHMES cells where it 
has been used to introduce missense mutations in the MECP2 and EEF1A2- genes, 
which have been associated with Rett syndrome and neurodevelopmental delay with 
intellectual disability, respectively135.  
1.4. Main project aims 
The aims of the project discussed in this thesis stem from a few work streams. First, 
as discussed above, DNA DSB formation, associated with γH2A.X foci occurrence, 
has been shown to play a role in the aetiology of many neurological and 
neuropsychiatric conditions, as well as in processes related to learning and memory. 
In mice, increase in neuronal activity as a result of an exploratory activity resulted in 
a transient increase in DSB formation, repaired within 24 hours. In the hAPP mice, 
this phenotype was exacerbated, and in vitro experiments revealed that the Aβ-
induced DSB formation was dependent on NR2B-containing NMDAR activativity107 
Second, genetic and functional studies have implicated the sortilins in cognition, as 
well as in various neurodegenerative and psychiatric disorders. Third, knocking out 
members of the receptor family have been associated with increased APP processing 
and Aβ accumulation (SORLA and sortilin in vivo and in vitro; SORCS1-3 in vitro). 
More recently SorCS2 has also been shown to play a role in NMDAR subunit 
trafficking51. With this in mind, the aims of my PhD project were to:  
1) Investigate the levels of DNA DSB formation in WT, Sorcs2-/- and Sorl1-/- mice, 
exposed to a novel environment task, previously reported to introduce a 
transient increase in the number of DSBs in brain areas important for learning 
and memory.  
2) Knock out SORCS2 and SORL1 in the human neuronal cell line LUHMES and 
assess the effect of the introduced mutations on DSB formation.  
3) Explore potential mechanisms that could account for the observed effect of 
knocking out SORCS2 on DSB formation in vivo and in vitro. 
4)  Introduce the rare EOAD- associated, SORL1 missense mutation G508S and 
examine its impact on SORL1 expression and Aβ production.
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Chapter 2 Materials and Methods 
2.1. Materials 
2.1.1. Buffers, solutions and gel loading dyes 
Table 2.1. Table listing all buffers, solutions and loading dyes used. 
Buffer/ Solution/ 
loading dye 
Component Volume/ weight/ 
concentration 
Laemmli protein 
sample buffer (2x) 
 
Tris (1M, pH 6.8)  
Glycerol 
SDS (20% solution) 
DTT (1M) 
Bromophenol Blue 











SDS (20% solution) 
EDTA 
Orange G 





PBS-T (PBS-Tween) Tween-20 in PBS (1x) 0.2% (v/v) 
PBS-T (PBS-Triton) Triton X-100 in PBS (1x) 0.2% (v/v) 
PBS-T blocking 
buffer  
Semi-skimmed milk (Marvel) 
Tween-20 in PBS (1x) 
5% (w/v) 
0.2% (v/v) 
TBS-T (TBS-Tween) Tween-20 in TBS (1x) 0.2% (v/v) 
TBS-T (TBS-Triton) Triton X-100 in TBS (1x) 0.2% (v/v) 
TBS-T blocking 
buffer  
Semi-skimmed milk (Marvel) 
Tween- 20 in TBS (1x) 
5% (v/v) 
0.2% (v/v) 
1% Triton lysis 
buffer 
(store at -20oC) 
Tris-HCl (1M, pH 8.0) 
EDTA (0.5M) 
Triton X-100 
Qs to 50ml dH2O 





1 tablet to 10ml 
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Buffer/ Solution/ 
loading dye 
Component Volume/ weight/ 
concentration 
TBE buffer (20x) Tris base 
Boric Acid 
EDTA (0.5M, pH 8.0) 







NuPAGE SDS Running buffer 
(20x) (Tris-Acetate) 







NuPAGE Transfer buffer (20x) 
Methanol 




2.1.2. PCR and cDNA synthesis reagents  
Table 2.2. Table of PCR and cDNA synthesis reagents. 
Reagent Supplier Catalogue 
Number 
Bovine Serum Albumin (BSA) New England Biolabs B9000S 
Dimethyl Sulfoxide (DMSO) Sigma D4540 
Deoxynucleoside Triphosphates 
(dNTPs) 
Thermo Scientific 4303442 
MgCl2 Sigma N8080130 
MgSO4 New England Biolabs B1003S 
Multiscribe Reverse 
Transcriptase 
Thermo Scientific 4311235 
PCR buffer Thermo Scientific N8080130 
PCR enhancer Thermo Scientific 11495017 
Q5 High-Fidelity DNA polymerase New England Biolabs M0491S 
Q5 reaction buffer New England Biolabs M0491S 
Random Hexamers Thermo Scientific N808-0127 
Rnase Inhibitor Thermo Scientific N8080119 
Taq DNA polymerase Sigma D1806-1.5KU 
Taq reaction buffer Sigma D1806-1.5KU 
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2.1.3. LUHMES cell culture reagents 
Table 2.3. Table listing LUHMES cell culture reagents. 
Reagent Supplier Catalogue 
Number 
Advanced DMEM/F12 Life Technologies 12634028 
b-FGF Biolegend 571502 
Geltrex LDEV-Free Reduced Growth 
Factor Basement Membrane Matrix 
Thermo Scientific A1413202 
N6,2′-O-Dibutyryladenosine 3′,5′-cyclic 
monophosphate sodium salt (cAMP) 
Sigma D0627 
Distilled Water Life Technologies 15230089 
DMSO Sigma D4540 
Dulbeco PBS (DPBS) Sigma D8537 
Fibronectin Sigma F1141 
GDNF (recombinant, human) R&D 212-GD-010 
L-glutamine  Life Technologies 25030081 
N2 supplement  Life Technologies 17502-048 
Pierce 16% Formaldehyde (PFA) (w/v),  
Methanol-free 
Thermo Scientific 28908 
Poly-L-ornithine, hydrobromide (PLO) Sigma P3655 
Tetracycline hydrochloride Sigma T7660 
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2.1.4. Primary neuron culture reagent 
Table 2.4. Table with primary neuron culture reagents. 
Reagent Supplier Catalogue 
Number 
B27 supplement  Thermo Scientific 17504-044 
DMEM/F12 medium Thermo Scientific 21331-020 
DNAse I Sigma AMPD1 
Dulbeco PBS (DPBS) Sigma D8537 
EDTA Sigma E7889 
Floxuridine  Sigma 50-91-9 
GlutaMAX Thermo Scientific 35050-061 
Laminin Thermo Scientific 23017-015 
Leibovitz's L-15 Medium  Thermo Scientific 11415-064 




Poly-D-Lysine hydrobromide Sigma P7886-50MG 
Primocin Lonza VZA-1021 
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2.1.5. CRISPR/Cas9 reagents 
Table 2.5. A table listing all reagents used in the CRISPR/Cas9 genome editing experiments. 
 
 
2.1.6. Oligonucleotides used in the CRIPSR/Cas9 genome 
editing experiments 
Table 2.6. Table listing all oligonucleotides used in the CRISPR/Cas9 genome editing 
experiments. 
Oligonucleotide  Sequence 
Oligonucleotides used to knock out SORCS2 in LUHMES cells 
SORCS2 exon 1 top CACCGCGGGATGGCTTCGCGGGCGC 
SORCS2 exon 1 bottom AAACGCGCCCGCGAAGCCACTCCGC 
SORCS2 exon 3 top CACCGGTAGAAATTGTCGATGACGG 
SORCS2 exon 3 bottom AAACCCGTCATCGACAATTTCTACC 
SORCS2 exon 25 top CACCGACATCAGCTTCCGCTCCGAT 
SORCS2 exon 25 bottom AAACATCGGAGCGGAAGCTGATGTC 
Oligonucleotides used to knock out SORL1 in LUHMES cells 
SORL1 exon 31 top CACCGTCGGTACCCGTCGCACACCC 
Reagent Supplier Catalogue 
Number 
ATP (10mM) New England BioLabs P0756S 
DTT (10mM) Thermo Scientific R0862 
E.coli Stbl3 strain Life Technologies C7373-03 
FastDigest BbsI Thermo Scientific FD1014 
PlasmidSafe buffer (10x) Epicentre  E3101K 
PlasmidSafe exonuclease Epicentre  E3101K 
Tango buffer (10x) Thermo Scientific  BY5 
T4 ligation buffer (10x) New England BioLabs B0202S 
T4 PNK New England BioLabs M0201S 
T7 ligase with rapid ligation 
buffer (2x) 
Enzymatics L602L 
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SORL1 exon 31 bottom AAACGGGTGTGCGACGGGTACCGAC 
Oligonucleotides used to introduce the G508S mutation in LUHMES cells  
SORL1 exon 10 top CACCGACTTACCAGTGGCGATGATG 





2.1.7. PCR and sequencing primers 
Table 2.7. Table with PCR and sequencing primers. 
Primer Sequence 
SORCS2 exon 1 forward 5’ CCTTTCTCTGCGCTCTCG 3’ 
SORCS2 exon 1 reverse 5’ CCGCCCCTGATGACCATA 3’ 
SORCS2 exon 3 forward 5’ CAGAGTGCCCAGGACTGTAC 3’ 
SORCS2 exon 3 reverse 5’ ATGTGCCCTAGGTATGCAGG 3’ 
SORCS2 exon 25 forward 5’ CCTCCACTGACAACCGCTTT 3’ 
SORCS2 exon 25 reverse 5’ GGCCCTTTCTAGATCTGCCT 3’ 
SORL1 exon 10 forward 5’ TTTACAGGGAACGCTAGGCA 3’ 
SORL1 exon 10 reverse 5’ TTGAGAACAGGCAAGCACAC 3’ 
SORL1 exon 9-12 forward 5’ CCATTTGCTGACTTCCACCG 3’ 
SORL1 exon 9-12 reverse 5’ TAGTGAGGTCCAGGAAGTGC 5’ 
SORL1 exon 31 forward 5’ CTGCTCAGAGCTGTGCCAGT 3’ 
SORL1 exon 31 reverse 5’ AGCCTTCCCTGGAGGTACAC 3’  
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2.1.8. RT-PCR primers 
Table 2.8. Table listing the RT-PCR primers used to screen for SORCS2 isoforms. 
Primer Sequence 
SORCS2 pair (1) forward 5’ GATCAGCTTCCTCCTGCGAG 3’ 
SORCS2 pair (1) reverse 5’ CCTGGCCGTTTCCTTTTGAA 3’ 
SORCS2 pair (2) forward 5’ TTCAAAAGGAAACGGCCAGG 3’ 
SORCS2 pair (2) reverse 5’ AGTTGATGCTCAGGACCACG 3’ 
SORCS2 pair (3) forward 5’ CTGTCCAGGGCAACCACTCA 3’ 
SORCS2 pair (3) reverse 5’ CTCCGTGGGTGAAAAGACAGA 3’ 
SORCS2 pair (4) forward 5’ TCATCCTCTACAAGTTCAAAAGCAG 3’ 
SORCS2 pair (4) reverse 5’ CCTGAGTGGTTGCCTAGAGTCTG 
SORCS2 pair (5) forward 5’ AGTTCAAAAGGAAACAGGCCAG 3’ 
SORCS2 pair (5) reverse 5’ GCCTGAGTGGTTGCCTAGAG 3’  
SORCS2 pair (6) forward 5’ GATCCCCACGCAGGCAAC 3’ 
SORCS2 pair (6) reverse 5’ CCCTCCGTGGGTGAAAAGAC 3’ 
SORCS2 pair (7) forward 5’ TTCAAAAGCAGGAAACGGCCA 3’ 
SORCS2 pair (7) reverse 5’ CAGCGTCCACATGTCTCAGAT 
SORCS2 pair (8) forward 5’ TGCTGAACGCACAGAAGATCA 3’ 
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2.1.9. qRT-PCR probes  











Gene  Probe Number Supplier 
ATP5B ge-DD-6-ATP5B Primerdesign ltd. 
ENOX2 ge-DD-6-ENOX2 Primerdesign ltd. 
ERCC6 ge-DD-6-ERCC6 Primerdesign ltd. 
RNF20 ge-DD-6-RNF20 Primerdesign ltd. 
RPLPO Hs00420895_gH Applied Biosystems 
SCLY ge-DD-6-SCLY Primerdesign ltd. 
SDHA ge-DD-6-SDHA Primerdesign ltd. 
SORCS1 Hs00364666_m1 Applied Biosystems 
SORCS2 Hs00325181_m1 Applied Biosystems 
SORCS3 Hs01039447_m1 Applied Biosystems 
SORL1 Hs00268342_m1 Applied Biosystems 
SORL1 Hs00983791_m1 Applied Biosystems 
SORT1 Hs00361760_m1 Applied Biosystems 
TBP Hs00427620_m1 Applied Biosystems 
UBC ge-DD-6-UBC Primerdesign ltd. 
UBE4A ge-DD-6-UBE4A Primerdesign ltd. 
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2.1.10. Antibodies 








Antibody Concentration Supplier Catalogue 
Number 
Primary Antibodies 
53BP1 1:1000 Abcam ab36823 
β-tubulin 1:1000 Abcam ab15568 
γH2A.X 1:50 (IF);  
1:400 (ICC) 
Merk 05-636 
GAPDH 1:10, 000 Merk MAB374 
SORLA 1: 750 R&D systems AF5699 
SORCS2 1:750 R&D systems AF4238 
SORCS2 (custom made) 1:1000 Dako F7100 
Vinculin 1:1000 Cell Signalling  13901S 
Secondary Antibodies 
Alexa Fluor® 488 Donkey 




Alexa Fluor® 568 Donkey 






1:1000 Dako P0260 
Rabbit Anti-Sheep 
Immunoglobulins/HRP 
1:1000 Dako P0163 
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2.2. Methods 
2.2.1. Animals and behavioural experiments 
2.2.1.1. Animals 
Mice were bred and housed at the animal facility at Aarhus University, in groups of up 
to five mice per cage. WT and knockout mice were derived from different cohorts as 
breading was done on homozygous mice (i.e. full knockout and full WT breading). 
Mice of the same genotype were littermates; all mice (knockout and WT) were on the 
same background: C57Bl/6JBomTac (Taconic). Behavioural experiments were 
carried out using sex- and age-matched mice- male, 5-6 months old. Each of the 
behavioural tests described below were carried out in Denmark, using naïve animals 
in a randomized order by an investigator blinded to the mouse genotype. No animals 
were excluded from the subsequent analysis.   
2.2.1.2. Exploration of a novel environment  
Mice in the control group (here defined as ‘home cage’) were kept in their original 
cages. Mice in the novel environment (‘Novel E’) and the recovery from the novel 
environment (‘recovery’) groups were transferred to the testing room, where they were 
individually exposed to a novel environment for 2h. The novel environment consisted 
of an Open Field Arena with four different novel objects and mint-like odour. After the 
exploratory activity, the mice in the Novel E group were sacrificed. The mice belonging 
to the recovery group were returned to the initial cages, where they recovered from 
the behavioural task for 24h before being sacrificed together with the mice from the 
home cage group. The behaviour of the mice during the novel environment task, as 
well as in their home cages was not recorded.  
2.2.1.3. Perfusion and tissue processing 
Mice were perfused transcardially with cold PBS containing heparin (10,000 U/L), 
followed by ice-cold 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). 
Whole brains were dissected and post-fixed overnight in 4% PFA in PBS. Following 
post-fixation, brains were rinsed in sterile PBS, transferred to fresh PBS and shipped 
to Edinburgh. Here, they were cryoprotected first in 10% sucrose and then in 30% 
sucrose at 4oC until the tissue sank to the bottom of the tube. Brains were 
subsequently embedded in OCT compound on dry ice and stored at -80oC. Coronal 
sections (14μm thick) containing the brain areas of interest (i.e. dentate gyrus, the 
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CA2 and the CA3 region of the hippocampus) were obtained using the cryostat and 
mounted directly onto Superfrost slides (Cat No 10149870, Thermo Scientific). Slide 
were stored at -80oC until required. For the initial experiments, three serial sections 
corresponding to bregma -1.64mm were mounted onto the same slide and stained as 
described in 2.2.4. For the subsequent experiments, three brain sections 
corresponding to bregmas -1.64mm, -2.155mm and -2.555mm were obtained, 
mounted onto the same slide and stained. 
 
2.2.2. LUHMES cell culture protocol 
Low passage number proliferating LUHMES cells (P3) were kindly provided by Dr 
Faith Davies and Professor Cathy Abbott (Institute of Genetics and Molecular 
Medicine, The University of Edinburgh).  
LUHMES cells were grown and differentiated at 37°C in a humidified 95% air and 5% 
CO2 atmosphere. Cell culture flasks were pre-coated with PLO (1mg/ml) and 
fibronectin (1mg/ml) in distilled H2O (dH2O) for at least 3 hours at 37oC. Following 
incubation, the coating solution was aspirated, and the flasks washed two times with 
dH2O and air-dried before cell seeding.  
LUHMES cells were thawed by warming up the cryovial in a water batch set at 37oC. 
5ml of warm Advanced DMEM/F12 without additives were slowly added to the thawed 
cells, which were then centrifuged at 300g for 5 minutes. The supernatant was 
aspirated, cells resuspended in 5ml warm proliferation medium and transferred to a 
pre-coated T25 cell culture flask. Proliferation medium consisted of Advanced 
DMEM/F12, L-glutamine (200 mM), N2 supplement (100x), and b-FGF (160 μg/ml). 
Proliferating LUHMES cells were maintained until reaching about 85% confluence and 
then passaged. Medium was aspirated and cells were detached by adding trypLE, 
collected in Advanced DMEM/F12 without additives and centrifuged at 300g for 5 
minutes at room temperature (RT). The cell pellet was resuspended in proliferation 
medium. For generating frozen stocks, cells were resuspended in proliferation media 
containing 20% foetal calf serum (FCS) and 10% DMSO and transferred to pre-cooled 
cryovials. Cryovials were stored in Mr Frosty™ for at least 48 hours at -80°C before 
being transferred for storage in liquid nitrogen. 
Proliferating LUHMES cells were differentiated according to the protocol described by 
Scholtz et al. (2011)133. Four million cells were plated in a pre-coated T75 flask 
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containing 12ml of proliferation medium. After 24 hours, proliferation medium was 
exchanged with differentiation medium, consisting of Advanced DMEM/F12, L-
glutamine (200 mM), N2 supplement (100x), cAMP (100mM), tetracycline (1 mg/ml), 
and recombinant human GDNF (20 μg/ml). Following 48 hours of predifferentiation, 
cells were detached as described above, counted and replated in pre-coated cell 
culture plates. Seeding densities and differentiation medium volume are listed in 
Table 2.11. Differentiated cells were grown up to day 14 and fed every second day by 
replacing half the medium with freshly prepared differentiation medium. 
Table 2.11. Table showing the seeding densities and differentiation medium volume required 
for a given size of cell culture plastic plate. 
Cell culture plate 6 well 12 well 24 well 
Growth area (cm2) 9.6 3.5 1.9 
Volume of medium per well 2ml 1ml 500µl 
Cell number to seed per 
well 
1.1x106 0.55x106 0.15x106 
 
 
2.2.3. Primary hippocampal neuron culture 
Acid-etched coverslips, placed in 24-well plates, were coated with Poly-D-lysine for at 
least 2 hours at 37oC. Following incubation, the coverslips were washed three times 
with dH2O and air-dried for 30 minutes. Laminin was then added to each coverslip 
and incubated for another 2 hours at 37oC. 
Postnatal day 0 (P0) WT and Sorcs2-/- mouse pups were decapitated, the brains 
removed, and hippocampi isolated in ice cold DPBS. The dissected tissue was 
immediately transferred to ice cold Leibovitz's L-15 medium and kept on ice. 
Subsequently, the hippocampi were centrifuged for a minute at 1200rp, the 
supernatant was carefully removed and the sedimented tissue was digested for 30 
minutes at 37oC in filter-sterilised papain solution. The papain solution was prepared 
in advance and contained 10ml of pre-warmed L-15 medium, 40µl EDTA (0.5M) and 
167µl papain. The pH of the solution was adjusted by adding 60µl of NaOH (0.2M). 
After 30 minutes, the digestion was stopped by adding 5ml of DMEM/FCS (i.e. DMEM 
supplemented with 10% FCS, primocin (100µg/ml) and 5µl of DNAse I. The tissue 
was centrifuged for 1 minute at 1200rpm and resuspended until fully dissolved in 1ml 
Chapter 2 Materials and Methods  53 
of DMEM/FCS containing DNAse I (0.01mg/ml). Further 10ml of DMEM/FCS were 
added and the suspension was centrifuged for 5 minutes at 1200rpm. The 
supernatant was removed carefully, and the pellet was resuspended in Neurobasal 
medium containing B-27 Supplement (1ml of B27 in 50ml of Neurobasal medium), 
GlutaMAX (2mM), Primocin (100 μg/mL), floxuridine (20µM) and uridine (20µM). Cells 
were counted and seeded at a density of 150,000 cells per coverslip. The neurons 
were grown for 12 days at 37°C, in 5% CO2. Cells were fed every second day with 
Neurobasal medium supplemented with B27 before being fixed with 4% PFA in PBS. 
 
2.2.4. Immunofluorescence on frozen brain sections 
A modified immunofluorescence version of the protocol described by Crowe et al. 
(2011)116 was performed as follows: brain sections containing areas of interest were 
thawed at RT for 15 minutes, incubated for 10 minutes in 4% PFA in PBS and then 
thoroughly washed in PBS (1X) containing 100 mM glycine (Cat. No 3570, EMD 
Millipore) followed by PBS (1X), each wash for 30 minutes. Antigen retrieval was 
subsequently performed by placing the slides in sodium citrate buffer (1X), pH 6.0 
(Cat. No C1909, Sigma) heated to 95°C, and pulse-heated for 20 minutes in the citrate 
buffer in the microwave. Slides were allowed to cool for 20 minutes inside the 
microwave, followed by 30 minutes at RT. Slides were then washed 3 times in PBS 
(1X) for 15 minutes each wash and incubated for 1.5 hours in blocking solution 
consisting of 5% normal goat serum (Cat. No D9663, Sigma), 1% BSA (Cat. No 
422351S, VWR), 0.1% Triton-X and 0.05% Tween-20 in PBS (1X) at RT. Slices were 
subsequently incubated with mouse anti-γH2A.X primary antibody (1:50) diluted in 
PBS (1X) containing 5% normal donkey serum and 1% BSA overnight at 4°C. The 
day after, slides were further incubated for another 30 minutes at 37°C. Following 
three washes with PBS (15 minutes each), sections were incubated with 3% Sudan 
black solution prepared in 70% ethanol for 10 minutes at RT. Slides were rinsed in 
dH2O and secondary antibody (Alexa fluor-donkey anti-mouse 488), diluted 1:500 in 
5% normal goat serum in PBS (1x), was subsequently added. Sections were 
incubated with secondary antibody for 1 hour at 37°C, and washed 3 times in PBS 
(1x), followed by 3 times in dH2O, each wash for 15 minutes. DAPI (1:1000 in PBS) 
was subsequently applied for 10 minutes and washed off with PBS (3 washes, 5 
minutes each). Sections were mounted in ProLong Gold antifade mountant (Cat No. 
P36934, Thermo Scientific).  
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Specific areas within the dentate gyrus, the CA2 and the CA3 region of the 
hippocampus were selected. Z-stacked confocal images, with a step size of 0.25µm, 
were acquired on a Nikon STORM/ A1+ microscope at 60x magnification, using the 
NIS Elements software. The optimal laser intensity and gain, which did not give a 
signal in the no-primary antibody control, were established and kept constant among 
all experimental groups. Three images, belonging to the frontal, middle and dorsal 
part of the hippocampus, were obtained for each mouse. Images were blinded and 
analysed using the software package Fiji143. The number of neurons having one or 
more γH2A.X-positive foci, as well as the total number of nuclei within a given area 
were manually counted. The percentage of γ-H2A.X-positive nuclei was determined 
for every image.  
 
2.2.5. Creating mutant cell lines using CRISPR/Cas9 genome 
editing 
2.2.5.1. Cloning of gRNA oligonucleotides into the pSpCas9(BB)-2A-GFP 
(Px458) vector 
Guide RNAs (gRNAs) (Table 2.1.) were received as powder and lyophilised in dH2O 
to a final concentration of 100µM. gRNAs were phosphorylated and annealed as 
follows.  
The following master mix was prepared for each gRNA:  
Component Volume 
(µl) 
gRNA top (100µM) 1 
gRNA bottom (100µM) 1 
T4 ligation buffer, 10x 1 
T4 polynucleotide kinase 1 
ddH2O 6 
 
The mixture was then incubated in a thermocycler using the following parameters: 
37oC for 30 minutes, followed by 95oC for 5 minutes and ramped down to 25oC at 5oC 
per minute. 
The phosphorylated and annealed gRNAs were subsequently diluted 1:200 by adding 
1µl of the gRNA mix to 199µl of ddH2O. The gRNAs were then ligated into the 
pSpCas9(BB)-2A-GFP plasmid (kindly provided by Dr Lora Boteva and Professor 
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Nick Gilbert, Institute of Genetics and Molecular Medicine, The University of 
Edinburgh) by setting up the following reaction: 
Component Volume (µl) 
Diluted gRNA duplex 1 
pSpCas9(BB)-2-GFP, 100ng 1 
Tango buffer, 10x 2 
DTT, 10mM 1 
ATP, 10mM 1 
Fast Digest BbsI 1 
T4 ligase 0.5 
ddH2O 11.5 
 
The ligation reaction was incubated for a total of 1 hour, comprising of 6 cycles of 
37°C for 5 minutes, followed by 21°C for 5 minutes. Following incubation, the 
reactions were cleaned from any residual linearised DNA by treating them with 
PlasmidSafe ATP-dependent DNase for 30 minutes at 37oC, followed by 70oC for 30 
minutes.  
Component Volume (µl) 
Ligation reaction 11 
PlasmidSafe Buffer 1.5 





The reaction was then stored at -20°C until transformation. 
 
2.2.5.2. gRNA transformation 
The pSpCas9(BB)-2A-GFP plasmid, with the gRNA ligated into it, was transformed 
into One Shot Stbl3 chemically competent E.coli (Cat No C737303, Thermo Scientific) 
as follows: A vial of Stbl3 cells was thawed on ice for each transformation reaction. 
2µl of the PlasmidSafe-treated ligation reaction was added to the cells and mixed 
gently. 1µl of the pUC19 control (10pg) was included for estimating the transformation 
efficiency. The cell-DNA mixes were incubated on ice for 30 minutes, and then heat-
shocked at 42oC for 45 seconds, followed by 2 minutes on ice. 250µl pre-warmed 
(37oC) S.O.C. medium was added to each vial, after which the vials were incubated 
at 37oC for 1 hour with constant horizontal agitation. Following incubation, three 
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different volumes (25µl, 75µl and 150µl) were spread on pre-warmed ampicillin- 
selective L-broth (LB) agar plates and incubated at 37oC overnight.  
The next day single colonies were identified, and ten colonies per gRNA were 
individually picked into 5ml LB, containing 100µg/ml ampicillin. After an overnight 
incubation at 37oC with constant agitation, glycerol stocks were prepared by adding 
200µl of 50% glycerol to 800µl of each culture. The mix was transferred to a cryovial 
and stored at -80oC. DNA was isolated from the rest of the culture using a mini prep 
kit (Cat No. 27104, Qiagen), following the manufacturer’s instructions. The obtained 
DNA was then sequenced to insure insertion of the gRNA into the pSpCas9(BB)-2A-
GFP plasmid.  
Once the correct gRNA insertion was confirmed using sequencing analysis, the 
desired plasmids were recovered from the glycerol stocks by scraping some bacteria 
and streaking it onto a pre-warmed LB agar plate, containing ampicillin (100µg/ml). 
Plates were incubated at 37oC overnight. As before, single colonies were picked 
initially into 5ml of LB with ampicillin and incubated for 6 hours at 37oC, which were 
then transferred to 250ml of LB with ampicillin (100µg/ml) and incubated overnight at 
37oC. DNA was extracted using the Endo-free Maxiprep kit (Cat No. 12362, Qiagen) 
following the manufacturer’s instructions.  
2.2.5.3. Transfection of proliferating LUHMES cells 
Low passage number proliferating LUHMES cells (P5) were grown as described 
above until reaching 75% confluence. Two hours before transfection, cells were fed 
with fresh proliferation media. Subsequently, cells were harvested and counted. For 
each transfection reaction, 2x106 cells were aliquoted into a new 4ml transfection tube 
and centrifuged at 90g for 10 minutes at RT. All medium was carefully aspirated, and 
the cell pellet was resuspended in 100µl freshly prepared nucleofect solution provided 
by the basic nucleofector kit for primary neurons (Cat No VAPI-1003, Lonza). The 
required DNA was added to the mixture. Generally, 2µg of the Cas9 plasmid 
containing the gRNA of interest was transfected, and in the experiments that required 
the incorporation of a repair template- 10µl of ssODN at concentration 10 µM. A 
transfection reaction where 2µg of a GFP-positive control plasmid was added to the 
cells served as a positive control. Each suspension was then transferred to a 
nucleofector cuvette and nucleofected using program D-33 on the Amaxa 
Nucleofector II D device. 500µl of prewarmed RPMI (Cat No BE12-752F, Lonza) was 
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gently added to each cuvette following nucleofection. The cells were then incubated 
at 37oC for 5 minutes and gently added to precoated 6-well plates containing 2ml of 
freshly made proliferation medium.  
Forty-eight hours following transfection, cells were lifted as described before and 
centrifuged at 90g for 10min. The cell pellets were then resuspended in 500µl of warm 
DPBS. Cells that were successfully transfected were sorted into precoated 96-well 
plates, containing 100µl of freshly prepared proliferation medium, by Elisabeth Freyer 
(Institute of Genetics and Molecular Medicine, The University of Edinburgh) using 
FACS (fluorescence-activated cell sorting). After seven days, 100µl of fresh 
proliferation medium was added to each well, and after ten days- single cell colonies 
were identified and transferred to 24-well plates for further expansion. In general, at 
this stage, one third of the cells was kept for genotyping, and the rest were split into 
two wells of a 24-well plate.  
 
2.2.6. Genotyping of the generated mutant clones 
2.2.6.1. DNA extraction 
The collected cells were centrifuged at maximum speed for 5 minutes at RT. The 
media was gently removed, and the cell pellet was resuspended in 200µl of PBS. 
DNA was isolated using the DNeasy Blood and Tissue kit (Cat No 69504, Qiagen), 
according to the manufacturer’s instructions. The quality and concentration of the 
obtained DNA was assessed using NanoDrop.   
2.2.6.2. General PCR protocol 
PCR amplification was carried out using a Sigma protocol in a total reaction volume 
of 20µl as follows: 0.2µl Sigma Taq Polymerase (5U/μl), 2µl Sigma buffer (10x) and 
0.6µl dTNPs (5mM), 0.5µl primers (20µM).  
PCR reaction with additives was set up for the GC-rich regions using 0.3µl Sigma Taq 
Polymerase (5U/μl), 2µl Sigma buffer (10x), 2µl PCR enhancer, 0.52µl MgSO4 
(50mM), 0.6µl BSA (1/10), 0.6µl DMSO, 0.6µl dNTPs (5mM) and 0.6µl primers 
(20µm).  
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PCR with high fidelity DNA polymerase was set up for genotyping the generated 
G508S knock-in clones as follows: for 25µl reaction- 0.25µl Q5 high-fidelity DNA 
polymerase, 5µl Q5 reaction buffer (5x), 0.5µl dNTPs (10mM), 2.5µl primers (10µM).  
All used primer pairs are listed in Table 2.7. Template and water volumes were 
adjusted based on the starting genomic DNA concentration. 
Generally, all PCR reactions were run on a standard touch-down PCR program, 
altering the Primer Melting Temperature. 









minus 1oC per cycle for 10 cycles 
 
72oC 1 min 
 






72oC 1 min 
 
   
72oC 10mins 
 
   
Hold at 10oC until ready to take off block 
End 
   
2.2.6.3. General sequencing protocol 
PCR products were prepared for Sanger sequencing. Generally, 1µl of PCR product 
(10-50ng/ 100bp) was cleaned from excess nucleotides and primers by using 
ExoSap-IT (Cat No 78250.40, Life Technologies). The following master mix was 
prepared:  
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Component Volume (µl) 




The reactions were incubated at 37oC for 60 minutes, followed by 80oC for 20 minutes 
in a thermocycler.  
The following sequencing reaction was set up for each sample, using the primers 
listed in 2.1.7.  
Component  Volume 
(µl) 
ExoSap-IT treated PCR product 5 
Big Dye v3.1 (Cat No 4337457, 
Thermo Scientific) 
1 
Big Dye sequencing buffer, (5x, 
Thermo Scientific) 
1 
Primer (3.2µM) 1 
dH2O 2 
 
The reactions were run in a thermocycler using the following conditions:  









60oC 4 min 
 
Hold at 10oC until ready to take off block 
   
The sequencing reactions were subsequently cleaned by adding 2.5µl of EDTA 
(125mM), followed by 30µl of 95% ethanol. The samples were mixed by inverting four 
times and incubated for 15 minutes at RT. Subsequently, they were centrifuged at 
3000rpm for 30 minutes at 4oC, the ethanol was removed, and the DNA was washed 
from excess salts by adding 30µl 70% ethanol to each reaction. Samples were then 
centrifuged for another 15 minutes at the same speed, the ethanol was removed, and 
Chapter 2 Materials and Methods  60 
the pellet was left to air dry at RT for 30 minutes. Reactions were stored at -20°C prior 
to processing on 3730 Genetic Analyser (Applied Biosystems). 
2.2.6.4. TOPO cloning  
When a PCR reaction showed two bands on the agarose gel or failed to give a clean 
sequencing tracing, TOPO TA cloning was performed according to the manufacturer’s 
instruction (Cat No 450071, Life Technologies). In brief, 2μl of fresh PCR product was 
mixed with 2μl dH2O, 1μl of salt solution and 1μl TOPO vector provided with the TOPO 
TA cloning kit. The reaction was mixed and incubated at room temperature for 30 
minutes, before being transformed into chemically competent E. coli cells (DH5α) as 
described in section 2.2.3.2. Twenty colonies were picked per PCR reaction. Each 
colony was boiled in 50µl dH2O for 10 minutes and then used as a PCR template. 
PCR amplification was performed following the general PCR protocol described in 
2.2.4.2.  
 
2.2.7. Quantitative reverse transcriptase PCR (qRT-PCR)  
Cell pellets from proliferating or differentiated LUHMES cells were obtained and 
resuspended in RLT buffer from the RNeasy mini kit (Cat No 74104, Qiagen) with 
10% (v/v) 2-mercaptoethanol. Once resuspended, the pellets were immediately 
frozen on dry ice and stored at -80oC until required. Total RNA was extracted from 
each sample using the RNeasy mini kit, according to the manufacturer’s instructions. 
The quality and concentration of the obtained RNA was assessed using the 
NanoDrop.   
Total RNA (1µg per sample) was reverse transcribed with Multiscribe Reverse 
Transcriptase using random hexamers in a 80µl reaction, following the manufacturer’s 
protocol. A ‘minus RT’ control, in which 25ng RNA of each sample was used to make 
cDNA in the absence of the Multiscribe Reverse Transcriptase, was included to detect 
genomic contamination. Meanwhile, a ‘no RNA’ containing all components of the kit 
used except for the RNA was also included. cDNA was then stored at -20°C until 
required.  
PCR amplification of the cDNA obtained for each sample was quantified using the 
TaqMan® Universal PCR Mix No AmpErase® UNG (Cat No 4324018, Life 
Technologies), and the threshold cycle (Ct) was determined using the Applied 
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Biosystems 7900HT Fast Real-Time PCR System and the corresponding SDS 
software. TaqMan probes were used for the detection of both the genes of interest 
(GOIs) and the reference genes (see section 2.1.9.). Eight reference gene controls 
were analysed in the sample set and the GeNorm software was used to identify the 
most stably expressed ones. A standard curve, generated from a dilution series, was 
run for each of the GeNorm selected stable reference genes, as well as the GOIs. 
The baseline and Ct values were determined for each gene and the GOI expression 
levels were calculated using the standard curve method for absolute quantification, 
where unknowns are compared to the generated standard curve and values are 
extrapolated. The GOI expression values were subsequently normalised to the 
geometric mean of the reference genes. 
 
2.2.8. Western blot analysis 
2.2.8.1. Protein extraction 
Protein was normally extracted from three wells of a six-well plate, with each well 
containing 1.1x106 cells. After aspiration of cell medium, cells were placed on ice and 
washed once with ice cold DPBS. 50ul of ice cold 1% Triton lysis buffer were added 
to each well, and the plate was left on ice. After one minute, cells were scraped off 
the bottom of the well with a cell scraper, and the lysed cells from the three wells were 
collected into a single microcentrifuge tube. The lysates were then thoroughly mixed 
on a tube rotator at 4°C for 30 minutes, followed by a centrifugation at a maximum 
speed (13,300g) at 4°C for 15 minutes. Supernatants were transferred to a new tube 
and the pellets were discarded. 10µl of the lysate obtained were aliquoted into a new 
tube, and equal volume of Laemmli buffer (2x) was added to the rest of the sample. 
The former was used to quantify the protein concentration using the Bio-Rad BSA 
protein assay (Cat No 5000116, Bio-Rad).  
 
2.2.8.2. Quantification of protein lysate concentration 
The Bio-Rad BCA protein assay kit was used to quantify protein levels in cell lysate 
samples. Protein standards, ranging from 0mg/ml to 2mg/ml, were prepared by 
diluting a known concentration of BSA (2mg/ml, Cat No 23209, Life Technologies) 
with dH2O as diluent (see below). 5ul of each protein standard concentration was 
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pipetted in duplicate into a 96 well plate. Cell lysates were diluted 1:2, and 5ul of each 
was pipetted into the plate in triplicate. 
Table 2.12. Table showing the amount of BSA (2mg/ml) and dH2O required for generating a 
given concentration from the standard curve. 
Concentration 
(mg/ml) 
2mg/ml BSA (µl) dH2O (µl) 
0 0 20.0 
0.2 2.0 18.0 
0.4 4.0 16.0 
0.6 6.0 14.0 
0.8 8.0 12.0 
1.0 10.0 10.0 
1.2 12.0 8.0 
1.4 14.0 6.0 
1.6 16.0 4.0 
1.8 18.0 2.0 
2.0 20.0 0 
 
The assay working reagent was made up by mixing reagents A and S in the ratio 50:1. 
25ul of reagent A+S was added to each well, followed by 200µl of reagent B. The 
plate was incubated at RT for 10 minutes, and absorbance was measured at 450nm 
using a FLUOstar Omega plate reader. Concentrations of cell lysates were 
extrapolated from the standard curve.  
Following quantification, Laemmli sample buffer (2x) was added in a 1:1 ratio, and the 
samples were subsequently boiled in a heat block for 5 minutes at 95oC. Samples 
were stored at -20oC until required.  
 
2.2.8.3. SDS-PAGE electrophoresis  
NuPAGE Tris-acetate (3 -8%) precast gels were purchased from Life Technologies 
(Cat No EA03752BOX) and placed in a XCell SureLock Mini-cell tank according to 
the manufacturer’s instructions. Approximately 200ml of Tris-acetate running buffer 
(Cat No LA0041, Life Technologies) were added to fill the upper (inner) buffer 
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chamber, with the buffer level exceeding the level of the wells. Up to 25µl of each 
sample (based on the estimated total protein concentration) were added to the wells, 
alongside 7µl of All Blue protein ladder (Cat No 1610373, Bio-Rad). The lower (outer) 
chamber was filled in with running buffer, and the gel was run at 150V for 1 hour and 
30 minutes until the blue dye front reached the bottom of the gel.   
2.2.8.4. Western blot transfer  
After electrophoresis, proteins were transferred from the gel to a membrane using the 
wet blotting method. Transfer buffer was prepared by making up NuPAGE Transfer 
buffer (1x) in dH2O with 10% methanol (or 20% when large proteins were examined). 
Pads were subsequently soaked in transfer buffer until saturated and any air bubbles 
were removed by squeezing them out before use. PVDF membranes (Cat No 
LC2002, Life Technologies) were activated in methanol for 30 seconds, briefly 
washed in dH2O and equilibrated in transfer buffer for several minutes.  
The tank was disassembled, and the gel was removed from the plastic cassette using 
a gel knife. A transfer sandwich was assembled by placing a piece of pre-soaked filter 
paper on top of the gel, after which the gel was turned over and the pre-wet membrane 
was placed on the gel, followed by another pre-soaked filter paper. Any bubbles were 
removed using a plastic roller. Three pre-soaked blotting pads were placed in the 
cathode core of the transfer module. The transfer sandwich was carefully placed on 
them, followed by another three pre-wet blotting pads. The anode core was placed on 
top of the pads, and the assembly was transferred to the XCell SureLock Mini-cell 
tank and secured in place with a gel tension wedge provided. Transfer buffer was 
added to the inner chamber, and 500ml of dH2O were added to the lower chamber. 
Transfer was carried out at 30V for 1.5 hours at 4oC 
2.2.8.5. Immunostaining using HRP-conjugated secondary antibodies  
Following transfer, the membrane was blocked in 5% dried semi-skimmed milk in 
TBS-0.2% Tween 20 for 1 hour at RT with constant agitation. Primary antibodies 
(listed in section 2.1.10) were diluted in blocking solution and added to the membrane. 
The membrane was incubated with the antibody solution at 4oC overnight.  
The next day, the membrane was washed three times for 10 minutes in TBS-0.2% 
Tween 20 and subsequently incubated for 1 hour at RT with secondary HRP-
conjugated antibody (raised against the host species of the primary antibody used) 
diluted in 5% dried semi-skimmed milk in TBS-0.2%Tween 20. After another three 
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washes with TBS-0.2%Tween 20, blots were visualised using the Pierce ECL Plus 
Western Blotting Substrate (Cat No 11527271, Thermo Scientific), according to the 




Pre-differentiated LUHMES cells were plated down (0.15x106 cells per well) and 
grown on acid-etched coverslips, placed in 24-well plates and coated with PLO and 
fibronectin, followed by geltrex. After 14 days of differentiation, neurons were fixed 
with 4% PFA in PBS for 10 minutes at RT, after which they were washed once in 
warm PBS and stored in TBS at 4oC until required.  
After a quick wash with TBS, cells were permeabilised by adding 500µl of 0.2% Triton 
in TBS (1x) to each well for 5 minutes. Following three quick rinses with TBS, cells 
were incubated in blocking solution consisting of 5% normal donkey serum in 0.2% 
Tween-TBS for 1 hour at RT. Mouse monoclonal anti-γH2A.X primary antibody 
(1:400) and rabbit polyclonal anti-53BP1 primary antibody (1:1000) were diluted in 
blocking solution and added to the coverslips. Following an overnight incubation at 
4oC, the cells were washed with 0.1% Tween-TBS (3x10 minutes) and then incubated 
with the corresponding antibodies for 1 hour at RT. Secondary antibodies were Alexa 
Fluor 488-donkey anti-mouse IgG (1:300) and Alexa Fluor 596-donkey anti-rabbit IgG 
(1:500), and were diluted, together with DAPI (1:1000), in 4% normal donkey serum 
in 0.1% Tween-TBS. Cells were then washed with TBS (3x 10 minutes) and mounted 
with ProLong Gold antifade mountant (Cat No P10144,Thermo Scientific). 
Z-stacked confocal images, with a step size of 1µm, were acquired on a Nikon 
STORM/ A1+ microscope at 100x magnification, using the NIS Elements software. 
The optimal laser intensity and gain, which did not give a signal in the no-primary 
antibody control, were established and kept constant among all experimental groups. 
Imaged areas were chosen based on the DAPI staining to avoid bias.  
Once obtained, the images were blinded and analysed using the software package 
Fiji143. Around a hundred nuclei (corresponding to four images from different areas 
within the same coverslips) were analysed for each cell line. Nuclei with apoptotic 
morphology, as examined based on the DAPI staining (i.e. condensed staining and 
nuclear ‘blebbing’) were excluded from the analyses. Nuclei completely covered with 
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intense γH2A.X staining were also excluded from the analysis, as it has been 
previously suggested that this staining pattern corresponds to apoptotic cells, as well. 
The total number of nuclei, as well as the number of foci positive for γH2A.X and 
53BP1 were determined for each image. The average number of foci per nucleus was 
determined for each image, and the average of the four images was calculated for 
each clone.  
 
2.2.10. ELISA 
At day 2, pre-differentiated LUHMES neurons were plated down in 6-well plates, pre-
coated with PLO and fibronectin, at density of 1.1x106 cell per well. Neurons were fed 
every two days, starting from day 6, when 700µl of fresh differentiation media was 
added to each well. From there on, 900µl were taken out and 1ml of freshly made 
differentiation media was added to each well every other day. Following 14 days of 
differentiation, for each cell line medium from three wells was collected in a 15ml 
falcon tube and spun at 2700rpm for 20 minutes at 4oC. After spinning the supernatant 
was carefully collected, medium aliquoted and stored at -80oC until required. Cell 
lysates from the corresponding wells were collected as described above (section 
2.2.6.1.). All steps were performed on ice. 
Aβ42 sandwich ELISA (Cat No. KHB3441, Thermo Scientific) and Dopamine 
competitive ELISA (Cat No. AMS.EA1301Hu, Amsbio) were performed following the 
manufacturer’s instructions. Coefficient of variation (CV) was calculated for the 
technical replicates. When the CV between the technical replicates was higher than 
the intra-assay variation (CV<3.6% for the Aβ42 ELISA and CV<10% for the Dopamine 
ELISA), the most different value from the replicate was discarded. The average of the 
replicates for each sample was calculated and the concentration of extracellular Aβ42/ 
Dopamine was extrapolated from the standard curve. The obtained values were 
normalised to the protein concentration (as calculated using the BSA assay) in the 
respective cell lysates from the same wells. 
 
2.2.11. Alamar Blue Assay 
Pre-differentiated LUHMES neurons (day 2) were plated down in 24-well plates, pre-
coated with PLO and fibronectin, at 150,000 cells/well. Neurons were fed every two 
days, starting from day 6, when 300µl of fresh differentiation media was added to each 
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well. From there on, 250µl were taken out and 300µl of freshly made differentiation 
media was added to each well every other day. 
Viability was measured at day 6 and day 14 by replacing the medium with freshly 
made differentiation medium containing 10% (v/v) Alamar Blue (Cat No DAL1025, 
Thermo Scientific). Cells were incubated with the Alamar Blue solution for 2 hours. 
After 2 hours, the solution was transferred to a new 24-well plate and fluorescence 
measured in a FLUOstar OMEGA plate reader using an excitation wavelength of 540-
570nm, and an emission wavelength of 580-610nm.  
 
2.2.12. Statistical analysis 
For the ‘novel environment’ experiment’ the results obtained for the Sorcs2-/-, Sorl1-/- 
and WT mice were analysed using the R package ‘nparLD’. NparLD was specifica lly 
developed for repeated measurement data in factorial experiments. It utilises rank-
based, nonparametric, as such, is for small datasets. The data was first stratified into 
independent groups based on the experimental group (i.e. ‘home cage’, ‘novel E’ and 
‘recovery’) and the genotype (i.e. WT and KO mice). The repeated measurements for 
each mouse comprised of images taken from the frontal, middle and dorsal part of the 
hippocampus (so individual mice constituted the repeated grouping factor). 
The rank mean percentage of γH2A.X- positive nuclei in each of the three 
experimental groups (‘home cage’, ‘novel E’ and ‘recovery’) within the same genotype 
(WT or KO mice) was compared for each brain region (dentate gyrus, CA2 or CA3 
region of the hippocampus) using the “F1.LD.F1” function of the R package “nparLD”. 
Two homogenous groups (environments) were measured repeatedly (brain areas) in 
x experimental units (mice). This was coded as ‘Y (percentage of γH2A.X- positive 
nuclei) = repeated measure (brain area) + group (environment) + repeated measure 
(mouse)’. The same function was used to compare the rank mean percentage of 
γH2A.X- positive nuclei between two genotypes (WT and KO mice) for each 
experimental group (‘home cage’, ‘novel E’ and ‘recovery’) and brain region (dentate 
gyrus, CA2 or CA3 region of the hippocampus). Two homogenous groups 
(genotypes), measured repeatedly (brain areas) in x experimental units (mice). This 
was coded as ‘Y (percentage of γH2A.X- positive nuclei) = repeated measure (brain 
area) + group (genotype) + repeated measure (mouse)’. The F2-LD-F1 model was 
used to compare the slopes (i.e. the rate of break generation and recovery) between 
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two genotypes for each brain region (dentate gyrus, CA2 or CA3 region of the 
hippocampus). In this case four homogenous groups (two different genotypes within 
two environments) were measured repeatedly (brain areas) in x experimental units 
(mice). This was coded as ‘Y (percentage of γH2A.X- positive nuclei) = repeated 
measure (brain area) + group (genotype) + group (environment) + repeated measure 
(mouse)’. The mean rank differences between grouping factors were tested using the 
non‐parametric ANOVA‐type statistic for all comparisons. 
In all other analysis, GraphPad Prism version 7.00 for Windows (GraphPad Software, 
La Jolla California USA, www.graphpad.com) was used throughout to draw graphs 
and perform unpaired student’s t-tests. 
Sample size estimation and post-hoc statistical power analyses were calculated using 
the GPower 3 software, taking into account the corresponding effect sizes, α error 
probability (set to 0.05), the total sample size and the number of groups. Power was 
defined as ‘1- β error probability’. Experiments where the power was below 0.8 were 
considered underpowered.  Where non-parametric tests were performed, power and 
sample size were approximated based on equivalent parametric tests. The sample 
size required for a non-parametric test was determined by multiplying the sample size 
calculated for the corresponding parametric test by a correction factor, referred to as 
asymptotic relative efficiency (ARE). 
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Chapter 3 DNA damage and repair in Sorcs2-/- 
and Sorl1-/- mice 
3.1. Introduction 
3.1.1. Background  
The maintenance of cellular genome integrity is vital for long-lived cells, such as 
neurons where excessive and/or unrepaired damage will otherwise lead to neuronal 
loss. Exacerbated DNA damage has been implicated in the process of brain aging 
and age-related cognitive decline, as well as in neurodegenerative disorders including 
AD144, 145, 146, 147.  
Recently, experiments with mice have associated DSB formation and repair with 
learning and memory processes. Suberbielle et al. (2013)107 showed that in WT mice, 
exploration of a novel environment triggers the formation of transient DSBs in brain 
areas important for learning and memory as a result of increased neuronal activity. 
Subsequent experiments have suggested that DSB formation, in the context of 
neuronal activity, is a physiological mechanism, which depends upon the activation of 
Topoisomerase IIβ and is required for the rapid expression of early-response 
genes118.  
Meanwhile, hAPP-J20 mice (an AD mouse model) not only showed increased DSB 
formation at baseline, but also increased levels of DNA damage following recovery 
from an exploratory activity. This suggests that excess Aβ levels increase DSB 
formation and impair DNA repair. Additionally, in WT primary hippocampal neurons, 
both Aβ- and activity-induced formation of DSBs relied on the activation of NR2B-
containing NMDARs, while their repair on that of NR2A-containing NMDARs107.  
3.1.2. Aim 
My aim was to investigate the impact of knocking out either Sorcs2 or Sorl1 in mice 
on activity induced DSB formation. I hypothesised that, bearing in mind the role of the 
sortilin family in APP processing148 and processes relevant to learning and memory, 
knocking out Sorl1 and/or Sorcs2 in mice could potentially replicate the effects of 
elevated Aβ levels on both generation and repair of activity induced DSBs.  
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3.1.3. Experimental Design 
To address this hypothesis, I assessed the levels of γH2A.X (a marker for DNA DSB 
formation) in Sorcs2-/- and Sorl1-/- and corresponding WT mice at baseline, as well as 
immediately after or following recovery from exploration of a novel environment.  
I received two sets of mouse brains from our collaborators, Assoc. Prof Simon Glerup 
and Dr Ditte Olsen, Aarhus University, Denmark. The first set of brains was derived 
from Sorcs2-/- and corresponding WT mice, while the second- from Sorl1-/- and 
corresponding WT mice. The two sets of mice (Sorcs2-/- and Sorl1-/-, and 
corresponding WTs) were bred independently from each other, and I received the 
brains at different times. All mice were on the same background: C57Bl/6JBomTac 
(Taconic). WT and knockout mice were derived from different cohorts as breading 
was done on homozygous mice (i.e. full knockout and full WT breading), and mice of 
the same genotype were littermates. All mice used in the experiments below were 
sex- and age-matched- male, 5-6-month-old, and WT and knockout mice from the 
same batch were bred simultaneously.  
The behavioural part of the experiment was performed by Dr Ditte Olsen and Mathias 
Kaas Ollendorff in Denmark. In brief, mice in the control group (here defined as ‘home 
cage’) were kept in their original cages and sacrificed at the end of the experiment. 
Mice in the novel environment (‘Novel E’) and the recovery from the novel 
environment (‘recovery’) groups were exposed to a novel environment that constituted 
an Open Field Arena with four different novel objects and mint-like odour. The mice 
were allowed to explore the novel environment for two hours after which the mice in 
the Novel E group were sacrificed, while the mice in the recovery group were returned 
to their home cages, where they recovered from the behavioural task for 24 hours 
before being sacrificed (Figure 3.1.). The behaviour of the mice in the home cages, 
as well as during exploration of the novel environment was not recorded. However, it 
has been previously reported that the Sorcs2-/- mice exhibit increased activity in a 
novel environment, which disappears following habituation. No changes in the activity 
levels of Sorcs2-/- mice in the home cage has been observed (Ditte Olsen; manuscript 
in preparation). 
In both sets, the mice were sacrificed by direct perfusion with 4% PFA through the 
circulatory system. After perfusion, the brains were dissected and shipped to 
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Edinburgh. I received whole brains on which I performed the experiments described 
below.  
 
Figure 3.1. Experimental design of the behavioural experiments performed by our 
collaborators in Denmark. Mice from all genotypes (WT, Sorcs2-/- and Sorl1-/-) were divided in 
three groups: ‘home cage’ (yellow), ‘Novel E’ (pink) and ‘recovery’ (green). The ‘home cage’ 
group shows the levels of DNA DSBs at a baseline, while the mice in the ‘Novel E’ and 
‘recovery groups’- the extent of DSB formation following exploratory activity and recovery from 
it, respectively.  
 
3.2. Optimisation and validation of the γH2A.X 
immunostaining protocol  
In order to assess the levels of DNA damage and repair in knockout and 
corresponding WT mice, I first developed an immunofluorescent (IF) protocol for 
staining frozen brain sections with γH2A.X.  
Initially, I tested the IF protocol described by Suberbielle et al. (2013)107 on frozen 
sections from a WT mouse brain, provided by Dr Matthieu Vermeren and Dr Toby 
Hurd (Institute for Genetics and Molecular Medicine, The University of Edinburgh). 
Using this protocol, I observed high levels of background staining even in the absence 
of both primary and secondary antibody, suggestive of auto-fluorescence (Figure 
3.2.A). Thereafter, different approaches for optimising the IF protocol were 
undertaken, including blocking with different solutions (such as BSA and/or donkey or 
goat serum), increasing the blocking and washing times and using different antibody 
(both primary and secondary) concentrations. Following more than ten trial 
experiments, some progress in reducing the background auto-fluorescence was 
made (Figure 3.2.B), but its generally high levels, combined with the lack of detectable 
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nuclear staining, suggested that either the γH2A.X antibody or the used IF protocol 
did not work. 
In order to determine whether or not the used γH2A.X antibody was specific for 
detecting DNA DSBs in tissues, frozen mouse testes (provided by Dr James Crichton 
and Dr Ian Adams, Institute for Genetics and Molecular Medicine, The University of 
Edinburgh) were used as a positive control, since phosphorylation of the H2A.X 
histone has been shown to mark main events of the spermatogenic process 
associated with chromatin reorganisation149. After an extensive literature review, I 
tested six IF protocols, previously used for staining frozen testis sections and 
spermatogenic cell cultures (modified in order to be used in tissue) with γH2A.X. 
Following this process, I developed a protocol that detected nuclear staining in the 
testis sections (Figure 3.2.C). Subsequently, I tested this protocol on sections from 
the WT mouse test brain. Unfortunately, when used on frozen brain tissue, no γH2A.X 
staining and high background levels were seen again (Figure 3.2.D).  
Given that the γH2A.X antibody detected DNA DSBs in frozen testes, but not brain 
sections, it was concluded that either the protocols I had been trying so far were 
incompatible or the mouse brain I had been using had very low, undetectable levels 
of DSB formation. To account for the latter, I contacted Prof Tara Spires-Jones 
(Centre for Discovery Brain Sciences, The University of Edinburgh) who provided me 
with an APP/PS1 mouse brain. The APP/PS1 mouse is an AD mouse model similar 
to the hAPP-J20 mice used by Suberbielle et al.107. Thus, the APP/PS1 mice were 
likely to exert high levels of baseline neuronal DSB formation as the hAPP-J20 mice 
used by Suberbielle et al. Around the same time, I came across a study describing a 
γH2A.X IF protocol for staining frozen rat brain sections116. Using a slightly modified 
version of this protocol, I detected a faint γH2A.X signal in brain sections I obtained 
from the APP/PS1 mouse (Figure 3.2.E). Increasing the γH2A.X antibody 
concentration (from 1:400 to up to 1:10) improved the signal to noise ratio (Figure 
3.2.E- H).  
Subsequently, the staining was further optimised on brain sections from the beginning 
of the hippocampus (bregma: -1.28 mm) of Sorcs2-/- mice that belonged to the Novel 
E group, as it was hypothesised that this group was likely to show the highest level of 
DNA DSB formation. As for the APP/PS1 mouse, I was able to detect γH2A.X staining 
at 1:100 dilution (Figure 3.3.A). Even though I could detect the γH2A.X signal, the 
levels of auto-fluorescence were still quite high. In order to overcome this, I decided 
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to include a Sudan Black step in the protocol, as well as to use green- instead of red-
fluorescent secondary antibody. Using a different secondary antibody and Sudan 
Black before, but not after, incubation with secondary antibody, reduced the levels of 
auto-fluorescence drastically. After titrating the primary antibody concentration, the 
1:50 dilution was selected as the optimal one as it was the lowest showing the best 
signal to noise ratio (Figure 3.3.B-D). 
 
Figure 3.2. Optimisation of the γH2A.X IF protocol. [A-B] Representative images depicting 
autofluorescence levels (red) and the lack of γH2A.X staining (red) in the test WT mouse brain, 
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acquired with epifluorescent microscope at 40x magnification. [C] A representative image of 
mouse testis sections stained for γH2A.X (green) and DAPI (blue), obtained with 
epifluorescent microscope at 10x magnification. [D] A representative image of APP/PS1 
mouse brain sections immunostained for γH2A.X (green) and DAPI (blue), following the 
protocol which gave the best result in the testes; image acquired with epifluorescent 
microscope at 40x magnification. [E-H] Representative images of APP/PS1 mouse brain 
sections immunostained for DAPI (blue) and γH2A.X (green) at concentrations 1:400 [E], 
1:100 [F], 1:50 [G] and 1:10 [H], following the Crowe et al. (2011) protocol; images acquired 
with epifluorescent microscope at 40x magnification. In all images, white arrows point towards 
nuclei positive for γH2A.X, and scale bars correspond to 10um. 
 
 
Figure 3.3. Further optimisation of γH2A.X IF protocol on Sorcs2-/- brain sections. [A] A 
representative image of Sorcs2-/- brain sections stained for DAPI (blue) and γH2A.X (green) 
at concentration 1:100, acquired with confocal microscope at 100x magnification. The red 
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channel depicts auto-fluorescence. White arrows point towards either γH2A.X foci (green) 
within nuclei or foci-like auto-fluorescence (yellow). [B-D] Representative images of Sorcs2-/- 
brain sections stained for DAPI (blue) and γH2A.X (green) at concentrations 1:100 [B], 1:50 
[C] and 1:10 [D], following optimisation with Sudan Black. White arrows point towards nuclei 
positive for γH2A.X. The images were acquired using confocal microscope at 60x 
magnification. In all images, scale bars correspond to 10um.  
 
3.3. An attempt of developing an automated method 
for assessing levels of DNA DSBs 
In order to make the process of counting the total number of nuclei, as well as the 
percentage of nuclei positive for γH2A.X more efficient and unbiased, I tried to 
develop an automated method for assessing the levels of DNA DSBs using the 
software package Fiji143, as it has been previously used for identifying γH2A.X foci 
within nuclei. This required the delineation (also known as ‘segmentation’) of the 
nuclei in order to subsequently use them as a ‘mask’ to identify γH2A.X foci within 
them. Unfortunately, due to the highly compacted distribution of the nuclei within the 
dentate gyrus and the CA regions of the hippocampus, precise nuclear segmentation 
was impossible (Figure 3.4.B). This inability to ‘segment’ and count the nuclei correctly 
prevented me from using this method of automated counting.  
 
Figure 3.4. Attempt of developing an automated method for assessing DNA DSB formation. 
[A] A representative confocal image acquired for the dentate gyrus, showing only the nuclei in 
the DAPI channel (blue), 60x magnification. [B] At attempt to ‘segment’ and count the nuclei 
automatically using the Fiji software. Red arrows point at regions where the software was 
unable to separate the nuclei from each other correctly.  
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3.4. Preliminary results: assessing levels of DNA 
DSBs in Sorcs2-/- and Sorl1-/- mice  
3.4.1. Assessing levels of DNA DSB formation in Sorcs2-/- and 
corresponding WT mice (preliminary results)  
Initially, my goal was to identify the same area of the dentate gyrus and the CA3 region 
of the hippocampus for each animal and count the number of nuclei positive for 
γH2A.X within it. I stained three consecutive sections from the beginning of the 
hippocampus (bregma: -1.64 mm) of Sorcs2-/- and corresponding WT mice, belonging 
to one of the three experimental groups (‘home cage’, ‘Novel E’ and ‘recovery’) 
described in Figure 3.1. Using confocal microscopy, I took z-stacks from specific 
areas within the dentate gyrus (the end of the infra-pyramidal blade of the granule cell 
layer) and the CA3 hippocampal region. The exact location of the selected areas is 
indicated with a red rectangle in Figure 3.5.A. Within these areas, I counted manually 
the total number of nuclei, as well as those positive for γH2A.X, whilst blinded with 
respect to genotype and condition (Figure 3.5.B; Appendix A, Table A1).  
One-way ANOVA identified a significant effect of the environment on the level of DNA 
DSB formation in the CA3 region of the WT mice (p=0.0448; Figure 3.5.C, left). 
However, post-hoc analysis did not identify any significant difference in the 
percentage of γH2A.X-positive nuclei between the three conditions (‘home cage’, 
‘Novel E’ and ‘recovery’) in this brain region (Figure 3.5.C, left; Appendix Table A2). 
Meanwhile, I observed the same pattern as Suberbielle et al. (2013)107, i.e. transient 
increase in the number of γH2A.X-positive nuclei following exploratory activity in the 
dentate gyrus of the WT mice (Figure 3.5.C, right). In this brain region, the percentage 
of γH2A.X-positive nuclei  detected in the ‘Novel E’ group was significantly higher than 
the one detected in both the ‘home cage’ (p=0.0007) and the ‘recovery’ (p=0.0033) 
groups (Figure 3.5.C, right; Appendix Table A2). No difference in the levels of DSB 
formation was observed between the home cage and recovery groups (p=0.2344; 
Appendix Table A2).  
Sorcs2-/- mice did not show the same pattern of a transient increase in the proportion 
of γH2A.X-positive nuclei following exploration of a novel environment in either the 
dentate gurus (p=0.1050) or the CA3 region (p=0.4751) of the hippocampus (Figure 
3.5.D). Further inspection of the data (Appendix A, Table A1) suggested that these 
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differences were the result of increased DNA DSB formation in the Sorcs2-/- mice in 
the home cage group. Comparison of the percentage of γH2A.X-positive nuclei 
between knockout and wild type mice at baseline (home cage) indicated a significant 
difference in both the dentate gyrus (p= 0.0225) and the CA3 region (p= 0.0153) 
(Figure 3.5. E).  
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Figure 3.5. Assessing levels of DSB formation in the frontal part of the hippocampus of Sorcs2-
/- mice and corresponding WT mice. [A] An image of the mouse hippocampus showing the 
regions of the dentate gyrus and the CA3, where the number of γ-H2A.X-positive nuclei was 
counted. Adapted after https://biodiscovery.eu/products/dapi/. [B] A representative image 
obtained with confocal microscope, showing DNA DSBs (stained with γH2A.X in green) within 
nuclei (stained with DAPI in blue), 60x magnification. Scale bars correspond to 10µm. [C-D] 
Percentages of γH2A.X-positive nuclei in dentate gyrus and the CA3 region of the 
hippocampus (averaged from three consecutive sections per mouse, n=3) in WT [C] and 
Sorcs2-/- [D] mice belonging to one of the three experimental groups. [E] Comparison between 
the percentage of γH2A.X-positive nuclei in the dentate gyrus and the CA3 region of the 
hippocampus of WT and Sorcs2-/- mice in the home cage group. Error bars represent means 
± SD; One-way ANOVA [C-D] or unpaired t-test [E]; ‘*’, ‘**’ and ‘***’ indicate p < 0.05, p<0.001, 
p<0.001, respectively. 
 
3.4.2. Assessing levels of DNA DSB formation in Sorl1-/- and 
corresponding WT mice 
As for the first batch of Sorcs2-/- and WT mice, I stained three consecutive sections 
from the beginning of the hippocampus (bregma: -1.64mm) of Sorl1-/- and 
corresponding WT mice, belonging to one of the three experimental groups described 
in Figure 3.1. Using confocal microscopy, I acquired z-stacks from one, specifically 
defined area within the dentate gyrus and the CA3 region of the hippocampus (as 
described in 3.4.1. and shown in Figure 3.5.A). Due to the long imaging time, half of 
the images were acquired by Dr Jonathan Phillips and the other half by me, using the 
same imaging parameters. Independent from each other and blinded to genotype and 
condition, we counted the total number and the number of γH2A.X-positive nuclei in 
all acquired images. The obtained counts are reported in Appendix A, Table A3.   
No significant difference in the percentage of γH2A.X-positive nuclei was observed 
between the three conditions (‘home cage’, ‘Novel E’ and ‘recovery’) for either of the 
two genotypes in both the dentate gyrus (WT mice p=0.4859; Sorl1-/- mice p=0.2357) 
and the CA3 region of the hippocampus (WT mice p=0.6388; Sorl1-/- mice p=0.6571)  
(Figure 3.6.A-B; Appendix A, Table A4). Surprisingly, I observed that the WT mice in 
the ‘home cage’ group showed higher number of γH2A.X-positive nuclei than the WT 
mice from the Sorcs2-/- mice experiment (Appendix A, Table A1 and A3). Since the 
WT mice from the two batches were on the same background, I compared the 
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percentage of DSB-positive nuclei between the two groups.This indicated a 
significantly higher percentage of γH2A.X-positive nuclei in both the dentate gyrus 
(p=0.0498) and the CA3 region (p=0.0002) of the hippocampus of the WT mice that 
accompanied the Sorl1-/- mice compared to those  that accompanied the Sorcs2-/- 
mice (Figure 3.6.C). Increased levels of DSBs were also observed in the CA3 region 
(p=0.0064), but not the dentate gyrus (p=0.8129) of Sorl1-/- mice compared to Sorcs2-
/- mice (Appendix B, Figure B1).  
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Figure 3.6. Assessing DSB formation in Sorl1-/- and corresponding WT mice. Percentages of 
γH2A.X-positive nuclei in dentate gyrus and the CA3 region of the hippocampus (averaged 
from three consecutive sections per mouse, n=3-4) in WT [A] and Sorl1-/- [B] mice, belonging 
to one of the three experimental groups. [C] Comparison between the percentage of γH2A.X-
positive nuclei in the CA3 region of the hippocampus (left) and the dentate gyrus (right) of WT 
mice belonging to either the first or the second batch we received. Error bars represent means 
Chapter 3 DNA damage and repair in Sorcs2-/ and Sorl1-/- mice 80 
 
± SD; One-way ANOVA [A-B] or unpaired t-test [C]; ‘***’ and ‘*’ indicate p<0.001 and p < 0.05, 
respectively. 
 
3.5. Assessing levels of DNA DSBs in the Sorcs2-/- 
mice- sampling throughout the entire hippocampus 
 
Following detection of a significant difference between the three experimental groups 
in the dentate gyrus of the WT mice that accompanied the Sorcs2-/- mice (Figure 
3.5.C), as well as in the baseline DSB levels in the frontal part of the dentate gyrus 
and the CA3 region of the hippocampus of the assessed Sorcs2-/- mice (Figure 3.5.E), 
I went on to investigate if these differences were observed more widely throughout 
the hippocampus. This was suggested by the external expert in my thesis committee- 
Prof Tara Spires-Jones (Centre for Discovery Brain Sciences, The University of 
Edinburgh). This time, I decided to include the CA2 region of the hippocampus, as 
well, as Sorcs2 has been previously shown to be highly expressed in that region20. I 
stained slices from the frontal (bregma: -1.64mm), the middle (bregma: -2.12mm) and 
dorsal end (bregma: - 2.75mm) of the hippocampus of Sorcs2-/- and WT mice, 
belonging to the described above groups. As described in 3.4.1, I obtained confocal 
images from specifically defined areas within the dentate gyrus and the CA2 and CA3 
region of the hippocampus in these sections. As before, due to time constraints, half 
of the images were acquired by Dr Jonathan Phillips and the other half by me. Blinded 
to both genotype and condition, I counted the total number of nuclei and the number 
of nuclei positive for DSBs in the dentate gyrus and the CA2 and CA3 region of the 
hippocampus. In order to confirm that my counting was accurate and unbiased, 10% 
of the images (selected at random) were counted by Dr Phillips, who was also blinded 
to genotype and condition. Comparison of the counts showed 80-90% agreement 
between the two of us. Actual counts are reported in Appendix A, Table A5.   
Following a discussion with Dr Mairead Bermingham (a post-doc in our group) and 
given the small sample size of my study (n=3 mice per genotype per experimental 
group), I decided to analyse the obtained results using ‘NparLD’150. NparLD is an R-
based package that was developed for analysing repeated measurement data in 
factorial experiments. In addition, the fact that it is non-parametric is helpful with small 
sample sizes, as this analysis does not require the data to be normally distributed. All 
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the analysis described below was performed by Dr Bermingham. The data was first 
stratified into independent groups based on the experimental group (i.e. ‘home cage’, 
‘novel E’ and ‘recovery’) and the genotype (i.e. WT and Sorcs2-/-), but also into 
repeated measurements (i.e. images taken from the frontal, middle and dorsal end of 
the hippocampus) with individual mice constituting the grouping factor. For each 
individual group (e.g. Sorcs2-/- mice belonging to the ‘home cage’ group), the 
percentage numbers of γH2A.X- positive nuclei were converted to ranks. The mean 
rank differences in the percentage of γH2A.X-positive nuclei were compared across 
the groups.  
Using this method, as expected given previously published findings107, a significant 
increase in the percentage of γH2A.X-positive nuclei was detected in the dentate 
gyrus (p=4.53x10-9), the CA2 (p=1.46x10-5) and the CA3 (p=0.035) regions of the 
hippocampus of WT mice following exploration of the novel environment (, Figure 
3.7.A; Appendix A, Table A6). The percentage of γH2A.X-positive nuclei returned 
back to baseline levels following 24-hour recovery period in all three brain regions 
(min p=1.78x10-6; Figure 3.7.A; Appendix A, Table A6). By contrast, no significant 
differences were found in the percentage of DSBs across the three experimental 
groups in any of the brain regions examined in the Sorcs2-/- mice (min p=0.074; Figure 
3.7.B; Appendix A, Table A6). Moreover, as for the preliminary results described in 
3.4.1, Sorcs2-/- mice showed statistically significantly higher percentage of γH2A.X-
positive nuclei in the home cage group when compared to corresponding WT mice 
(Figure 3.8.A). However, this difference was observed only in the dentate gyrus 
(p=0.025), and not in the CA2 (p=0.138) or the CA3 region (p=0.176) of the 
hippocampus (Figure 3.8.A).  
Further analysis also carried out by Dr Bermingham, compared the impacts of the 
three environmental conditions on the formation of DSBs between the genotypes. 
These models identified a significant difference in the way WT mice responded to the 
novel environment when compared to Sorcs2-/- mice. In the dentate gyrus, the 
percentage of γH2A.X-positive nuclei was significantly affected by the interaction 
between genotype and exposure to a novel environment (p=0.001, Figure 3.8.B, left). 
It appeared that, in addition to the greater number of DSBs observed in the home 
cage group, the Sorcs2-/- mice also do not acquire as many DSBs on exposure to the 
novel environment. Similarly, a significant genotype by environment interaction was 
observed in the CA2 (p=0.021) and CA3 (p=0.049) regions (Appendix B, Figure B2). 
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No significant interaction was identified between the genotype and the recovery from 
the novel environment (min p=0.139, Figure 3.8.B, right; Appendix A, Table A7; 
Appendix B, Figure B2). In these analyses- fitting the interaction between genotype 
and environment, the main effect of the novel environment was significant in the 
dentate gyrus and CA2, but not in the CA3 region (Appendix A, Table A8). No main 
effect of genotype was observed in any of the three brain regions examined (Appendix 
A, Table A9).  
 
 
Figure 3.7. Comparison of the levels of DSB formation between the three experimental groups in WT and Sorcs2-/ -mice. Rank mean percentages of 
γH2A.X-positive nuclei in dentate gyrus, the CA2 and CA3 region of the hippocampus in WT [A] and Sorcs2-/- [B] mice belonging to one of the three 
experimental groups-‘home cage’ (HC), ‘Novel E’ (NE) and ‘recovery’ (R).. N=3, non‐parametric ANOVA type statistic, ‘*’, ‘**’ and ‘****’ indicate p<0.05, 
p<0.01 and p<0.0001, respectively;  
 
 
Figure 3.8. Assessing the difference in the levels of DNA DSB formation between WT and Sorcs2-/- mice belonging to one of the three experimental 
groups. [A] Comparison of the rank mean percentage of γH2A.X-positive nuclei in the dentate gyrus, the CA2 and CA3 region of the hippocampus of WT 
and Sorcs2-/- mice. [B] Comparison of the rate of DSB formation (left) and repair (right) between WT and Sorcs2-/- mice. N=3, non‐parametric ANOVA‐
type statistic, ‘*’ indicates p<0.05. 
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3.6. Discussion 
As described above, I optimised and validated an immunofluorescence protocol for 
staining frozen brain sections using γH2A.X as a marker of DSB formation. 
Subsequently, I reproduced the previously reported finding that exploration of a novel 
environment triggers transient increase in DSB formation in the hippocampus of adult 
WT mice. Meanwhile, Sorcs2-/- mice from the same batch did not show the same 
pattern. They appeared to acquire fewer DSBs following the novel environment task 
compared to wild types, despite the fact that Sorcs2-/- mice have been previously 
reported to be more active in an open field test6. At the same time, Sorcs2-/- mice 
belonging to the ‘home cage’ group showed statistically higher levels of DSBs in the 
dentate gyrus. 
A major caveat to the findings of this chapter is the relatively small number of animals 
used (n=3 for the Sorcs2-/- batch and n=3-4 for the Sorl1-/- batch), as well as the fact 
that each experiment was performed only once. Post-hoc power analyses revealed 
that both experiments were powered to detect changes in the formation of DSBs 
following exposure to the Novel E or recovery from it in the Sorcs2-/-, Sorl1-/- and 
corresponding WT mice. These analyses were based on the results obtained for the 
WT mice accompanying the Sorcs2 knockouts. For this group of mice, the differences 
in the proportion of γH2A.X-positive nuclei observed across the three conditions in all 
three brain regions were in the range of the minimal effect size (1.36) that the study 
was sensitive to detect for this sample size (n=3) and if powered to 80%. Even more 
so, the effect size observed when the level of DSB formation was compared across 
the three conditions in the dentate gyrus of WT mice was much higher- 2.88. Thus, 
the non-significant change in the number of γH2A.X-positive nuclei across the three 
experimental groups observed in the Sorcs2-/- mice is likely to represent a true lack of 
difference.  
Similarly, these experiments were powered to assess the effect of the genotype-
environment interaction, as well as of the environment alone on the formation of 
γH2A.X foci. In the case of the dentate gyrus, for example, the observed effect sizes 
for the genotype-environment interaction (1.17) and the environment alone (2.00) 
were much higher than the predicted by the sensitivity test change of 0.83 at 80% 
power. This experiment was, however, under-powered for assessing the effect of the 
genotype in this model. In the dentate gyrus, the predicted minimum genotype effect 
size (0.72) was bigger than the actual (0.50). Subsequent sample size analysis 
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estimated that a total of 42 animals (or 7 mice per genotype per condition) is required 
to reliably assess the effect of the genotype given the observed in this model effect 
size. 
Meanwhile, despite being powered to detect differences in the number of DSB-
positive nuclei across the three experimental groups, I did not observe the same 
pattern of DSB formation upon exploration of a novel environment in the WT mice that 
matched the Sorl1-/- mice. These WT mice displayed significantly higher levels of 
baseline DSBs in the dentate gyrus and the CA3 region of the hippocampus when 
compared to the WT mice from the first set. Given this unexpected finding, it was not 
possible to compare the levels of DSB formation in the Sorl1-/- mice either at baseline 
or following exploration of a novel environment. There are a number of possible 
reasons that can explain these surprising results. Perhaps the most likely explanation 
is changes in the animal facility that took place prior to the experiment. This was 
subsequently noted by our collaborators Dr Ditte Olsen and Mathias Kaas Ollendorff 
(personal correspondence). There were also some discrepancies in the way the novel 
environment experiment was performed in the two batches of mice. In the first 
experiment, WT and Sorcs2-/- mice were exposed to the novel environment 
individually. Subsequently, Sorl1-/- and matched WT mice performed the exploratory 
task together with their cage-mates. It has been previously reported that exposing 
mice to a novel environment with other, familiar mice reduces anxiety levels and 
increases exploratory activity107. Thus, it can be speculated that the elevated levels of 
DSBs I observed in the WT mice from the first batch upon exploratory activity might 
be due to increased stress levels from being exposed to novelty on their own, rather 
than the novel environment itself. However, this seems unlikely to be the case. 
Suberbielle et al. (2013)107 showed that the observed increase in neuronal DSB 
formation following exploratory activity is solely dependent on neuronal activity, and 
not the release of corticosterone or other stress factors, as removing the adrenal gland 
exerted no effect on this process. However, in that study, mice were subjected to a 
novel environment with their cage-mates and with mice from a different litter. This 
might constitute an additional factor of novelty that has not been accounted for in the 
experiment described here.  
These observations raise the question whether the novel environment protocol used 
in our study is sufficient to trigger the formation of DSB. Recently, Alvarez-Castelao 
et al. (2017)151 described a new cage with an enriched novel environment (EE), which 
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comprised a labyrinth with changeable side walls, running wheels and toys of different 
size, texture and colour. Exposure to this EE altered the expression of over 200 
proteins important for neuron and synapse function151. Although this study was 
performed in younger mice (six weeks of age) and entailed chronic exposure to the 
described EE (21 days), it would be interesting to look at the impact of this type of 
cage on the mice described here. In addition, both locomotor activity and habituation 
have been previously shown to decrease with the time WT mice spend in a novel 
environment. Therefore, two hours might be too long exposure period, enough for the 
mice to get used to the novel environment and stop exploring. Moreover, such 
habituation might subsequently allow DSB repair. Therefore, it would be also 
interesting to test whether shorter exposure to the described novel environment could 
result in a stronger and more reliable phenotype in WT mice.  
Despite the caveats described above, the increased DSB formation observed in the 
Sorcs2-/- mice at baseline constitutes an interesting finding. It is unlikely that this could 
be explained by the hyperactivity phenotype in an open field test previously reported 
for these mice6, since no differences in their behaviour or activity levels compared to 
the WT mice was observed for the home cage condition (Dr Ditte Olsen, personal 
correspondence). However, there are a few possible reasons of why the Sorcs2-/- 
mice might have higher levels of neuronal DSBs at baseline.  
Hypothesis 1: Knocking out Sorcs2 leads to elevated Aβ levels and thus DSB 
formation. 
Given the link described above between Aβ and DSB formation, as well as that 
between members of the sortilin family and APP processing148, an obvious hypothesis 
is that lack of SorCS2 in mice can lead to increased Aβ production and thus DSB 
formation. Increased Aβ levels have been reported in mice where Sorl137 or Sort1152 
have been knocked out, and knock-down of SORCS2 in HEK293 cells led to 
increased APP processing148. However, to date, there is no study investigating the 
effect of knocking out SORCS2 on Aβ accumulation in either mice or human neurons. 
Hypothesis 2: Knocking out Sorcs2 disturbs the balance between NR2A- and NR2B-
containing NMDA receptors, leading to aberrant network activity and increased DSB 
formation. 
As mentioned previously, the activation of NR2B- and NR2A-containing NMDA 
receptors has been shown to be necessary for the formation and repair of DSBs, 
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respectively. NR2A- and NR2B-containing NMDA receptors have been implicated in 
the induction of LTP and LTD, respectively153. Meanwhile, SorCS2 has been shown 
to be crucial for the induction of NMDAR-dependent hippocampal LTP and LTD in 
mice5. Additionally, SorCS2 has been associated with the recycling and trafficking of 
NR2A-containing NMDA receptors to dendritic and synaptic compartments of striatal 
medium spiny neurons51. Therefore, it could be hypothesised that lack of SorCS2 
might result in impaired NMDAR function and consequently increased formation 
and/or insufficient repair of activity-induced DSBs. Since no DNA DSB repair deficits 
were observed in the Sorcs2-/- mice, it is more likely that knocking out Sorcs2 impairs 
the formation rather than the repair of DSBs.  
Hypothesis 3: Knocking out Sorcs2 leads to increased oxidative stress and thus DNA 
damage 
Oxidative stress has been shown to cause DSBs154 and activation of NR2B-containing 
NMDA receptors has been linked to elevated levels of oxidative stress155. However, 
according to Suberbielle et al. (2013), treatment with a ROS scavenger had no effect 
on NDMAR-induced DSB formation. Moreover, no oxidative stress has been reported 
in hAPP-J20 mice at the age used in their study107. On the other hand, SorCS2 has 
recently been implicated in neuronal protection from oxidative stress by playing 
indirect role in the synthesis of the endogenous ROS scavenger glutathione. Lack of 
SorCS2 has been associated with increased oxidative damage and death of 
hippocampal neurons following PTZ kindling in a mouse model of epilepsy22. 
Therefore, it is reasonable to speculate that the increased baseline levels of DSB we 
detect in the Sorcs2-/- mice could be, at least partly, due to increased oxidative stress. 
However, Malik et al. (2019)22 did not report increased baseline levels of oxidative 
stress in the Sorcs2-/- mice, but rather an exacerbated response to it.  
In summary, increased Aβ levels have been linked to both increased oxidat ive 
stress156 and altered balance between NR2A- and NR2B-containing NMDAR 
activity157. Likewise, enhanced NMDAR activity has been associated with elevated 
levels of oxidative stress155 and Aβ production158. Therefore, all of the above 
hypotheses can feed into each other and contribute simultaneously to the observed 
elevated levels of DSBs in the Sorcs2-/- mice. In order to investigate this, I knocked 
out SORCS2 in the LUHMES neuronal cell line and performed various experiments 
to address hypotheses 1 and 2. The link between SORCS2 and protection against 
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oxidative stress was not known until the very end of my PhD project, and thus 
hypothesis 3 was not investigated. 
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Chapter 4 Knocking out SORCS2 in the LUHMES 
neuronal cell line 
4.1. Introduction 
To determine whether the increased levels of DNA DSBs discovered in Sorcs2-/- mice 
could be replicated in SORCS2 knockout (KO) human neurons, and, if so, to address 
the underlying mechanism(s), I knocked out SORCS2 in the human neuronal cell line 
LUHMES using CRISPR/Cas9 genome editing. 
The LUHMES (Lund Human Mesencephalic) cell line is a karyotypically normal 
human foetal mesencephalic cell line conditionally immortalised with the v-myc 
oncogene133. Proliferation of these neuronal precursor cells can be terminated by 
adding tetracyclin, thus halting v-myc expression. Subsequent addition of 
neurotrophic growth factors results in differentiation into post-mitotic dopaminergic 
neurons within five days. Five to six days after initiating differentiation, the expression 
of stem cell and neuronal precursor markers, such as SOX2 and PAX3, is significantly 
reduced, while that of neuronal markers, such as synaptophysin, synapsin and PSD-
95, is strongly upregulated. While the expression of most neuronal markers peaks at 
day 6 and remains stable thereafter, the electrophysiological properties of 
differentiated LUHMES cells have been shown to progressively increase with the 
majority of cells generating spontaneous action potentials after 10-12 days of 
differentiation133. In addition to expressing pre- and post-synaptic, and dopaminergic 
markers, differentiated LUHMES cells have also been shown to express proteins 
relevant to AD, including APP, Aβ, sAPPβ, tau, p-tau and γ-secretase134,159.  
The ability to knock out genes using CRISPR/Cas9 genome editing and examine the 
effect of the mutations introduced following neuronal differentiation, makes the 
LUHMES cell line a useful model system135.  
4.1.1. Aim 
The aim of the work described in this chapter was to use CRISPR/Cas9 genome 
editing to generate mutant LUHMES cell lines in which the SORCS2 gene was 
knocked out.  
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4.2. Assessing the expression of the Vps10p-
domain receptor family in the LUHMES neuronal 
cell line 
To date, no study has examined the expression of the sortilin gene family in the 
LUHMES neuronal cell line. In order to address this, the expression profiles of all five 
family members were assessed using quantitative reverse transcriptase PCR (qRT-
PCR) and the TaqMan system. For each gene, a probe that amplified all (or the 
majority of) isoforms was selected. The expression of all genes of interest was 
normalised to the expression of three reference genes from a panel of eight, identified 
as the most stable in this sample set by the GeNorm software (Figure 4.1.). All family 
members, except SORCS3, were detected in both proliferating cells and neurons from 
different differentiation days (day 6, 8, 10 and 12) (Figure 4.2.). A drop in the 
expression levels of SORL1, SORCS1 and SORCS2 upon differentiation (day 6) was 
observed, while SORT1 mRNA levels remained relatively stable up to day 10. For 
each of the genes detected, expression peaked at day 12 (Figure 4.2.A). Amongst 
the family members detected, SORCS2 showed the highest expression in both 
proliferating cells and neurons, with its mRNA levels being approximately four times 
higher at day 12 compared to those of the rest of the family members.  
To follow up the qRT-PCR results for SORCS3, I designed a primer pair, targeting the 
same SORCS3 region as the TaqMan probe. RT-PCR with these primers detected 
SORCS3 in a human brain cDNA sample, but not in cDNA samples from both 
proliferating and differentiated LUHMES cells (Figure 4.2.B). These results, combined 
with the qRT-PCR data, suggest that the SORCS3 gene is not expressed in LUHMES 
cells.  
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Figure 4.1. Reference gene expression stability analysed using the GeNorm software. [A] The 
average expression stability measure (depicted as geNorm M on the y-axis) of the eight tested 
reference genes (shown on the x-axis). The reference genes were ranked according to their 
stability from left (least stable) to right (most stable) on the x-axis. [B] Determination of the 
optimal number of reference genes for normalization was calculated using pairwise variation 
(V) analysis. V values (geNorm V) are indicated on the y-axis, and the optimal number of 
reference genes on the x-axis. V value of 0.15 was set as a threshold and any values lower 
than this indicated the number of reference genes sufficient for valid normalisation.  
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Figure 4.2. Assessing the expression of the sortilin family in proliferating and differentiated 
LUHMES cells. [A] SORT1, SORL1, SORCS1 and SORCS2 expression levels over the course 
of differentiation of proliferating LUHMES cells into neurons. The x-axis shows days of 
differentiation with day 0 corresponding to proliferating cells and days 6, 8, 10 and 12 to 
neurons at different stages of differentiation. The y-axis shows the mRNA quantity normalised 
to the geometric mean of the most stable reference genes selected by the GeNorm software. 
The experiment was performed on two independent growths, and the graphs displayed 
correspond to one experiment. [B] RT-PCR assessing the expression of SORCS3 in LUHMES 
proliferating cells and neurons. 1.5% agarose gel stained with SYBR Safe. The first track 
(indicated as ‘M’ for marker) was loaded with 1kb+ ladder, second track was left empty, tracks 
3-7 were loaded with amplified cDNA from LUHMES proliferating cells and neurons of different 
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differentiation days. Brain cDNA (track 8) was included as positive control, and genomic DNA 
(track 9) as a control for genomic contamination. The last track was loaded with a non-template 
control (NTC). The band appearing at 200bp is the expected product size corresponding to 
SORCS3. No band was observed for any of the samples derived from both proliferating and 
differentiated LUHMES cells. 
 
4.2.1. Detecting SORCS2 in proliferating and differentiated 
LUHMES cells 
The qRT-PCR results indicated that SORCS2 was expressed in both proliferating and 
differentiated LUHMES cells. To obtain information about protein levels, I collected 
protein from WT LUHMES cells at proliferating stage and two differentiation days (day 
12 and day 14). Using a commercially available anti-SORCS2 antibody (AF4238, 
R&D), I detected a band of the expected protein size (approximately 130kDa) in both 
proliferating and differentiated LUHMES cells. However, in proliferating cells 
additional bands of different sizes were also detected. These could either constitute 
background bands or be suggestive of more than one SORCS2 isoform being 
expressed at this cellular stage (Figure 4.3).  
 
Figure 4.3. Detecting SORCS2 in proliferating and differentiated LUHMES cells. A 
representative western blot image, the band appearing in both proliferating and differentiated 
(day 12 and day 14) LUHMES cells at approximately 130kDA corresponds to SORCS2 (top 
panel). Red arrows point at additional bands observed in the protein samples derived from 
proliferating cells. Samples were probed for vinculin (approximately 110kDA, bottom panel), 
as well, to verify equal loading. The expected product sizes are marked on the left of the image.  
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4.3. Knocking out SORCS2 in LUHMES cells using 
CRISPR/Cas9 genome editing 
4.3.1. Experimental design 
Generating functional knockouts using CRISPR/Cas9 genome editing is a multi-step 
process. The generic workflow is shown in Figure 4.4., and each stage is explained 
below. 
A guide RNA (gRNA) is required to target the Cas9 protein to the genomic site of 
interest. There are two major considerations in the gRNA design and selection: (i) the 
presence of a 5’-NGG PAM site adjacent to the desired cut site and (ii) the 
minimisation of the gRNA’s off-target activity. There are many online tools that identify 
suitable target sites within a genomic sequence of interest and rank the available 
gRNAs based on their predicted off- and on-target activity. I used two such tools: MIT 
Target Finder (http://crispr.mit.edu) and DNA 2.0 
(https://www.dna20.com/eCommerce/cas9/input) to design gRNAs. Where possible, 
gRNAs ranked top by both programs were selected. When the two tools differed, 
gRNAs indicated by Target Finder were selected. Subsequently, I sequenced the 
target regions of the LUHMES genome to identify potential mismatches with the 
human reference genome that might compromise the gRNA activity. No mismatches 
were identified (data not shown). 
The Cas9-expressing plasmid pSpCa9(BB)-2A-GFP was chosen as a gRNA delivery 
method as it carries a GFP reporter gene, allowing for the selection of successfully 
transfected cells using fluorescent activated cell sorting (FACS). The gRNAs selected 
were annealed and ligated into the plasmid (Figure 4.4.B), which was subsequently 
transformed into the competent Stbl3 E.coli strain. Ten colonies were picked for each 
gRNA transformation and DNA isolated. Sanger sequencing was used to confirm the 
correct insertion of the gRNAs in the plasmid. For each gRNA, one colony was picked, 
DNA was extracted and the insertion sites and gRNA sequence checked by 
sequencing analysis.  
The pSpCa9(BB)-2A-GFP plasmid, containing the cloned gRNA, was transfected into 
low passage proliferating LUHMES cells using nucleofection as this has been 
previously reported as a preferred transfection method for human neurons 135. The 
top 3% of GFP-positive cells were FAC sorted to single cells into 96-well plates (three 
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plates per transfection) and allowed to grow for ten days. Colonies were picked and 
transferred to 24-well plates and then further expanded for generating frozen stocks, 




Figure 4.4. A figure showing all stages of the experimental workflow of the conducted 
CRISPR/Cas9 genome editing experiments: [A] gRNA selection and validation. A schematic 
representation of SORCS2 exon 3 selected for CRISPR/Cas9 targeting and the gRNA 
sequence within it. Arrowheads indicate the predicted cut site. A sequence trace showing no 
mismatches with the reference human genome within the gRNA sequence. [B] Schematic 
representation of the pSpCa9(BB)-2A-GFP plasmid, indicating the site of gRNA ligation. [C] 
Transfection of the pSpCa9(BB)-2A-GFP plasmid, with the ligated gRNAs, into proliferating 
LUHMES cells, followed by selection of the GFP-positive cells using FACS, and expansion of 
potentially edited clones for further validation.   
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4.3.1.1. Targeting the SORCS2 gene 
SORCS2 is located on chromosome 4 and has three protein-coding, one processed 
and five predicted transcripts (Figure 4.5). In order to achieve a complete SORCS2 
KO, I first checked which of the protein-coding and predicted transcripts were 
expressed in LUHMES. I designed RT-PCR primers targeting areas unique for each 
transcript or, when this was not possible, primers detecting a group of transcripts. No 
primers were designed for the processed transcript, as this type of transcripts does 
not contain an open reading frame and thus does not code for protein.  
From all screened transcripts, the only one that was not found in either human brain 
or LUHMES neuron cDNA was the predicted transcript XM_005247987.4 (primer pair 
4; Figure 4.6.B). All other predicted transcripts were detected in both human brain and 
LUHMES neuron cDNA (Figure 4.6.B). The protein-coding transcript, 
ENST00000329016.10, which differs from the full length SORCS2 transcript 
(ENST00000507866.6) by missing the first exon, was also detected in LUHMES 
neurons despite its existence being poorly supported according to its TSL (transcript 
support level) score in the Ensembl genome browser (primer pair 8, Figure 4.6.B). 
Unfortunately, it was impossible to determine whether the ENST00000505529.1 
transcript specifically was expressed in LUHMES as it did not have any unique regions 
and needed to be grouped with other SORCS2 transcripts (primer pair 2, Figure 
4.6.A). However, this transcript shows a very high TSL score according to the 
Ensembl genome browser. Meanwhile, ENST00000507866.6 constitutes the full-
length protein-coding SORCS2 transcript and I had previously detected SORCS2 in 
protein samples from differentiated LUHMES cells. Therefore, this transcript was not 





Figure 4.5. A diagram showing all protein-coding and predicted SORCS2 transcripts (apart from ENST00000505529.1, which was identified from the 
Ensembl genome browser). The second image shows the region where the identified SORCS2 transcripts differ from each other- exons 25-27. Individual 
tracks (from top to bottom) show the scale, the position in the genome, the structure of the protein-coding (dark blue) and predicted (bright blue) transcripts. 
The big rectangles correspond to exons, while the smaller ones- to 3’UTR ends. The thin lines with arrowheads represent intronic areas. The Names of 
the transcripts are listed on the left side of the top image. [Adopted after the UCSC genome browser.]  
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Figure 4.6. Detecting SORCS2 protein-coding and predicted transcripts in LUHMES neurons. 
[A] A schematic diagram of the exons where the SORCS2 transcripts differ. Protein-coding 
transcripts are shown in dark blue and predicted transcripts in bright blue. [B] RT-PCR with 
different primer pairs, designed to detect unique regions within the various SORCS2 
transcripts. 1.7% agarose gel stained with SYBR Safe. ‘M’ indicates tracks loaded with 50bp 
ladder. Primer pairs are shown as 1, 2, 3, etc., and the transcript(s) amplified by a given primer 
pair are listed in [A]. Each pair was run on both brain cDNA (left track) and LUHMES neuron 
cDNA (right track). ‘NTC’ stands for non-template control, which included a mix of all primers 
used. Expected PCR product sizes: 177bp (pair 1), 145bp (pair 2), 108bp (pair 3), 184bp (pair 
4), 170bp (pair 5), 114bp (pair 6), 197bp (pair 7), 192bp (pair 8).  
 
4.3.2. Targeting SORCS2 exon 25  
I started by targeting the first exon common for all protein-coding transcripts- exon 25. 
I transfected proliferating cells of low passage number with the pSpCa9(BB)-2A-GFP 
plasmid containing gRNA, targeting this exon. The transfection efficiency was 2.17% 
and the top 3% of GFP-positive cells were FAC sorted into 96-well plates. From the 
sorted single cells, 12 clonal cell lines grew successfully and were further expanded 
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into 24-well plates. In the process of transferring, three of the clones died, and the 
rest were grown further for isolating DNA, RNA and generating frozen stocks. 
4.3.2.1. Genotyping of the expanded clonal cell lines 
DNA was isolated from each of the successfully expanded clones and PCR performed 
with primers flanking the targeted exon. PCR amplification of exon 25 suggested the 
presence of indels in at least four clonal lines, with one of them, clone 9, showing two 
bands of different sizes on the agarose gel and three clones- 1, 5 and 7, showing 
three bands (Figure 4.7.A). The latter three clones were discarded. 
TOPO cloning, followed by Sanger sequencing, identified clone 9 as a compound 
heterozygote, carrying a deletion of 1bp on one allele, predicted to result in a 
frameshift mutation, and 6bp deletion on the other. This was the only clone predicted 
to carry a frameshift mutation. Sanger sequencing of the remaining five clones, 
showing a single band on the agarose gel (Figure 4.7.A), revealed that three of them, 
clones 3, 4 and 6, remained WT after the CRISPR process (hereafter referred to as 
‘CRISPR WT’), and one line- clone 8, was a homozygote for a 3bp deletion around 
the gRNA cut site. Clone 2 showed multiple sequencing traces around the predicted 
cut site and was discarded as a clone derived from a mixed cell population.   
4.3.3.2. Assessing the expression of SORCS2 in the CRISPR clones 
In order to assess the expression of SORCS2 in the above clones, I performed qRT-
PCR on cDNA derived from proliferating cells. SORCS2 expression levels were 
normalised to the expression levels of two optimum reference genes identified by the 
GeNorm software- RPLP34 and ERCC6 (data not shown). As can be seen in Figure 
4.7.B, all clones showed lower SORCS2 mRNA levels than WT LUHMES neurons 
grown simultaneously, including two of the three CRISRP WT lines. However, none 
of the other clones, including clone 9 that carried a frameshift mutation on one allele, 
showed mRNA lower than the CRISPR WT clones. Therefore, based on the qRT-
PCR results obtained, it was concluded that this round of CRISPR targeting did not 
produce any SORCS2 KO clones. 
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Figure 4.7. Results of CRISPR/Cas9 genome editing of SORCS2 exon 25. [A] Genotyping of 
the isolated CRISPR clones. PCR with primers, flanking SORCS2 exon 25, on WT genomic 
DNA (WT) and nine surviving clones (1-9), run on 1.7% agarose gel loaded with 1 Kb Plus 
ladder and stained with SYBR Safe. The first track was loaded with the ladder (‘M’), the second 
track was left empty, the third track was loaded with PCR product from WT LUHMES cells and 
the rest with samples from the nine clones isolated. The expected PCR product size was 
223bp. [B] qRT-PCR assessing SORCS2 mRNA levels in the isolated clones, excluding the 
clones that were identified as derived from mixed cell populations (clones 1, 2, 5 and 7). The 
x-axis shows the clones, while the y-axis shows the mRNA quantity normalised to the 
geometric mean of the most stable reference genes selected by the GeNorm software. The 
graph represents results from a single experiment.  
 
4.3.3. Targeting SORCS2 exon 1 
As targeting SORCS2 exon 25 did not generate SORCS2 KO clones and because of 
concerns that mutations introduced in such downstream exons were less likely to lead 
to functional knockouts, I decided to target the first exon of the full length, protein-
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coding SORCS2 transcript ENST00000507866.6. As described previously, I 
transfected proliferating LUHMES cells with the pSpCa9(BB)-2A-GFP plasmid 
containing gRNA targeting this exon. Using this gRNA, the transfection efficiency was 
7.88%. Ten days after FAC sorting of the GFP-positive cells into 96-well plates, I 
identified 65 clonal cell lines, which were then split into two wells of a 24-well plate. 
One third of the cell suspension was kept for genotyping. Three clones (1.21, 1.22 
and 1.23) did not survive the transfer process.   
4.3.3.1. Genotyping of the identified clonal cell lines, where SORCS2 exon 1 
was targeted 
DNA was isolated from 62 clones. PCR screening with primers flanking SORCS2 
exon 1 identified 34 clonal cell lines as carrying a single band (Figure 4.8.A). 
Additionally, 12 clones showed two bands on the gel, and two clones- three (Figure 
4.8.A). The latter were discarded. Susan Anderson performed Sanger sequencing 
analysis of all PCR products that showed a single band on the gel. Subsequently, I 
carried out the analysis of the sequencing data. High quality traces were obtained for 
26 out of the 34 clones sequenced. Analysis of the traces identified one clone– 1.30, 
as a CRISPR WT, eight clones as heterozygotes, showing double sequence around 
or after the cut site, and the remaining 17 clones as homozygotes, carrying the same 
indel on both alleles (Table 4.1.). Subsequently, I repeated the PCR on all ten samples 
that did not give a product the first time, together with the ones that failed to sequence. 
The second round of PCR identified two clones as showing two bands on the gel, 
another two as carrying more than two alleles (showing three bands on the gel) and 
additional seven as showing a single band (Figure 4.8.B). I set up and sent those for 
sequencing. Two of the sequenced clones did not give clean traces. However, from 
the rest, three clones carried homozygous inframe deletions and one clone- a deletion 
within a regulatory region (Table 4.1.).  
Twelve clones either failed to PCR amplify or showed unreadable sequencing traces. 
I therefore decided to obtain fresh DNA samples from them and repeat the 
genotyping. Unfortunately, the majority of clones did not recover after thawing. 
However, five (1.5, 1.29, 1.44, 1.51 and 1.59) clones survived. Susan Anderson 
isolated DNA from these clones and performed PCR amplification and Sanger 
sequencing. DNA isolated from clone 1.44 failed to PCR amplified even though the 
same amount of DNA was used as a template as for the other clones. Therefore, it 
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was concluded that clone 1.44 might carry a big deletion affecting the primer binding 
sites. The results from the genotyping are included in Table 4.1.   
 
 
Figure 4.8. Genotyping of the 62 clones isolated after targeting SORCS2 exon 1. 1.7% 
agarose gels loaded with 1 Kb Plus ladder (tracks labelled with ‘M’) and stained with SYBR 
Safe. Tracks loaded with samples from the CRISPR clones are labelled as 1.1., 1.2, 1.3, etc. 
LUHMES genomic DNA was included as a positive control (tracks labelled as ‘Ctrl’), and non-
template control tracks are depicted as ‘NTC’. [A] Initial PCR screening of the isolated clones 
with primers, flanking the targeted SORCS2 exon 1. Due to pipetting error during setting up 
the PCR, the positive control (‘Ctrl’) did not give a band of the expected product size. [B] 
Subsequent PCR screening on the DNA samples that failed either to amplify the first time or 
to give clean sequencing traces. The tracks loaded with 1 Kb Plus ladder are marked with ‘M’. 




Table 4.1. A table listing all isolated clones after targeting SORCS2 exon 1, the obtained for each PCR and sequencing results, as well as the type and 
the consequences of the introduced mutation.  
Clone PCR  Sequencing Frameshift VEP predicted impact 
1.1 Single band 6bp deletion No Inframe deletion (moderate effect) 
1.2 Three bands Not sequenced, 
discarded 
  
1.3 Single band 6bp deletion No Inframe deletion (moderate effect) 
1.4 Single band Sequencing failed   
1.5 Single band 137bp deletion Yes Frameshift variant (high/modifier effect), affects a transcription 
factor binding site and a regulatory region (promoter) 
1.6 Single band 85bp deletion Yes Frameshift variant (high/modifier effect), affects a putative 
regulatory region (promoter) 
1.7 No PCR product    
1.8 No PCR product    
1.9 No PCR product    
1.10 No PCR product    
1.11 Single band Double sequence trace 
around the cut site 
  
1.12 Single band 1bp mismatch  
+ 6bp deletion 
No Inframe deletion (moderate effect) 
1.13 Single band Double sequence trace 
around the cut site 
  
 
Clone PCR Sequencing Frameshift VEP predicted impact 
1.14 Three bands Not sequenced, 
discarded 
  
1.15 Single band 54bp deletion No Inframe deletion (moderate effect) 
1.16 Double band    
1.17 Single band 6bp deletion  
+ double sequence trace 
around the cut site 
  
1.17 Single band 6bp deletion  
+ double sequence trace 
around the cut site 
  
1.18 Single band Sequencing failed   
1.19 Single band 1bp deletion Yes Frameshift mutant (high effect) 
1.20 Single band 136bp deletion No Inframe deletion (moderate effect) 
1.21 Dead    
1.22 Dead    
1.23 Dead    
1.24 Single band Double sequence trace 
around the cut site 
  
1.25 Double band    
1.26 Double band    
 
Clone PCR  Sequencing Frameshift VEP predicted impact 
1.27 Double band    
1.28 Three bands Not sequenced, 
discarded 
  
1.29 Single band In progress   
1.30 Single band WT sequence No  WT 
1.31 Three bands Not sequenced, 
discarded 
  
1.32 Single band Double sequence trace 
around the cut site 
  
1.33 Double band N/A   
1.34 Double band    
1.35 Double band    
1.36 Single band 81bp deletion No Inframe deletion, affecting a putative promoter and a CTF-
binding site (moderate/ modifier effect) 
1.37 Single band Did not work   
1.38 Single band 74bp deletion No Inframe deletion, affecting a putative promoter and a CTF-
binding site (moderate/ modifier effect) 
1.39 Single band Did not work   
1.40 Single band Double sequence trace 




Clone PCR  Sequencing Frameshift VEP predicted impact 
1.41 Single band Double sequence trace 
around the cut site 
  
1.42 Single band 266bp deletion No Inframe deletion, affecting a putative promoter and a CTF-
binding site (moderate/ modifier effect) 
1.43 Single band 7bp deletion Yes Frameshift mutation (high effect) 
1.44 PCR did not work    
1.45 Single band  48bp deletion No Inframe deletion (moderate effect) 
1.46 Double band    
1.47 Single band Double sequence trace    
1.48 Single band Did not work   
1.49 Double band    
1.50 Single band Double sequence trace    
1.51 Single band 150bp deletion Yes Frameshift variant (high/modifier effect), affects a putative 
transcription factor binding site and regulatory region 
(promoter) 
1.52 Double band    
1.53 Single band 26bp deletion Yes Frameshift mutation (high effect) 
1.54 Single band 9bp deletion No  Inframe deletion, affecting a putative promoter and a CTF-
binding site (moderate/modifier effect) 
1.55 Dead    
1.56 Single band 6bp deletion No Inframe deletion (moderate effect) 
 
Clone PCR  Sequencing Frameshift VEP predicted impact 
1.57 Single band Did not work   
1.58 Did not work    
1.59 Single band 2bp insertion Yes Frameshift mutation (high effect) 
1.60 Single band 12bp deletion No Inframe deletion 
1.61 Single band Did not work   
1.62 Single band Did not work   
1.63 Double band    
1.65 PCR did not work    
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4.3.3.2. Identifying SORCS2 knockouts amongst the clones, carrying 
variants predicted to have an effect on the protein sequence 
Given the fact that mRNA levels do not necessarily correspond to protein levels160, I 
decided to screen for potential SORCS2 KOs using western blot analysis. Normally, 
inframe deletions do not affect translation, while frameshift mutations alter the reading 
frame and ultimately introduce a premature stop codon. Bearing this in mind, I 
screened all clones that carried a frameshift mutation (1.5, 1.6, 1.19, 1.29, 1.44, 1.51, 
1.53 and 1.59), as well as clones 1.42 and 1.44. Clone 1.42 had a large inframe 
deletion that was predicted to affect a putative promoter and a CTF-binding site by 
the Ensembl VPN tool. Meanwhile, DNA isolated from clone 1.44 failed PCR amplify 
and was thus assumed to carry a big deletion. Clone 1.30, which remained a WT after 
the CRISPR process (CRISPR WT), was also included in the analysis as a control.  
The selected CRISPR-edited clones were differentiated into neurons alongside WT 
LUHMES cells of a similar passage number. During the process of differentiation, 
clone 1.6 and 1.19 died and I was unable to revive the remaining frozen vials. After 
14 days of differentiation, I collected protein samples from all of the remaining clones, 
which I then used to analyse SORCS2 expression using western blot. Detecting 
SORCS2 with a commercially available antibody (AF4238, R&D) identified clones 1.5, 
1.29, 1.44, 1.51, 1.59 (Figure 4.9.B) and 1.42 and 1.53 (Figure 4.9.A) as SORCS2 
KOs.  Meanwhile, the CRISPR WT clone 1.30 showed protein levels close to that of 
the control WT LUHMES cell line as determined by visual inspection (Figure 4.9.A). 
These results were confirmed using a second, custom-made antibody (F7100, kind 
gift of Assoc. Prof Simon Glerup), specific for SORCS2 (Figure 4.9.A). However, when 
probed with this antibody, clone 1.42 showed a faint band of the correct size 
suggesting that it is not a knockout.    
 
Figure 4.9. Western blot analysis identifying SORCS2 KO clones amongst the ones predicted 
to carry mutations, affecting the protein sequence. [A] Representative western blot images, 
indicating clone 1.53, but not clone 1.42 as SORCS2 KO. Protein samples from WT LUHMES 
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and the CRISPR WT clone 1.30 were included as controls. Clone 1.30 showed SORCS2 
protein levels similar to the WT. Probing the same membrane with two different antibodies 
against SORCS2- AF4238 (top panel) and F7100 (middle panel) confirmed the results. 
Samples were probed for GAPDH (bottom panel), as well, to verify equal loading. The 
expected product sizes (SORCS2- 130kDa and GAPDH- 37kDA) are marked on the left of the 
images. [B] Representative image of a western blot, indicating clones 1.5, 1.29, 1.44, 1.51 and 
1.59 as SORCS2 KOs. Two LUHMES WT lines of a similar passage number and grown at the 
same time were included as controls. Protein lysate from HEK cells, carrying a SORCS2 
expression plasmid, was used a positive control. Probing for GAPDH verified equal loading. 
The expected product sizes (SORCS2- 130kDa and GAPDH- 37kDA) are marked on the left 
of the images. Western blots were repeated on at least three independently collected protein 
lysates from each clone.  
 
4.3.4. Targeting SORCS2 exon 3 
I decided to target exon 3 by CRISPR/Cas9 genome editing simultaneously, as one 
SORCS2 transcript, ENST00000329016.10, which lacks exon 1 was also detected in 
LUHMES neurons using RT-PCR (Figure 4.6.). As exon 2 was too short for gRNA 
design, I targeted SORCS2 exon 3. I transfected proliferating LUHMES cells with 
gRNA homologous to a region within this exon. The efficiency of the transfection was 
considerably lower- 1.33%, compared to that obtained when targeting exon 1 (7.88%). 
However, after ten days, I identified 73 clonal cell lines. Each line was split into two 
wells of a 24-well plate and one third of the cell suspension was kept for genotyping. 
4.3.4.1. Genotyping of the identified clonal cell lines where SORCS2 exon 3 
was targeted 
In order to genotype the 73 clones where exon 3 was targeted, Susan Anderson set 
up a PCR assay using intronic primers flanking the targeted exon. Initial screening 
identified 48 clonal cell lines as potentially homozygous, showing a single band on 
the gel. Fifteen clones had two bands, and five others were discarded due to the 
presence of three bands (Figure 4.10.).  
All 57 samples where there was a single band on the gel were subjected to 
sequencing analysis by Susan Anderson, and I analysed the results. Of the 57 
sequenced samples, 18 had double traces in the region of the predicted gRNA cut 
site (Table 4.2). The VEP tool was used as before to predict the effect of the mutations 
on the protein sequence of the remaining 39 clones. Twelve clones carried inframe 
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deletions, ten clones had frameshift mutations and three clones carried a mutation 
affecting a splice donor site, as well as an enhancer region. The latter were predicted 
to have a damaging effect by VEP. Another clone was heterozygous for one base pair 
mismatch (Table 4.2). Additionally, the DNA extraction failed for one clone, and the 
PCR assay did not work for four others (Figure 4.10). I decided not to repeat the 




Figure 4.10. Genotyping of the 73 clones isolated after targeting SORCS2 exon 3, using 
primers, flanking the targeted exon. 1.7% agarose gel stained with SYBR Safe. Tracks labelled 
with ‘M’ were loaded with 1 Kb Plus ladder. Tracks loaded with samples from the CRISPR 
clones are labelled from 3.1. to 3.73. LUHMES genomic DNA was included as a positive 
control (tracks labelled as ‘Ctrl’). ‘NTC’ corresponds to non-template control. The expected 
PCR product size was 476bp. 
 
 
Table 4.2. A table listing all isolated clones after targeting SORCS2 exon 3, the obtained for each PCR and sequencing results, as well as the type and 
the consequences of the introduced mutation.  
Clone PCR  Sequencing Frameshift VEP predicted impact 
3.1 Single band Double sequence trace around the cut site   
3.2 Single band 9bp deletion No Inframe deletion (moderate effect) 
3.3 Single band Double sequence trace around the cut site   
3.4 Single band 1bp insertion Yes Frameshift mutation (high impact) 
3.5 Single band 33bp deletion No Inframe deletion (moderate effect) 
3.6 Single band Double sequence trace around the cut site   
3.7 Single band Double sequence trace around the cut site   
3.8 Single band Double sequence trace around the cut site   
3.9 Single band Mismatches around the cut site   
3.10 Single band Double sequence trace around the cut site   
3.11 PCR did not 
work 
   
3.12 Double band    
3.13 PCR Did not 
work 
   
3.14 Single band Double sequence trace around the cut site   
3.15 Single band Double sequence trace around the cut site   
3.16 Single band 12bp deletion   No Inframe deletion (moderate effect) 
 
Clone PCR  Sequencing Frameshift VEP predicted impact 
3.17 Double band    
3.18 Double band    
3.19 Single band Double sequence trace around the cut site   
3.20 Single band 12bp deletion No  Inframe deletion (moderate effect) 
3.21 Single band 9bp deletion No  Inframe deletion (moderate effect) 
3.22 Single band 126bp deletion No Donor splice site variant (high 
impact) 
3.23 Single band Double sequence trace around the cut site   
3.24 Three bands Not sequenced, discarded   
3.25 Single band Double sequence trace around the cut site   
3.26 Single band 95bp deletion Yes Donor splice site variant (high 
impact) 
3.27 Single band Double sequence trace around the cut site   
3.28 Single band Double sequence trace    
3.29 Single band Double sequence trace around the cut site   
3.30 Single band Sequencing did not work   
3.31 Single band 1bp insertion Yes Frameshift mutation (high impact) 
3.32 Single band 3bp deletion No Inframe deletion (moderate effect) 
3.33 Single band 3bp deletion No Inframe deletion (moderate effect) 
3.34 Single band 9bp deletion No Inframe deletion (moderate effect) 
 
Clone PCR  Sequencing Frameshift VEP predicted impact 
3.35 Single band 56bp deletion No Inframe deletion (moderate effect) 
3.36 Single band 3bp deletion Yes Frameshift mutation (high impact) 
3.37 Double band    
3.38 Single band 1bp mismatch   
3.39 Single band 10bp deletion Yes Frameshift mutation (high impact) 
3.40 Single band 2bp insertion Yes Frameshift mutation (high impact) 
3.41 Single band 191bp deletion Yes Donor splice site variant (high 
impact) 
3.42 Double band    
3.43 Single band Double sequence trace around the cut site   
3.44 Single band 1bp insertion Yes Frameshift mutation (high impact) 
3.45 Single band Sequencing did not work   
3.46  Three bands Not sequenced, discarded   
3.47 Double band    
3.48 Single band Double sequence trace    
3.49 Single band Multiple insertions   
3.50 Single band 6bp deletion No Inframe deletion (moderate effect) 
3.51 Single band 1bp insertion Yes Frameshift mutation (high effect) 
3.52 Single band 13bp deletion Yes Frameshift mutation (high effect) 
3.53 Single band Double sequence trace around the cut site   
 
Clone PCR  Sequencing Frameshift VEP predicted impact 
3.54 Double band    
3.55 Three bands Not sequenced, discarded   
3.56 Single band Double sequence trace around the cut site   
3.57 Single band Double sequence trace around the cut site   
3.58 Single band Double sequence trace around the cut site   
3.59 Single band Double sequence trace around the cut site   
3.60 Single band 1bp insertion Yes Frameshift mutation (high impact) 
3.61 Single band Double sequence trace around the cut site N/A N/A 
3.62 Single band Double sequence trace around the cut site   
3.63 Single band 17bp deletion Yes Frameshift mutation (high impact) 
3.64 Three band Not sequenced, discarded   
3.65 Single band Double sequence trace around the cut site   
3.66 Single band 6bp deletion No Inframe deletion (moderate effect) 
3.67 Failed DNA isolation 
3.68 Single band Double sequence trace around the cut site   
3.69 Single band Double sequence trace around the cut site   
3.70 Did not work    
3.71 Single band 12bp deletion No Inframe deletion (moderate effect) 
3.72 Double band    
3.73 Single band Double sequence trace around the cut site   
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4.3.4.2. Identifying SORCS2 knockouts amongst the clones carrying variants 
predicted to have an effect on the protein sequence 
As mentioned above, lines carrying a frameshift mutation are mostly likely to be 
knockouts. Therefore, I grew up and differentiated the following clones into neurons: 
3.36, 3.39, 3.40, 3.52, 3.60 and 3.63, which carried frameshift mutations and clones 
3.22, 3.26 and 3.41, which had mutations predicted to exert damaging effect on 
translation. LUHMES WT neurons of a similar passage number were cultured in 
parallel to the edited lines. During the process of differentiation, clones 3.22, 3.52 and 
3.60 died and I was unable to revive the remaining from them frozen vials.  
After 14 days of differentiation, I collected protein samples from all clones, which I 
then probed for SORCS2 using western blot. Detecting SORCS2 with the 
commercially available antibody AF4238 (R&D) identified clones 3.26, 3.36, 3.39, 
3.40, 3.41 and 3.63 as knockouts (Figure 4.11.). 
 
 
Figure 4.11. Western blot analysis identifying SORCS2 KO clones. A representative western 
blot image (top panel), showing clones 3.26, 3.36, 3.39, 3.40, 3.41 and 3.63 as SORCS2 KOs. 
Protein samples from WT LUHMES neurons of a similar passage number were included as 
controls. Samples were probed for GAPDH (bottom panel) to verifying equal loading. Protein 
lysate from HEK cells carrying a SORCS2 expression plasmid was used a positive control. 
The expected protein sizes (SORCS2- 130kDa and GAPDH- 37kDA) are marked on the left 
of the images. Western blots were repeated on at least three independently collected protein 
lysates from each clone.   
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4.4. Discussion 
The aim of the work described in this chapter was to generate knockouts of the 
SORCS2 gene in LUHMES cells using the CRISPR/Cas9 genome editing system. 
Using qRT-PCR, I have shown that LUHMES neurons express four members of the 
sortilin family in what appears to be developmentally regulated manner. Additionally, 
RT-PCR detected potentially all, including predicted, SORCS2 protein coding 
transcripts in LUHMES neurons, apart from XM_005247987.4.  However, since some 
transcripts did not have unique regions, I needed to group them together with others. 
Thus, it was impossible to predict whether the ENST00000505529.1 transcript 
specifically was expressed in LUHMES.  
After establishing which SORCS2 isoforms were likely to be expressed in LUHMES 
neurons, I designed gRNAs aiming to knock out the gene. I started with a gRNA that 
targeted the first common exon for all transcripts (including ENST00000505529.1)- 
exon 25. Only 12 single cell colonies survived following sorting, and three out of these 
12 clones remained WT after the CRISPR process. Meanwhile, only one (clone 9) 
carried a frameshift mutation only on one allele of the SORCS2 gene. The mRNA 
levels detected in this clone were not lower than those detected in the clones that 
remained WT after the CRISPR process. Moreover, two out of the three CRISPR WT 
clones showed reduced SORCS2 mRNA levels when compared to a WT cell line. 
This unexpected finding could be explained by either gRNA off-target activity or 
intrinsic cell line variability.  
There are a few possible reasons for the unsuccessful attempt of knocking out 
SORCS2 by targeting exon 25. First, the low number of single cell colonies identified, 
combined with the low proportion of clones carrying a mutation in the targeted area 
suggests that the used gRNA was either toxic and/or had lower efficiency. As 
mentioned in the introduction, two online tools were used for gRNA design- DNA 2.0 
and the MIT Target Finder. When these tools ranked different gRNAs as best, the 
ones indicated by Target Finder were selected. This was the case when designing 
the gRNA targeting SORCS2 exon 25. However, following this experiment, problems 
in the Target Finder algorithm were announced. Since then, many online tools 
predicting the efficiency of the available gRNA for a given area have been designed. 
Using one such tool (http://chopchop.cbu.uib.no/index.php), I found out that all 
available gRNA for SORCS2 exon 25, including the one I used, display low efficiency 
and are predicted to have many off-targets.    
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Even if the gRNA used was efficient, it would have been still difficult to achieve a 
complete SORCS2 KO by targeting exon 25. Frameshift mutations close to the 
carboxy terminal are known to be less deleterious compared to these introduced next 
to a translation start site (TSS), as they are more likely to produce truncated proteins 
rather than to activate NMD pathways161. Thus, in order to achieve functional 
SORCS2 KO, I designed gRNAs targeting exon 1 and 3. Exons 1 and 3 are located 
in the beginning of all protein coding SORCS2 transcripts (including the predicted 
ones), apart from ENST00000511199.1 which lacks exon 1 and 
ENST00000505529.1 which starts from exon 25. However, it is unlikely that these 
transcripts result in protein products as, according to Ensembl, they have very high 
TSL scores (TSL5 and TSL4, respectively) and thus are not very well supported by 
mRNA and/or expressed sequence tags (ESTs).   
Targeting SORCS2 exon 1 and 3 resulted in a large number of clonal lines derived 
from single cells, most of which were edited (only one clonal line remained CRISPR 
WT after targeting SORCS2 exon 1 and none after targeting exon 3). From these, I 
identified a number of SORCS2 KO clonal lines, derived from each of the used 
gRNAs: clones 1.5, 1.29, 1.44, 1.51, 1.53 and 1.55 (derived from gRNA targeting 
SORCS2 exon 1), and 3.26, 3.36, 3.39, 3.40, 3.41 and 3.63 (derived from gRNA 
targeting SORCS2 exon 3). It is highly likely that these clones constitute complete 
knockouts, as no bands of the expected protein size of 130kDA were observed when 
using two different antibodies against the human SORCS2 protein. Moreover, since 
targeting exon 1 knocked out SORCS2, it is highly unlikely that the 
ENST00000511199.1 transcript is translated in LUHMES. This is in agreement with 
the high TSL assigned to it by Ensembl.  
The majority of the identified single cell colonies constituted compound heterozygotes 
as they showed more than one allele after PCR amplification. Thus, it is possible that 
some of these compound heterozygotes are knockouts for the SORCS2 gene, as 
well. However, since I had already identified a reasonable number of SORCS2 KOs 
and also due to time restraints, this was not further investigated. Additionally, some 
clones showed three bands on the PCR gel. These were discarded as they were most 
probably derived from more than one single cell, thus representing mixed cell 
populations.
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Chapter 5 Assessing the effect of knocking out 
SORCS2 on DNA DSB formation and potential 
underlying mechanisms in vitro 
5.1. Introduction 
As discussed in chapter 3, I detected increased levels of DNA DSB formation in the 
dentate gyrus of Sorcs2-/- mice compared to WT mice. Following on from this result, I 
first wanted to see whether these findings can be replicated both in the human 
neuronal cell line LUHMES, as well as in mouse hippocampal primary neurons. 
Additionally, I wanted to explore the effect of knocking out SORCS2 in vitro on the 
generation of DNA DSBs following treatment with etoposide. Etoposide is a 
chemotherapeutic agent that binds to DNA topoisomerase II (TopoII), trapping the 
enzyme in a covalent complex with the cleaved DNA and preventing break re-
ligation162. Thus, its application allows the accumulation of DNA damage. There are 
two distinct isoforms of TopoII expressed in the mammalian system- TopoIIα and 
TopoIIβ. The former is mainly expressed in dividing cells, whereas the latter is 
expressed in postmitotic cells, such as neurons, where it is primarily involved in 
transcription-related processes163. Recently, TopoIIβ has also been implicated in the 
formation of DNA DSBs following neuronal activity and has been shown to be required 
for the expression of early-response genes118. Additionally, treatment of primary 
neurons with etoposide altered the expression of nearly 700 genes, with the majority 
of them being downregulated. However, twelve genes were upregulated, including 
the early-response genes Fos, FosB and Npas4118. Secondly, if knocking out 
SORCS2 was found to be associated with increased DSB formation, I wanted to 
explore potential mechanisms underlying this finding. Suberbielle et al. (2013)107 
showed that treatment with Aβ oligos led to increased DSBs in WT primary neurons, 
and that this process was dependent on NR2B-containing NMDAR activity. 
Meanwhile, NR2A-containin NMDARs were required for DSB repair107. Similarly to 
etoposide, stimulating primary neuronal cultures with the synthetic NMDAR agonist, 
NMDA, was associated with the formation of DNA DSBs within early-response genes, 
including Fos, FosB, Npas4, and Egr1, as well as within genes encoding for other 
transcription factors and a few non-coding RNAs118. In mice, SorCS2 is required for 
the induction of hippocampal NMDAR-dependent LTP and LTD5, as well as for the  
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trafficking of the NMDA receptor subunit NR2A in striatal neurons51. Furthermore, 
knocking down SORCS2 in HEK293 cells has been previously shown to upregulate 
APP processing46. Thus, both increased Aβ production and/or dysregulated NMDA 
receptor signalling would constitute potential mechanisms underlying any increase in 
DNA DSB formation observed in the knockout cell lines. Additionally, elevated 
extracellular dopamine levels have been linked to increased DNA damage and 
neurodegeneration in vitro164,165. Therefore, given the role of SorCS2 in the 
development of the dopaminergic system6, the levels of extracellular dopamine 
secreted by the SORCS2 KO LUHMES neurons were also investigated as a potential 
source of DNA damage.  
 
5.1.1. Aims 
The aims of the experiments described in this chapter were to:  
• Investigate the levels of DNA DSB formation in the generated SORCS2 KO 
LUHMES lines both with and without treatment with etoposide. 
• Investigate the levels of DNA DSB formation in untreated and etoposide-
treated primary hippocampal neurons derived from Sorcs2-/- and WT pups. 
• Investigate potential mechanisms that could account for the observed 
increase in DNA DSB formation upon knocking out SORCS2 in vivo and in 
vitro.  
 
5.2. Assessing the levels of DNA DSB formation in 
the SORCS2 KO LUHMES lines 
5.2.1. Assessing DNA DSB formation in the SORCS2 KO 
LUHMES lines 
In order to assess whether the higher levels of DSBs observed in the Sorcs2-/- 
compared to WT mice could be replicated in human neurons, I grew and differentiated 
SORCS2 KO (n=4) and WT (n=3) LUHMES lines of a similar passage number. Clones 
where SORCS2 exon 3 was disrupted were chosen for this initial experiment, as this 
meant that both the long and shorter isoform of SORCS2 were targeted. Following 14 
days of differentiation, neurons were fixed and stained for γH2A.X and 53BP1. As 
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discussed in chapter 1, γH2A.X staining is considered the ‘gold standard’ for detecting 
DNA DSBs111. Meanwhile, 53BP1 plays a critical role in the cell response to DNA 
damage, being quickly recruited to DSB sites, where it binds to γH2A.X and acts as a 
scaffold for the binding of additional DNA repair proteins166,167. Thus, co-labelling of 
γH2A.X-positive foci with 53BP1 provides clear evidence for the presence of DNA 
DSBs.  
As previously reported for primary cortical cultures, untreated LUHMES neurons 
showed very few γH2A.X/53BP1-positive foci, with 53BP1 appearing mostly as 
defuse staining (Figure 5.1.A). Approximately 100 nuclei (from four images belonging 
to different regions of the same coverslip) were counted for each WT and SORCS2 
KO line and the number of γH2A.X/53BP1-positive foci per nucleus was calculated. 
Nuclei showing apoptotic features (i.e. condensed and ‘blebbing’ nuclei), as well as 
those completely covered with intense, bright γH2A.X signal were excluded from the 
analysis (Figure 5.1.A). More than 90% of the analysed untreated WT neurons had 
fewer than 3 foci per nucleus with the majority of them showing 0 foci. These 
observations were consistent with previous studies of both untreated neurons115 and 
other non-neuronal cell types122. While the SORCS2 KO lines (n=4) had on average 
a greater number of γH2A.X/53BP1-positive foci per nucleus compared to WT 
controls (n=3), the difference was not significant (p=0.085; Figure 5.1.B). This result 
might have reflected a true lack of difference between the two groups or, alternatively, 
the small sample size might have led to insufficient power to detect a difference.  
To overcome these limitations, I repeated the experiment by including additional WT 
and SORCS2 KO clones in the analysis. This time, SORCS2 KO clones generated 
after targeting exon 1 (n=4) were added to the ones where exon 3 was disrupted (n=5) 
in an attempt to ensure that the observed phenotype is not the result of CRISPR off-
target activity, as any off-targets will differ between two gRNAs. As before, WT (n=9) 
and SORCS2 KO (n=9) clones were differentiated until day 14, fixed and stained for 
γH2A.X and 53BP1. Approximately 100 nuclei (from four images taken from the same 
coverslip) were examined for each cell line, and the number of foci where γH2A.X and 
53BP1 co-localised was counted. As for the initial experiment, there was no significant 
difference in the number of foci per nucleus between the WT and the SORCS2 KO 
clones (p=0.647, Figure 5.1.C). No significant difference was observed also when the 
number of γH2A.X/53BP1-positive foci per nucleus was compared between the 
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SORCS2 KO clone generated after targeting exon 1 and those obtained after 
targeting exon 3 (p= 0.7780, Figure 5.1.D). 
 
 
Figure 5.1. Levels of DNA DSB formation in untreated WT and SORCS2 KO LUHMES cell 
lines. [A] A representative z-stack confocal image (100x magnification). The thin arrow points 
at a nucleus (DAPI, blue) with diffuse 53BP1 staining (red), while the thick arrow points at a 
nucleus with a focus where γH2A.X (green) co-localised with 53BP1 (red) to give yellow 
staining. White rectangles show examples of nuclei excluded from the analysis due to either 
bright γH2A.X staining covering the whole nucleus or abnormal, apoptotic morphology. Scale 
bar corresponds to 10µm. [B] Initial experiment performed on a small number of WT (n=3) and 
SORCS2 KO (n=4) clones, comparing the number of γH2A.X/53BP1-positive foci per nucleus 
between the two genotypes. [C] The number of γH2A.X/53BP1-positive foci per nucleus in a 
follow-up experiment comparing WT LUHMES neurons (n=9) and SORCS2 KO clones (n=9) 
derived using two different gRNAs. [D] Comparison of the number of γH2A.X/53BP1-positive 
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foci per nucleus derived by targeting exon 1 or exon 3. Unpaired t-test, each point on the graph 
represents an individual clone; error bars represent mean ± SD.  
 
5.2.2. Assessing the levels of DNA DSBs in the SORCS2 KO 
LUHMES lines following treatment with etoposide 
As described above, in post-mitotic cells, etoposide prevents the re-ligation of DNA 
DSBs occurring as a result of TopoIIβ activity168. Therefore, treatment with etoposide 
would lead to the accumulation of otherwise naturally forming, TopoIIβ-dependent 
DNA breaks, providing a ‘snapshot’ of all events that took place over the course of 
the treatment. In order to be able to both visualise and reliably count the number of 
DNA breaks following treatment with etoposide, I started by titrating the concentration 
of the compound used until single foci-like staining was observed. A range of 
etoposide concentrations, starting from 50µM to 0.5µM, were applied to WT LUHMES 
neurons (day 14) for 4 hours. The cells were then fixed and stained for γH2A.X. Foci-
like staining pattern was observed after titrating the compound concentration down to 
2µM. However, 0.5µM resulted in a clearer foci staining and thus all subsequent 
experiments involving treatment with etoposide were performed using this 
concentration (Figure 5.2.A).  
Subsequently, I grew and differentiated into neurons WT (n=9) and SORCS2 KO 
(n=9) clones of a similar passage number. At day 14 of differentiation, I treated the 
neurons with etoposide (0.5µM) for 4 hours. Approximately 100 nuclei (from four 
images taken from the same coverslip) were screened, and the number of foci positive 
for both γH2A.X and 53BP1 was counted for each cell line. Knocking out SORCS2 
led to a significant increase in the number of γH2A.X/53BP1-positive breaks per 
nucleus (p= 0.0474, Figure 5.2.B). The observed increase in DSB formation was 
unlikely to be the result of CRISPR off-target activity as there was no difference in the 
number of γH2A.X/53BP1-positive foci per nucleus between the SORCS2 KO clones 
derived after targeting exon 1 and those generated after disrupting exon 3 (p= 0.9322, 
Figure 5.2.C). 
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Figure 5.2. DNA DSB formation in WT and SORCS2 KO LUHMES neurons following treatment 
with etoposide. [A] Representative z-stack confocal images (60x magnification) of LUHMES 
WT neurons treated with various etoposide concentrations: 50µM (top left), 2 µM (top right) 
and 0.5 µM (bottom left), as well as untreated (bottom right). White arrows pointing at nuclei 
(DAPI, blue), where γH2A.X staining (green) was detected following treatment with etoposide. 
Scale bars correspond to 10µm. [B] Comparing the number of γH2A.X/53BP1-positive foci per 
nucleus in WT LUHMES neurons (n=9) and SORCS2 KO clones (n=9) following etoposide 
treatment. [C] Comparison of the number of γH2A.X/53BP1-positive foci per nucleus between 
etoposide-treated SORCS2 KO clones derived by targeting exon 1 (n=4) or exon 3 (n=5). 
Unpaired t-test, ‘*’ corresponds to p<0.05; each dot on the graphs corresponds to an individual 
cell line; error bars represent mean ± SD. 
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5.2.3. Assessing neuronal viability in the SORCS2 KO clones 
Since DSB formation has been shown to affect neuronal function and survival169, I 
wanted to see whether knocking out SORCS2 has an impact on the overall neuronal 
viability. The same WT (n=9) and SORCS2 KO lines (n=9) used in the experiments 
described above were brought up and differentiated into neurons. Viability was 
measured at day 6 and day 14 of differentiation using the Alamar Blue assay, which 
provides a measure of the metabolic activity of the cells. At day 6, there was no 
significant difference in the viability of WT (n=9) neurons compared to that of SORCS2 
KO clones (n=9) (p=0.7144; Figure 5.3.A). However, at day 14, SORCS2 KO clones 
(n=7) showed a significant reduction in their viability compared to WT controls (n=9) 
(p=0.0047, Figure 5.3.B). All the cells in two SORCS2 KO lines lifted off the plate prior 
to day 14, preventing assessment of viability. 
 
Figure 5.3. Assessing neuronal viability, measured as fluorescent signal, in the SORCS2 KO 
clones using the Alamar Blue assay. [A] Comparison of neuronal viability between WT (n=9) 
and SORCS2 KO (n=9) cell lines at day 6 of differentiation. [B] Comparing neuronal viability 
of WT (n=9) and SORCS2 KO (n=7) at day 14 of differentiation. Unpaired t-test; each dot on 
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5.3. Investigating potential mechanisms underlying 
the increase in DNA DSBs upon SORCS2 
knockout 
5.3.1. Assessing the effect of knocking out SORCS2 on DNA 
DSB formation following NMDA stimulation in vitro 
NMDA is a potent NMDAR agonist, and non-cytotoxic NMDAR stimulation with this 
compound has been previously associated with increased γH2A.X foci formation in 
primary neuronal cultures107,115. Moreover, Madabhushi et al. (2015)118 showed that 
these foci were located primarily within early-response genes, similar to those 
detected following etoposide treatment. In addition, culturing primary neurons under 
conditions favouring the stimulation of either NR2B- or NR2A-containing NMDAR, 
implicated the former in the formation and the latter in the repair of DNA DSBs. Given 
these findings, as well as the role of SorCS2 in NMDA receptor trafficking51, I 
hypothesised that the SORCS2 KO LUHMES lines may exhibit a different response 
in terms of DNA DSB formation upon stimulation with NMDA compared to control 
lines.  
To address this hypothesis, first I determined the optimal NMDA concentration and 
treatment length that led to the highest increase in DSBs in WT neurons (day 14) 
compared to untreated controls. I used two previously established protocols for 
treating primary neurons with NMDA as a guidance. In one of the protocols, Crowe et 
al. (2006)115 applied different concentrations of NMDA (15µM and 50µM) and fixed 
the neurons after various exposure times, ranging from 10 minutes to 4 hours. They 
observed the highest increase in the number of DSBs in the neurons treated with 
15µM of NMDA for 10min115. In another study, Suberbielle et al. (2013)107 reported  
maximum effect after five-minute treatment with 50µM NMDA, followed by 1 hour 
recovery. In both studies the number of DSBs returned to baseline levels after 4 hours 
of drug application. In order to find the NMDA concentration, application procedure 
and time that worked best in LUHMES, I tested the same conditions as the ones 
described by Crowe et al. (2006)115 and Suberbielle et al. (2013)107. In day 14 
LUHMES neurons, the strongest effect in terms of γH2A.X foci formation was 
observed after applying 50µM NMDA for 5 minutes, followed by 1 hour of recovery in 
differentiation media (Figure 5.4.A).  
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Subsequent experiments performed on multiple day 14 WT LUHMES lines (n=3), 
stained for both γH2A.X and 53BP1, showed a significant increase in the number of 
DSBs per nucleus using these treatment conditions (p=0.0003, Figure 5.4.B). In 
parallel, SORCS2 KO lines (n=3), in which exon 3 was targeted, were also brought 
up and differentiated for 14 days. Statistical analysis showed no difference in the 
degree of NMDA-induced DNA DSB formation, examined as the average number of 
γH2A.X/53BP1 foci per nucleus, in the SORCS2 KO clones compared to treated WT 
neurons of a similar passage number (p=0.2668, Figure 5.4.C). Due to issues caused 
by a change in the cell culture plastics and time limitations, I was unable to repeat this 
analysis on a larger number of cell lines.  
 
 
Figure 5.4. DNA DSB formation in WT and SORCS2 KO LUHMES neurons following treatment 
with NMDA. [A] Representative z-stack confocal images (100x magnification) comparing 
untreated (left) LUHMES WT neurons with neurons treated with NMDA (right). Scale bars 
correspond to 10µm. [B] Comparison of the number of γH2A.X/53BP1-positive foci per nucleus 
in untreated and NMDA-treated WT LUHMES neurons (day 14). [C] Comparison of the number 
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of γH2A.X/53BP1-positive foci per nucleus in WT LUHMES neurons (n=3) and SORCS2 KO 
clones (n=3) following NMDA treatment. Unpaired t-test, ‘***’ stands for p<0.001; each dot on 
the graphs represents and individual cell line; error bars represent mean ± SD. 
 
5.3.2. Assessing extracellular Aβ levels in the SORCS2 KO 
LUHMES lines as a potential cause of DNA DSBs 
As discussed in the introduction, elevated levels of Aβ have been linked to epileptiform 
neuronal activity and increased DNA DSB formation both in vivo and in vitro107. 
Additionally, SORCS2, as all other members of the sortilin receptor family, has been 
implicated in APP processing and thus Aβ production46. Therefore, I hypothesised 
that increased Aβ levels might contribute to the exacerbated DNA DSB formation 
observed in the SORCS2 KO LUHMES lines following treatment with etoposide, and 
thus potentially in the Sorcs2-/- mice.  
To address this hypothesis, I decided to compare the levels of secreted Aβ42 between 
WT and SORCS2 KO clones. Initially, I differentiated SORCS2 KO clones generated 
by targeting exon 3 (n=3), together with WT lines (n=3). One of the WT lines died 
during the differentiation process. At day 14 of differentiation, I collected media from 
the SORCS2 KO (n=3) and the remaining WT (n=2) lines and performed Aβ42 
sandwich ELISA. However, the obtained results were below the assay detection limit 
of 15.6pg/ml (Table 5.1.).  
Serine proteases have been shown to rapidly degrade Aβ peptides in cell culture 
media170, and might have thus explained the low levels of extracellular Aβ42 detected 
in the collected samples. To account for this, as well as for the small sample size of 
the initial experiment, I cultured six WT lines and nine SORCS2 KO clones- four 
generated by targeting exon 1, and five obtained after disrupting exon 3. As before, I 
collected media from these lines following 14 days of differentiation. This time I added 
a protease inhibitor cocktail, containing the serine protease inhibitor AEBSF, to each 
of the medium samples at a final concentration of 1mM. Nonetheless, the amount of 
extracellular Aβ42 detected in the collected samples using the same ELISA kit was still 
below the assay detection range for all samples (Table 5.1.). Therefore, the results 
were considered unreliable and discarded.  
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Table 5.1. A table summarising the concentration of extracellular Aβ42 (pg/ml) obtained for 
each of the tested WT and SORCS2 KO cell lines from the two ELISA experiments. All 
samples measured were below the assay lowest detection limit of 15.6pg/ml. 
Cell line Extracellular Aβ42 
concentration (pg/ml) 
First ELISA experiment 
WT1 3.63 
WT2 2.45 
SORCS2 exon 3 clone 36 3.73 
SORCS2 exon 3 clone 39 3.04 
SORCS2 exon 3 clone 40 2.84 
Second ELISA experiment 
WT1  3.65 
WT2 4.14 
WT3 4.81 
WT 4  2.86 
WT 5 2.80 
WT 6 2.50 
SORCS2 exon 1 clone 5 2.98 
SORCS2 exon 1 clone 44 3.04 
SORCS2 exon 1 clone 51 3.1 
SORCS2 exon 1 clone 59 3.35 
SORCS2 exon 3 clone 26 3.77 
SORCS2 exon 3 clone 36 2.92 
SORCS2 exon 3 clone 39 3.35 
SORCS2 exon 3 clone 40 2.92 
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5.3.3. Assessing extracellular dopamine levels in the SORCS2 
KO LUHMES lines  
In mice, SorCS2 plays an important role in the development of the dopaminergic 
system6. Knocking out Sorc2 leads to increased dopaminergic innervation from the 
VTA to the frontal cortex, accompanied by reduced dopamine levels as a result of 
altered dopamine metabolism in this brain area6. In addition, both dopamine and its 
metabolite L-DOPA have been shown to induce DNA damage, via their interaction 
with copper ions164, and endogenous dopamine has been shown to play a role in 
controlling dopamine neuron firing patterns171. Given these findings, the role of 
TopoIIβ in gene expression following neuronal activity118 and the fact that the 
LUHMES cell line constitutes a homogenous population of dopaminergic neurons, I 
decided to test the hypothesis that altered dopamine secretion might contribute to the 
increase in DNA DSB formation observed in the SORCS2 KO cell lines following 
treatment with etoposide.  
Abbie Payne (an MSc student in our lab) grew and differentiated WT (n=6) and 
SORCS2 KO (n=9) cell lines of a similar passage number under the supervision of 
myself and Susan Anderson. As described in the above sections, both SORCS2 KO 
clones generated after targeting exon 1 and exon 3 were included to account for 
CRISPR off-target activity. At day 14, I collected media from each line and 
subsequently measured the amount of extracellular dopamine using a competitive 
dopamine ELISA kit. The amount of dopamine detected was normalised to the total 
amount of protein collected from the corresponding cell line and measured by a BCA 
assay. There was no significant difference in the amount of dopamine released by the 
SORCS2 KO clones when compared to the WTs (p= 0.0857, Figure 5.5).  
 
Figure 5.5. Assessing extracellular dopamine levels in the generated SORCS2 KO LUHMES 
clones. Extracellular dopamine levels (ng) normalised to the total protein among (g) in 
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SORCS2 KO (n=9) compared to WT (n=6) day 14 LUHMES neurons. Unpaired t-test, each 
dot represents an individual cell line; error bars represents mean ± SD. 
 
5.4. Assessing the levels of DNA DSB formation in 
Sorcs2-/- mouse primary neurons 
5.4.1. Assessing the baseline levels of DNA DSB formation in 
Sorcs2-/- primary neurons 
Since I detected elevated levels of DNA DBS formation in the dentate gyrus of Sorcs2-
/- mice, I decided to investigate whether I would observe the same increase in primary 
hippocampal neurons derived from these mice. All experiments described below were 
performed in the lab of our collaborator, Assoc. Prof Simon Glerup, Aarhus University, 
Denmark.  
Hippocampal primary neurons were obtained from Sorcs2-/- and WT pups (P0) and 
fixed after being maintained for 12 days in vitro (DIV12). Three independent cultures 
per genotype were stained for γH2A.X and 53BP1, and images were obtained using 
confocal microscope. As before, approximately 100 nuclei were counted, and nuclei 
showing apoptotic morphology or being fully covered with bright γH2A.X signal were 
excluded from the analysis. The number of γH2A.X/53BP1-positive foci per nucleus 
was calculated. There was no significant difference in the number of foci per nucleus 
when Sorcs2-/- neurons were compared to WT controls (p= 0.0580; Figure 5.6.B).  
 
5.4.2. Assessing the levels of DNA DSBs in Sorcs2-/- primary 
hippocampal neurons following treatment with etoposide 
Parallel to the experiment in the untreated neurons, three independent cultures of 
Sorcs2-/- and WT primary neurons (DIV 12) were treated with etoposide (0.5µM) for 4 
hours. Neurons were then fixed and stained for γH2A.X and 53BP1. Approximately 
100 nuclei were counted, and nuclei showing apoptotic morphology or being fully 
covered with bright γH2A.X signal were excluded from the analysis. As for the 
untreated cells, there was no significant difference in the number of γH2A.X/53BP1-
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positive foci per nucleus between the Sorcs2-/- and WT primary neurons (p=0.4238; 
Figure 5.6.C).  
 
 
Figure 5.6. Levels of DNA DSB formation in the Sorcs2-/- and WT primary neurons (DIV12) 
with and without treatment with etoposide. [A] A representative z-stack confocal image (60x 
magnification) of etoposide-treated cells. White arrow points at a nucleus (DAPI, blue) with 
foci positive for γH2A.X (green) and 53BP1 (red). Scale bar corresponds to 10µm. [B] 
Comparison of the number of γH2A.X/53BP1-positive foci per nucleus between untreated 
Sorcs2-/- and WT primary neurons (DIV12) from three independent cultures. [C] Comparison 
of the number of γH2A.X/53BP1-positive foci per nucleus in etoposide-treated Sorcs2-/- and 
WT primary neurons (DIV12) from three independent cultures. Unpaired t-test, each dot on 
the graph represents an independent culture; error bars represent mean ± SD.  
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5.5. Discussion  
Suberbielle et al. (2013)107 reported a transient increase in DSB formation (detected 
as formation of γH2A.X foci) in the neurons of WT mice, subjected to a learning and 
memory task, i.e. exploration of a novel environment. They linked the observed 
phenotype to physiological increase in neuronal activity. More specifically, they 
implicated NR2B-containing NMDARs in the formation, and NR2A-containing 
NMDARs in the repair of these DNA breaks. In addition, hAPP mice showed increased 
baseline levels of neuronal DNA DSBs, as well as compromised repair following 
exposure to the same novel environment. The authors attributed these differences to 
the aberrant network activity previously reported for hAPP mice. Further in vitro 
experiments showed that the observed Aβ-induced increase in DNA DSB formation 
is the result of altered balance between NR2A- and NR2B-containing NMDAR 
activity107.  
Similarly to Suberbielle et al., Madabhushi et al. (2015)118 detected increased γH2A.X 
foci formation as a result of neuronal activity in vivo (in a fear conditioning task), as 
well as in ex vivo hippocampal slices stimulated with NMDA or theta bursts and in 
primary neurons treated with KCl, bicucculin or NMDA. Stimulation of primary neurons 
with these compounds was also associated with increased expression of early-
response genes (e.g. Npas4 and Fos), and ChiP sequencing with γH2A.X confirmed 
that the detected DSBs lay in regions of the genome corresponding to these genes. 
Treatment with etoposide (TopoIIβ-specific poison in post-mitotic cells) upregulated 
the expression of the same set of early-response genes. Further experiments showed 
that the formation of DNA DSBs induced by neuronal activity occurred within promoter 
regions of early-response genes and was the result of TopoIIβ activity.  
As discussed in chapter 3, I detected increased levels of DSB formation in Sorcs2-/- 
mice compared to WT controls. Subsequently, as described in chapter 4, I knocked 
out SORCS2 in LUHMES cells in order to test whether the results from the mice could 
be replicated in human neurons and if so, to explore potential mechanisms that might 
explain the phenotype. As described in this chapter, first I examined the levels of DNA 
DSB formation in untreated SORCS2 KO clones by counting the number of foci where 
γH2A.X co-localised with the DDR protein 53BP1 per nucleus. Initial experiments 
performed on a small number of WT (n=3) and SORCS2 KO (n=4) lines showed no 
significant difference in the number of DSBs per nucleus and a high degree of inter-
clonal variation for both genotypes. When the experiment was repeated on a larger 
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sample size, including additional WT and SORCS2 KO clones in addition to the ones 
tested in the first experiment, the lack of significant difference between the two 
genotypes was confirmed. Overall, the levels of variation in this experiment were 
lower compared to the first experiment, especially in the control group. There was no 
difference in the number of DNA breaks per nucleus between the SORCS2 KO clones 
generated by targeting exon 1 compared to the KO clones obtained by disrupting exon 
3, which justified considering them as one group. 
Meanwhile, as previously reported, treating WT LUHMES neurons with etoposide led 
to a significant increase in the number of γH2A.X/53BP1-positive foci per nucleus. 
Moreover, SORCS2 KO clones (n=9) showed a significant increase in the number of 
γH2A.X/53BP1-positive foci per nucleus compared to WT lines (n=9) grown 
simultaneously. It is unlikely that the observed increase was the result of CRISPR off-
target activity as SORCS2 KO clones generated with two different gRNAs targeting 
exon 1 or exon 3 showed comparable levels of DNA damage.  
The lack of significant difference in the number of DSBs per nucleus between 
untreated WT and SORCS2 KO clones could be explained with the low and highly 
variable levels of DNA damage observed in the untreated cells, and especially in the 
SORCS2 KO clones. Meanwhile, treatment with etoposide leads to the accumulation 
of TopoIIβ-dependent DSBs, providing a more reliable measure of all events that took 
place over the course of the treatment. Nonetheless, the fact that I was able to detect 
significant difference in the number of DSBs after treatment with etoposide, but not in 
the untreated cells, may suggest that knocking out SORCS2 in vitro exacerbates 
TopoIIβ-dependent DNA DSB formation but has no effect on their repair. However, 
the experiment will need to be repeated for these results to be confirmed. 
Unfortunately, due to changes in the cell culture plastics and time constraints, I was 
unable to do so. 
Alongside the increased DSB formation observed in the etoposide-treated SORCS2 
KO neurons, I also detected reduced viability in these clones at day 14 but not day 6 
of differentiation. These results compliment a recently described role of SORCS2 in 
neuroprotection22. Moreover, the fact that the difference in the viability was observed 
at day 14 but not day 6 coincides with SORCS2 being expressed at low levels in 
LUHMES cells until after day 10 of differentiation, as described in chapter 4. 
Accumulation of DNA DSBs has been shown to affect neuronal function and survival. 
However, given that I did not observe any difference in the number of DSBs per 
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nucleus in the untreated SORCS2 KO versus WT clones, it is unlikely that the reduced 
viability detected is the result of accumulated DNA damage. 
As discussed above, neuronal activity triggers TopoIIβ-dependent DSB formation. 
Therefore, I hypothesised that altered neuronal activity could explain the elevated 
levels of DNA DSBs in the Sorcs2-/- mice and in the etoposide-treated SORCS2 KO 
LUHMES lines. As discussed above, increased Aβ levels and altered balance 
between NR2A- and NR2B-containing NMDAR activity have been associated with 
aberrant neuronal activity and exacerbated DNA DSB formation107. As in previously 
reported experiments in mouse primary neurons107,115, stimulating WT LUHMES 
neurons (day 14) with NMDA increased significantly the number of γH2A.X/53BP1-
positive foci per nucleus. SorCS2 is involved in the trafficking of NMDAR subunit 
NR2A51, which, as mentioned above, has been implicated in the repair of DNA 
DSBs107. I did not observe any difference in the extent of NMDA-induced DNA DSB 
formation in the SORCS2 KO clones compared to WT controls. However, this 
experiment was performed on a small number of clones and thus may not reflect a 
real lack of difference. Therefore, further experiments including a larger number of 
cell lines are required to assess the effect of knocking out SORCS2 on NMDA-induced 
DSB formation. Unfortunately, due to changes in cell culture plastics and time 
limitations, I was not able to repeat this experiment on a larger number of cell lines. 
However, if these preliminary results were confirmed in subsequent experiments, this 
would suggest that the elevated levels of DNA breaks observed in the etoposide-
treated SORCS2 KO LUHMES neurons are not the result of dysregulated NMDAR 
signalling.  
Previous work in HEK293 cells demonstrated that knocking down SORCS2 promotes 
APP amyloidogenic processing46. Unfortunately, I was unable to detect extracellular 
Aβ42 in the media collected from both WT and SORCS2 KO LUHMES neurons. This 
did not allow to rule out the possibility that elevated Aβ levels might contribute to the 
increased levels of DNA DSBs detected in the etoposide-treated knockout lines. Both 
Aβ40 and sAPPβ have been previously detected in mature LUHMES neurons133,134. 
Thus, it would be interesting to see whether knocking out SORCS2 in LUHMES exerts 
an effect on the production of these APP metabolites. Alternatively, a more sensitive 
Aβ42 assay could be used to try and detect differences in this particular Aβ species.  
Both untreated and treated Sorcs2-/- primary neurons showed no significant difference 
in the number of DNA DSBs per nucleus compared to WT controls. Major caveats of 
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this experiment were the small sample size and the high degree of variation between 
the different cultures, questioning whether the obtained results reflect a true lack of 
difference or the collected data lacks power to detect a difference between the two 
groups. Ideally, to overcome these limitations, the analysis would need to be 
performed on a larger number of independent cultures. Unfortunately, due to time 
limitation and problem with mice breeding, I was unable to obtain more than three 
cultures for each genotype. However, it should be noted that while not statistically 
significantly different, the absolute levels of DSBs observed in the Sorcs2-/- neurons 
is lower compared to the WTs. This is in contrast with the results obtained in the 
LUHMES neurons. If this difference was to be maintained on repetition with a larger 
dataset, possible explanation would include the origin of the neurons (i.e. the primary 
neurons were isolated from mice, while LUHMES are human neurons), as well as 
their type (hippocampal versus dopaminergic neurons) and electrophysiological 
properties. LUHMES neurons have been shown to fire spontaneous action potentials 
after day 10 of differentiation133. However, their electrophysiological properties 
following 14 days of differentiation cannot be directly compared to these of primary 
hippocampal neurons derived from new-born (P0) mice and maintained in culture for 
12 days.  
As mentioned above a possible interpretation of the results obtained might be that the 
observed elevated levels of etoposide-induced DNA breaks in the LUHMES KO lines 
are the result of altered mechanisms, specific to dopaminergic neurons. 
Endogenously released dopamine is involved in the regulation of dopamine neuron 
firing patterns in vivo by acting on the dopamine autoreceptor D(2)R171. Moreover, 
increased dopamine levels have been previously linked to DSB formation164. Despite 
its role in the development of the dopaminergic system, knocking out SORCS2 in 
LUHMES had no effect on the amount of dopamine secreted by these cells. However, 
the SORCS2 KO clones displayed much higher levels of variation in the amount of 
secreted dopamine than WT neurons. Nonetheless, based on these results, it is 
unlikely that altered extracellular dopamine levels could explain either the increased 
levels of etoposide-induced DNA DSBs in these cells or the discrepancy with the 
results obtained in the primary neurons.
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Chapter 6 Assessing the effect of introducing 
the rare EOAD-associated mutation G508S on 
SORL1 expression and Aβ production 
6.1. Introduction 
SORLA plays an important role in APP processing and thus Aβ production. APP 
amyloidogenic processing involves the endocytosis of APP molecules and their 
transport to late endosomes, where proteolytic breakdown of APP by β- and γ-
secretase results in the formation of Aβ172. SORLA has been shown to act as an APP 
sorting receptor, shuttling APP molecules from endosomes to the trans-Golgi network 
and thus preventing their entry into both amyloidogenic and non-amyloidogenic 
processing pathways37. In addition to its interaction with APP, SORLA also impacts 
on the amyloidogenic burden by direct binding of its Vps10p domain to Aβ41. In vitro, 
the association between SORLA and Aβ leads to increased lysosomal targeting and 
degradation of the Aβ peptides41. In keeping with these findings, loss of SorLA in mice 
accelerates Aβ production and senile plaque deposition37, 42, 43.  
Reduced SORLA levels have been described in post-mortem brains from individuals 
with AD88, 39. Moreover, GWASs of AD, including the most recent meta-analysis, have 
identified significant association with SORL1 variants65,68,69.  The associated variants 
are largely non-coding and are expected to exert their effects via altering expression 
levels. However, rare SORL1 coding variants, including missense, splice site and 
nonsense mutations, have also been linked to both familial and sporadic AD and both 
early and late onset forms of the disease41,73,76,77,80,173–176 . Functional studies have 
been performed to assess the impact of some of the identified missense 
mutations41,76. For example, the G511R missense mutation, associated with familial 
AD, was shown to disrupt SORLA binding to Aβ, resulting in decreased Aβ turnover41. 
Overexpression of five other SORL1 mutations: T588I and T2134M (found in EOAD 
cases)76 and E270K, A528T and T947M (found in LOAD cases)75 reduced SORLA 
interaction with APP and led to increased APP proteolytic processing and Aβ 
secretion. Additionally, two silent mutations located at the 3’ region of the gene were 
shown to decrease SORLA protein levels in post-mortem AD brains, as well as to 
reduce translation efficiency in vitro177. Nevertheless, the functional consequences of 
the majority of the SORL1 coding variants identified so far remains unknown.  
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In summary, there is strong evidence from multiple data types linking SORLA to AD.  
While the cellular mechanisms are not yet fully elucidated, it appears that decrease 
or loss of Sorl1 expression in animal models, as well as some missense mutations in 
SORLA, lead to increased levels of Aβ. Therefore, it can be hypothesised that 
knocking out SORL1 in human neurons or introducing SORL1 variants associated 
with EOAD would lead to an increase in Aβ production, and thus in DNA DSBs, as 
has been previously observed in hAPP mice and primary neurons treated with Aβ 
oligos107. 
 
6.1.1. Aims  
The aims of the work described in this chapter were to knock out SORL1 and to 
introduce the rare EOAD-associated missense mutation G508S into LUHMES cells 
using CRISPR/Cas9 genome editing. A further aim was to examine the impact of the 
mutations on SORL1 expression and Aβ production.  
 
6.2. Knocking out SORL1 in LUHMES cells using 
CRISPR/Cas9 genome editing 
6.2.1. First attempt to knock out SORL1 in LUHMES cells using 
CRISPR/Cas9 genome editing  
SORL1 is located on chromosome 11 and encodes for a large number of transcripts, 
the majority of which start after exon 25 of the full-length, protein-coding transcript. 
Previous work in the lab performed by Susan Anderson has shown that in addition to 
the canonical full-length isoform, LUHMES express several shorter isoforms whose 5’ 
ends lie within the second half of the 48 exons. Therefore, I decided to knock out the 
gene by targeting the first exon common for all expressed SORL1 transcripts- exon 
31. I transfected proliferating cells of a low passage number (P5) with the 
pSpCas9(BB)-2A-GFP plasmid containing a gRNA, targeting this exon. The 
transfection efficiency was low- approximately 1%, and the top 3% of GFP-positive 
cells were FAC sorted into 96-well plates. Ten days post-transfection, I identified 
seven colonies derived from a single cell. These were then transferred into 48-well 
plates and further expanded to 6-well plates. One clone (1.4) did not survive the 
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transfer process. Once the clones reached 85% confluency in the 6-well plates, frozen 
stocks were generated, and proportion of the cells were kept for DNA isolation and 
genotyping.  
6.2.1.1. Genotyping of the identified clonal lines 
DNA was isolated and PCR performed using primers flanking the targeted SORL1 
exon 31. Three of the isolated clonal lines showed a single band on the gel, three 
others had two bands and one was discarded as it had three (Figure 6.1.A). Where 
two bands were present on the gel (clones 1.2, 1.3 and 1.6), TOPO cloning was 
performed, and the resulting products were subjected to sequence analysis, the 
results of which are summarised in Table 6.1.  
Table 6.1. A table listing all clones isolated following targeting of SORL1 exon 31, the PCR 
and sequencing results, and the consequences of the mutations introduced.  
Clone PCR Sequencing Impact 
1.1 Three bands Not sequenced, discarded  
1.2 Double band Allele 1: 1bp insertion 
Allele 2: 11bp insertion 
Frameshift mutation 
1.3 Double band Allele 1: 2bp insertion 
Allele 2: 11bp insertion 
Frameshift mutation 
1.4 N/A- clone died 
1.5 Single band 11bp deletion Frameshift mutation 
1.6 Double band Allele 1: multiple deletions 
Allele 2: WT 
Frameshift mutation 
1.7 Single band 6bp deletion Inframe deletion 
 
6.2.1.2. Assessing SORL1 mRNA levels in the obtained SORL1 mutant 
clones 
In order to assess the expression of SORL1 in the CRISPR-edited clones identified, I 
performed qRT-PCR on cDNA derived from proliferating cells, using two TaqMan 
probes, located near the 5’ (SORL1 exon 2-3) and the 3’ end (SORL1 exon 46-47) of 
the full-length SORL1 transcript. The former aimed to detect expression levels of the 
full-length SORL1 protein-coding isoform, while the latter would also amplify 
additional protein-coding transcripts, found to be expressed in LUHMES. SORL1 
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mRNA levels were normalised to the expression levels of two reference genes (CYC1 
and TBP), identified from a panel of eight as the most stable in this sample set by the 
GeNorm software (data not shown). All clones, apart from 1.5, showed lower SORL1 
mRNA levels compared to a WT LUHMES line grown simultaneously (Figure 6.1.B). 
 
  
Figure 6.1. Results of targeting SORL1 exon 31 using CRISPR/Cas9 genome editing. [A] 
Genotyping of the isolated CRISPR-edited clones. PCR with primers, flanking SORL1 exon 
31, on genomic DNA isolated from a WT LUHMES line (‘Ctrl’) and the seven clones identified 
after FACS (1.1- 1.7), run on 2% LMP gel loaded with 1 Plus kb ladder and stained with SYBER 
Safe. The first track was loaded with the ladder (‘M’), the second was left empty, the third track 
was loaded with PCR product amplified from WT LUHMES DNA (‘Ctrl’) and the rest with 
samples from the seven isolated clones. ‘NTC’ stands for non-template control. Expected PCR 
product size- 462bp. [B] qRT-PCR assessing the SORL1 mRNA levels in the isolated clones, 
excluding clones 1.1 (which was discarded as it showed three bands on the gel) and 1.4 (which 
died during culturing). The x-axis shows the clones, while the y-axis- SORL1 mRNA levels 
normalised to the geometric mean of CYC1 and TBP. The blue bar corresponds to the WT 
line, while the red and the pink bars to clones, carrying frameshift or inframe mutations, 
respectively. Graphs present the results from a single experiment, and bars correspond to the 
average of three technical replicates. 
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6.2.2. Second attempt to knock out SORL1 in LUHMES cells 
The first attempt of knocking out SORL1 resulted in four clones with SORL1 mRNA 
levels lower than the WT. Amongst these, clones 1.2 and 1.3 showed the lowest 
expression (approximately 10% and 30% of the WT expression levels, respectively), 
suggesting they might constitute SORL1 knockouts. However, due to both the low 
number of surviving clones, as well as of potential KO clones, I decided to repeat the 
experiment using the same gRNA. This time the transfection efficiency was 8.22%. 
Twenty-six single-cell colonies were identified ten days post-FACS and transferred to 
48-well plates for further expansion, with proportion of cells from each clone kept for 
genotyping. One clone (2.24) did not survive the process of transfer, and another 
three (2.16, 2.23 and 2.25) died during expansion. Subsequently, I extracted DNA by 
boiling the cells in Tris buffer and performed PCR amplification, using the same 
primers as above. Amongst the identified clones, 14 showed single bands on the PCR 
gel, eight- double, and one was discarded as it had three bands (Figure 6.2.A). The 
DNA extracted from two clones failed to give a PCR product (Figure 6.2.A). 
Sequencing analysis of the clones with single bands identified two clones as CRISPR 
WTs, and the rest as carrying indels of different sizes (Table 6.2). Since mRNA levels 
do not necessarily correspond to protein, I screened the clones using western blot 
analysis. I selected one CRISPR WT (clone 2.9) and two clones predicted to carry 
frameshift mutations and thus potentially constituting SORL1 KOs (clones 2.11 and 
2.12) and differentiated them into neurons, alongside a LUHMES WT cell line of a 
similar passage number. After 14 days of differentiation, I collected protein samples 
from these cell lines and subjected them to western blot analysis. Neither of the two 
frameshift mutants showed changes in SORLA protein levels compared to the 
LUHMES WT line grown simultaneously (Figure 6.2.B). 
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Figure 6.2. Results of the second attempt to knock out SORL1 by targeting exon 31. [A] 
Genotyping of the isolated single cell colonies. PCR with primers, flanking SORL1 exon 31, 
run on 1.7% agarose gel loaded with 1 Plus kb ladder and stained with SYBER Safe. ‘M’ 
indicates tracks loaded with the ladder, and ‘Ctrl’- tracks loaded with PCR product amplified 
from WT LUHMES genomic DNA. PCR products derived from the isolated clones are labelled 
from 2.1 to 2.26. ‘NTC’ stands for non- template control. Expected PCR product size- 462bp. 
[B] Western blot analysis, assessing SORLA protein levels in two frameshift mutant clones 
(2.11 and 2.12) and one CRISPR WT line (2.9) compared to the protein levels of LUHMES 
WT line grown simultaneously. Membrane was probed for vinculin to verify equal loading. The 
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Table 6.2. A table listing all clones isolated following the second attempt to knock out SORL1 
by targeting exon 31, the PCR and sequencing results, and the consequences of the mutations 
introduced. 
Clone PCR Sequencing Impact 
2.1 Double band   
2.2 Single band Sequencing failed  
2.3 Single band Sequencing failed  
2.4 Three bands   
2.5 Single band 1bp insertion Frameshift mutation 
2.6 PCR failed   
2.7 Double band   
2.8 Double band   
2.9 Single band CRIPSR WT  
2.10 Single band 2bp deletion Frameshift mutation 
2.11 Single band 5bp deletion Frameshift mutation 
2.12 Single band 4bp deletion Frameshift mutation 
2.13 Single band 4bp deletion Frameshift mutation 
2.14 Double band   
2.15 Single band 1bp insertion Frameshift mutation 
2.16 Dead   
2.17 Single band 1bp insertion Frameshift mutation 
2.18 Double band   
2.19 PCR failed   
2.20 Single band 1bp insertion Frameshift mutation 
2.21 Single band 15bp deletion Inframe deletion 
2.22 Single band CRISPR WT  
2.23 Dead   
2.24 Dead   
2.25 Dead   
2.26 Double band   
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6.3. Introducing the Gly508Ser mutation in LUHMES 
cells using CRISPR/Cas9 genome editing 
Following the two unsuccessful attempts of generating SORL1 KO clones using a 
gRNA targeting exon 31, I decided to move on to using CRISPR/Cas9 genome editing 
in an attempt to introduce the G508S mutation in SORL1. G508S is a rare coding 
SORL1 variant, identified by Verheijen et al. (2016)77 that is associated with 
autosomal dominant EOAD. It is found in individuals with AD with family history of AD, 
but not in age- and origin-matched controls77. The variant constitutes a point mutation 
(g.70501G>A), affecting an amino acid that is highly conserved across species 
(Figure 6.3.A). Importantly, it is located within close proximity to the binding site for 
Aβ178. The G508S variant has been predicted to be damaging by PolyPhen2, SIFT 
and MutationTaster77. Although it was not mentioned in the paper, I noted that the 
variant lies at the last nucleotide of SORL1 exon 10 (Figure 6.3.A) and thus might also 
affect splicing. Therefore, it can be hypothesised that the G508S mutation might affect 
SORLA functions possibly by disrupting a splicing site and/or affecting its interaction 
with Aβ and thus its role in Aβ lysosomal targeting.  
In addition, I also expected to obtain clones with frameshift mutations in exon 10 as 
by-products of introducing the G508S mutation. Any unrepaired CRISPR/Cas9-
generated indels at this site might have altered splicing, leading to exon skipping or 
intron retention. Such events could have shifted the open reading frame, ultimately 
introducing premature stop codons and leading to activation of NMD pathways, and 
thus knocked out the full-length SORL1 protein-coding transcript. 
 
6.3.1. gRNA and ssODN design 
As mentioned in chapter 4, gRNA is required for the targeting of the Cas9 
endonuclease to the area of interest. Once delivered to the correct site, the 
endonuclease will create a DNA DSB, which will be repaired either by NHEJ or HDR 
mechanism, with the latter requiring the presence of a repair template. Exogenously 
introduced repair templates, mostly in the form of single stranded DNA 
oligonucleotides (ssODNs), have been utilised for introducing single-nucleotide 
mutations in order to investigate their functional consequences in vitro. This strategy 
has already been successfully implemented in LUHMES cells for introducing 
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missense mutations in the MECP2 and EEF1A2- genes, associated with Rett 
syndrome and neurodevelopmental delay and intellectual disability, respectively135.  
6.3.1.1. Designing a suitable gRNA for introducing the G508S mutation into 
the LUHMES neuronal cell line 
As before, gRNA was designed using the MIT Target Finder (http://crispr.mit.edu) and 
DNA2.0 (https://www.dna20.com/eCommerce/cas9/input) online CRISPR tools, and 
ligated into the pSpCa9(BB)-2A-GFP plasmid. However, this time, the gRNA was 
selected not only based on its predicted on- and off-target activity, but also 
considering the distance between the predicted cut site and the site of the intended 
missense mutation. Cut-to-mutation distance has been shown to play an important 
role in the efficiency of mutation incorporation. Both in vivo and in vitro studies have 
demonstrated that the frequency of the intended substitution declines with increasing 
the distance from the gRNA cut site179,180. Moreover, a paper published by Paquet et 
al. (2016)180 suggests that this distance dependence could be manipulated for 
achieving a desired ratio of homozygous to heterozygous to wild type genotypes 
(Figure 6.3.B). According to this study, a cut-to-mutation distance in the range of 10bp 
to 20bp results in the highest number of heterozygous mutants and a good proportion 
of CRISPR WT clones. This is particularly important since the majority of the clinically 
relevant single-nucleotide substitutions, including the EOAD-associated G508S 
mutation, are heterozygous. Thus, given the results described by Paquet et al. 
(2016)180 and in order to maximise the chances of obtaining a good proportion of 
heterozygote mutant, I selected a gRNA for which the distance between the Cas9 cut 
site and G508S mutation was 11bp (Figure 6.3.D).   
6.3.1.2. Designing a suitable repair template for introducing the G508S 
mutation in the LUHMES neuronal cell line  
The incorporation of a repair template, harbouring a mutation of interest, requires the 
activation of the HDR pathway, a process which, unlike the NHEJ, occurs at a 
considerably lower frequency in post-mitotic cells. A recently described method for 
increasing the efficiency of this process included designing an asymmetrical ssODN 
of a specific length. According to the study published by Richardson et al. (2016)181, 
the Ca9 protein remains bound to the target DNA region for several hours. However, 
the 3’ end of the PAM distal, non-target strand gets released much earlier than the 
other three strands, resulting in a 30bp free DNA stretch. Based on this observation, 
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Richardson et al.181 showed that designing a template that would first anneal to the 
free, non-target strand could dramatically increase the frequency of HDR events 
(Figure 6.3.C). Consistent with previous studies182,183, they found ssODNs 
complementary to the non-target strand much more efficient than those 
complementary to the target strand. In addition, Richardson et al.181 were the first 
ones to suggest that asymmetric DNA donor might be more efficient in promoting 
HDR events, when compared to the commonly used symmetric around the break 
point ssODNs182,183. Bearing this in mind, I designed an asymmetric template, 
complementary to the non-target strand and overlapping the PAM-distal side with 
36bp, and the PAM-proximal side with 91bp (Figure 6.3.D). 
Another problem frequently encountered in CRISPR-mediated knock-in experiments 
is the presence of unwanted indels alongside the intended mutation, probably as a 
result of high Cas9 nuclease activity during multiple rounds of editing. Thus, in order 
to circumvent this problem, I introduced a silent point mutation at the PAM site as this 
has been previously demonstrated to be efficient in preventing multiple rounds of 
editing (Figure 6.3.D). The PAM site I mutated corresponds to the amino acid proline, 
which is encoded by four synonymous codons. Each of these codons are used at 
different frequencies, and substituting from frequent to rare codon has been shown to 
alter translation efficiency184. To account for this, I introduced a silent mutation which 
changed the codon to one with a similar usage frequency.  
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Figure 6.3. Summary of the experimental design of introducing the G508S mutation in SORL1 
using CRISPR/Cas9 genome editing. [A] An image adopted after the UCSC genome browser 
(https://genome.ucsc.edu/) and showing the position of the affected by the G508S missense 
mutation nucleotide (marked with a red rectangular shape). First track shows the scale, the 
nucleotides and their co-ordinates in chromosome 11. Second track shows the affected by the 
mutation transcript, and the third track- the reference sequence corresponding to it. Tracks 
below show the conservation of the affected nucleotide amongst species. [B] A figure adopted 
after Paquet et al. (2016)180, showing the relationship between the cut-to-mutation distance (x-
axis) and the proportion of heterozygous for the mutation of interest clones (y-axis). Black 
arrows indicate the range of cut-to-mutation distance (bp) for obtaining an optimal number of 
heterozygous mutant and a good proportion of CRISPR WT clones. [C] A figure adopted after 
Richardson et al. (2016)181, depicting the interaction of the asymmetric ssODN with the first 
DNA strand released after the Cas9-mediated DNA cleavage. [D] A schematic representation 
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of the designed ssODN for introducing the G508S mutation. The repair template (shown in 
green) was designed to be complementary to the non-target strand (shown in black with blue 
letters indicating an intronic region). The PAM site and the introduced silent mutation are 
shown in yellow, the point mutation in red, and the gRNA sequence in bright blue. The pink 
arrow indicates the predicted Cas9 cut site, with the designed ssODN being asymmetric 
relative to it.   
 
6.3.2. Introducing the G508S mutation in LUHMES cells 
The pSpCas9 (BB)-2A-GFP plasmid, containing the cloned gRNA, was transfected 
into proliferating LUHMES cells along with the G508S repair template. Forty-eight 
hours post-transfection, the top 3% of GFP-positive cells were FAC sorted into 96-
well plates. Ten days after sorting, single cell colonies were identified. One third of 
each colony was kept for genotyping, and the rest of the cells were split into two 48-
well plates for further expansion. Once 85% confluency was reached, the cell lines 
from one of the 48-well plates were frozen down, while the other plate was further 
expanded to 6-well plates before freezing. 
6.3.2.1. First attempts to introduce the G508S mutation in LUHMES cells  
The first attempt to introduce the G508S mutation in proliferating LUHMES cells had 
a transfection efficiency of 5.84% (measured as the percentage GFP-positive cells 
identified by FACS) and resulted in the formation of 30 single cell colonies. As 
described above, a proportion of cells were kept for genotyping. DNA was extracted 
by boiling the cells in Tris buffer and PCR was performed using primers flanking the 
G508S mutation site. High fidelity DNA polymerase was used for genotyping the 
identified cell lines in order to ensure that any mismatches identified by sequencing 
would be the result of the CRISPR process rather than error during PCR amplification.  
From the 30 colonies identified, eight showed two bands on the gel (and were 
discarded as this suggested the presence of a large indel mutation), and two were 
discarded as they had three bands. Fifteen clones showed single bands when run on 
the gel and thus were subject to sequence analysis. The DNA isolated from four 
clones, however, failed to amplify (Figure 6.4.A). Of the 15 sequences obtained, only 
nine matched to the amplified area, and unfortunately none of them carried the 
intended G>A substitution.  
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Successful incorporation of the G508S mutation results in the formation of a SpeI 
restriction site. In order to quickly check whether any of the clones that failed to 
produce clean sequence traces (Table 6.3), carried the G508S mutation, I performed 
a restriction enzyme digest using the SpeI enzyme. The digests were run on a gel, 
and none of the samples showed evidence of incorporation of the G508S mutation 
(Figure 6.4.B). The results from the genotyping are summarised in Table 6.3. 
 
 
Figure 6.4. First attempt of introducing the G508S mutation in SORL1 using CRISPR/Cas9 
genome editing. [A] Genotyping of the isolated clones, following FAC sorting. PCR with 
primers, flanking SORL1 exon 10, run on 2% LMP gel loaded with 1 Plus kb ladder and stained 
with SYBER Safe. ‘M’ indicates tracks loaded with the ladder. Due to pipetting error the ‘Ctrl’ 
track, corresponding to PCR-amplified WT LUHMES genomic DNA, was empty. PCR products 
of DNA derived from the isolated clones are labelled from 1.1 to 1.30. ‘NTC’ stands for non-
template control. Expected product size 553bp. [B] Restriction enzyme digest on the clones, 
whose PCR products failed to give readable sequence traces. 1.8% LMP gels loaded with 1 
PLus kb ladder (indicated as ‘M’) and stained with SYBER Safe. Left gel represents 
optimisation of the SpeI digest using a control PCR. Digesting 1µl of the control PCR did not 
give any visible products on the gel, using 5µl of the PCR reaction resulted in complete digest, 
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Table 6.3. A table listing the genotyping results for all clones isolated following the first attempt 
of introducing the G508S mutation in SORL1, the PCR and sequencing results and the 
consequences of the mutations introduced.  
Clone PCR Sequencing Impact 
1.1 Three bands Not sequenced, 
discarded 
 
1.2 Double band   
1.3 Single band 18bp deletion Inframe deletion 
1.4 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.5 Single band Sequencing failed  SpeI digest did not identify 
presence of the G508S mutation 
1.6 Single band 17bp deletion Frameshift mutant, high effect 
1.7 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.8 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.9 Double band   
1.10 Double band   
1.11 PCR failed   
1.12 Double band   
1.13 Three bands Not sequenced, 
discarded 
 
1.14 PCR failed   
1.15 Single band 16bp deletion Inframe deletion 
1.16 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.17 Single band 1bp insertion Frameshift mutation 
1.18 Single band Multiple deletions  
1.19 Single band 3bp deletion Inframe deletion 
1.20 Double band   
1.21 Double band   
1.22 PCR failed   
Chapter 6 Assessing the effect of introducing the rare EOAD-associated mutation 
G508S on SORLA expression and Aβ production 151 
1.23 PCR failed   
Clone PCR Sequencing Impact 
1.24 PCR failed    
1.25 Double band   
1.26 Single band 1bp insertion Frameshift mutation 
1.27 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.28 Single band Sequencing failed SpeI digest did not identify 
presence of the G508S mutation 
1.29 Double band   
1.30 Single band 11bp deletion Frameshift mutation 
 
Since most of the lines from the first round of transfections were edited, but none of 
them carried the G508S mutation, I concluded that the gRNA was efficient in cutting, 
but perhaps the amount of the repair template used was insufficient. To test this, I 
carried out a second transfection, using 100uM instead of 10uM of the repair template. 
This time, the transfection efficiency dropped to 2.62% and only 19 single cell colonies 
were identified. To improve the quality of the PCR and subsequently to obtain cleaner 
sequencing results, I isolated DNA from the identified cell colonies using the Qiagen 
DNeasy kit rather than by boiling the cells. This time, most samples (apart from clones 
2.1 and 2.2) amplified successfully. Six clones showed three bands on the gel and 
were discarded, four clones had two bands and seven clones- one (Figure 6.5). All 
samples that showed single bands on the gel were subject to sequence analysis and 
sent for sequencing. Sequencing identified clone 2.8 as a homozygote for the silent 
PAM site mutation, and clone 2.4 as a CRISPR WT. However, none of the clones 
carried the G508S. The results from the genotyping are summarised in Table 6.4.  
 
Figure 6.5. Genotyping of the isolated clones, following a second attempt to introduce the 
G508S mutation in SORL1 using CRISPR/Cas9 genome editing. 1.8% LMP gel loaded with 1 
Plus kb ladder and stained with SYBER Safe. ‘M’ indicates tracks loaded with the ladder, and 
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‘NTC’- non template control. PCR products of genomic DNA derived from the isolated clones 
are labelled from 2.1 to 2.19. Expected PCR product size- 553bp.   
 
Table 6.4. A table listing the genotyping results for all clones after the second attempt of 
introducing the G508S mutation in SORL1, the PCR and sequencing results and the 
consequences of the mutation introduced.  
Clone PCR Sequencing Impact 
2.1 PCR failed   
2.2 PCR failed   
2.3 Single band 26bp deletion Inframe mutation 
2.4 Single band CRISPR WT  
2.5 Double band   
2.6 Double band   
2.7 Three bands Not sequenced, discarded  
2.8 Single band PAM site mutation 
(homozygous) 
 
2.9 Three bands Not sequenced, discarded  
2.10 Three bands Not sequenced discarded  
2.11 Single band 3bp deletion Inframe mutation 
2.12 Double band   
2.13 Three bands Not sequenced, discarded  
2.14 Double band   
2.15 Three bands Not sequenced, discarded  
2.16 Double band   
2.17 Three bands Not sequenced, discarded  
2.18 Single band 11bp deletion Frameshift mutation 
2.19 Double band   
 
6.3.2.2. Successful incorporation of the G508S mutation in LUHMES cells 
Since increasing the repair template amount coincided with a drop in the transfection 
efficiency, I decided to repeat the transfection using the same ssODN amount as in 
the first transfection, hoping to obtain more single cell colonies and in this way 
increase the chances of generating clonal lines carrying the G508S mutation. Even 
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though the transfection efficiency was low (1.22% of the FAC-sorted cells were GFP-
positive), ten days post-transfection I was able to identify 95 colonies derived from 
single cells. As before, DNA was extracted, and PCR was run using high fidelity DNA 
polymerase, with primers flanking the mutation site.  
Fourteen clonal lines were discarded as they showed three bands when the PCR 
reactions were run on a gel (Figure 6.6). Twenty-four clones were identified as 
heterozygotes as they had two bands of different sizes on the PCR gel (Figure 6.6), 
and another six clones showed double sequence traces around the Cas9 cut site. 
From the 50 clonal lines that showed a single band on the gel (Figure 6.6), 17 carried 
indels of various sizes and a couple showed mismatches around the mutation site. 
Five clonal lines remained WT after the CRISPR process and three were 
heterozygous for the G508S mutation (Figure 6.7). One clone carried the G508S 
mutation together with 2bp insertion on the same allele.  
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Figure 6.6. Results from the third attempt to introduce the G508S mutation in SORL1. 1.8% 
LMP gels loaded with 1 Plus kb ladder (indicated as ‘M’) and stained with SYBER Safe. PCR 
products of genomic DNA derived from the isolated clones are labelled from 3.1 to 3.95. ‘NTC’ 
stands for non-template control. Expected PCR product size- 553bp.  
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Figure 6.7. Representative sequencing traces. Yellow rectangles indicate the point of the 
introduced silent PAM site mutation, red- the site of the G508S point mutation, and red arrows- 
the predicted Cas9 cut site. Top trace corresponds to a CRISPR WT clone, middle trace 
corresponds to a CRISPR clone that was homozygous for the PAM site mutation, and bottom 
trace show the sequence of a CRISPR clone that was identified as heterozygous for both the 
PAM site and the G508S mutation. 
 
In order to determine whether some of the clones that showed two alleles on the gel 
were in fact compound heterozygotes carrying the G508S mutation on one allele, I 
performed restriction enzyme digest with SpeI as described in 6.3.2.1. From all 
samples, only three clonal lines- 3.44, 3.58 and 3.71 were digested (Figure 6.8.). 
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Thus, it was concluded that they constitute compound heterozygotes, carrying the 
G508S mutation on one allele, and an indel on the other. The genotyping results for 
all clones are summarised in Table 6.5.  
 
 
Figure 6.8. Identifying compound heterozygous mutants, carrying the G508S mutation using 
restriction enzyme digest. 1.8% LMP gels loaded with 1 Plus kb ladder (indicated as ‘M’) and 
stained with SYBER Safe. Clones that showed double bands on the genotyping gel (Figure 
6.6.) were digested with the SpeI enzyme. Red arrows indicate the resulted in digestion 
products in the clones, which carried the G508S mutation. A control PCR (labelled as ‘Ctrl’) 
and the 3.70 clone, which was identified as G508S heterozygous mutant by sequencing, were 
used as positive controls. Expected PCR product size 553bp; expected digest products size: 
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Table 6.5. A table listing the PCR and sequencing results from genotyping the isolated clones 
after the third attempt of introducing the G508S mutation in SORL1. The type and the 
consequences of the introduced mutations are also included. 
Clone PCR Sequencing Impact 
3.1 Double band   
3.2 Double band   
3.3 Single band 9bp deletion Inframe deletion 
3.4 Single band Multiple mismatches  
3.5 Single band PAM site mutation (homozygous)  
3.6 Single band PAM site mutation (homozygous)  
3.7 Single band PAM site mutation (homozygous)  
3.8 PCR failed   
3.9 Double band   
3.10 PCR failed   
3.11 Three bands Not sequenced, discarded  
3.12 Three bands Not sequenced, discarded  
3.13 Single band Matches SORL1 exon 11  
3.14 Single band Multiple mismatches  
3.15 Single band 3bp deletion Inframe mutation 
3.16 Double band   
3.17 Single band Double sequencing trace around 
the cut site 
 
3.18 Single band Double sequencing trace around 
the cut site 
 
3.19 Three bands Not sequenced, discarded  
3.20 Single band PAM site mutation (homozygous)  
3.21 Three bands Not sequenced, discarded  
3.22 Single band ‘Unclean’ sequence trace  
3.23 Three bands Not sequenced, discarded  
3.24 Double band   
3.25 Double band   
3.26 Double band   
3.27 Single band 3bp deletion Inframe deletion 
3.28 Three bands Not sequenced, discarded  
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Clone PCR Sequencing Impact 
3.29 Single band 3bp deletion Inframe deletion 
3.30 Single band 3bp deletion Inframe deletion 
3.31 Single band PAM site mutation + G508S 
mutation (heterozygous) 
 
3.32 Double band   
3.33  Single band CRISPR WT  
3.34 Three bands Not sequenced, discarded  
3.35 Double band   
3.36 Single band Sequencing failed  
3.37 PCR failed   
3.38  PCR failed   
3.39 Single band 3bp deletion Inframe deletion 
3.40 Double band   
3.41 Single band 3bp deletion Inframe deletion 
3.42 Single band 3bp deletion Inframe deletion 
3.43 Single band PAM site mutation (homozygous)  
3.44 Double band G508S mutation (compound 
heterozygous) 
 
3.45 Single band Multiple deletions  
3.46 Single band PAM site mutation (homozygous)  
3.47 Single band 6bp deletion Inframe deletion 
3.48 Single band 3bp deletion Inframe deletion 
3.49 PCR failed   
3.50 Single band 1bp mismatch  
3.51 Single band Sequencing failed  
3.52 Three bands Not sequenced, discarded  
3.53 Single band Double sequence trace  
3.54 Double band   
3.55 Three bands Not sequenced, discarded  
3.56 Double band   
3.57 Three bands Not sequenced, discarded  
3.58 Single band G508S mutation (compound 
heterozygous) 
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Clone PCR Sequencing Impact 
3.59 Single band G508S mutation + 2bp insertion 
(homozygous) 
 
3.60 Single band 11bp deletion Frameshift 
mutation  
3.61 Single band PAM site mutation (homozygous)  
3.62 PCR failed   
3.63 Single band Double sequence trace  
3.64 Three bands Not sequenced, discarded  
3.65 Double band   
3.66 Single band 3bp deletion Inframe deletion 
3.67 Double band   
3.68 Double band   
3.69 Single band  PAM site mutation (homozygous)  
3.70 Single band PAM site mutation (homozygous) + 
G508S mutation (heterozygous) 
 
3.71 Single band G508S mutation (compound 
heterozygous) 
 
3.72 Double band   
3.73 Single band Double sequence trace  
3.74 Single band CRISRP WT  
3.75 Three bands Not sequenced, discarded  
3.76 Single band PAM site mutation (heterozygous)  
3.77 Single band 3bp deletion Inframe deletion 
3.78  Single band 3bp deletion Inframe deletion 
3.79 PCR failed   
3.80 Double band   
3.81 Three bands Not sequenced, discarded  
3.82 PCR failed   
3.83 Single band 3bp deletion Inframe deletion 
3.84 Double band   
3.85 Double band   
3.86 Single band 4bp insertion Frameshift 
mutation  
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Clone PCR Sequencing Impact 
3.87 Three bands Not sequenced, discarded  
3.88 Double band   
3.89 Single band Sequencing failed  
3.90 Single band CRISPR WT  
3.91 Single band CRISPR WT  
3.92  Single band 1bp insertion Frameshift 
mutation 
3.93 Double band   
3.94 Double band   
3.95 Double band   
 
 
6.4. Assessing the effect of the G508S mutation on 
SORL1 expression and Aβ production 
Having knocked in the G508S mutation into LUHMES cells, I wanted to investigate its 
functional consequences in terms of SORL1 expression and of its impact on APP 
processing. In order to do this, I defrosted all clonal lines that were heterozygotes for 
the G508S mutation (clones 3.14, 3.31, 3.61 and 3.70), as well as the compound 
heterozygotes (3.44, 3.58 and 3.71) and the CRISPR WTs (3.33, 3.74, 3.90, 3.91). 
Unfortunately, in the process of defrosting, all knock-in lines but one, 3.70, died. The 
same happened with the CRISPR WTs, where only clone 3.90 survived, while all the 
compound heterozygotes survived. I differentiated clones 3.70, 3.90, 3.44, 3.58 and 
3.71 into neurons and performed all downstream experiments described below 14 
days post-differentiation. 
 
6.4.1. Assessing the effect of the G508S mutation on SORL1 
expression levels 
6.4.1.1. Assessing the effect of the introduced G508S mutation on splicing 
As mentioned in the introduction, the G508S mutation constitutes a G>A substitution 
at the last nucleotide of SORL1 exon 10. This nucleotide is part of a 5’ splice site 
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(CAG/GUAAGU sequence). Substitutions in this canonical sequence may alter 
splicing by affecting the interaction between pre-mRNA and proteins involved in intron 
removal185. 
In order to investigate whether the G508S mutation affects SORL1 splicing, I 
extracted RNA from WT LUHMES neurons (day 14), as well clones 3.90 (CRISPR 
WT) and 3.70 (G508S heterozygote), and reverse transcribed it to cDNA. Then, I 
performed an RT-PCR, using primers, located in SORL1 exons 9 and 12. These 
primers would be expected to give a product size of 395bp. However, if the G508S 
mutation led to the intron following exon 10 being retained, the amplified product 
would be predicted to be 607bp. As can be seen on Figure 6.9.A, the G508S mutation, 
does not affect SORL1 splicing, as PCR amplification produced a single band of the 
same size as that observed in WT LUHMES and brain cDNA at the predicted cDNA-
derived size of 395bp.  
6.4.1.2. Assessing SORL1 mRNA levels in the G508S heterozygous and 
compound heterozygous clones  
As mentioned above, coding variants in SORL1 implicated in AD have been shown to 
reduce SORL1 transcript levels. This has been attributed to either activation of NMD 
pathways or alteration of translation efficiency80,77,177. Therefore, despite the fact that 
the G508S mutation did not alter splicing, I decided to test whether it exerted an effect 
on SORL1 mRNA and/or protein levels.  
First, I assessed how the introduced G508S mutation affected SORL1 mRNA levels. 
I grew and differentiated clones 3.90 (CRISPR WT), 3.70 (G508S heterozygote 
mutant), 3.44, 3.58 and 3.71 (G508S compound heterozygote mutants), alongside 
LUHMES WT lines of a similar passage number. RNA was extracted from day 14 
neurons and reverse transcribed to cDNA. All clones were grown and differentiated 
three independent times. Some of the clones died before reaching day 14. Thus, for 
the G508S compound heterozygous clones 3.44 and 3.58 I was only able to collect 
RNA pellets from two, and for clone 3.71- from one independent growth. 
Subsequently, I performed qRT-PCR using two TaqMan probes, located near the 5’ 
(SORL1 exon 2-3) and the 3’ end (SORL1 exon 46-47) of the full- length SORL1 
transcript. The geometric mean of two reference genes (UBE4 and TBP) selected 
from a panel of eight, as the most stable in this sample set by the GeNorm software, 
was used to normalise SORL1 expression levels. All assessed clones, including the 
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CRISPR WT, showed significant reduction in SORL1 mRNA levels compared to 
simultaneously grown LUHMES WT lines using the TaqMan probe detecting all 
SORL1 transcripts (amplification of SORL1 exon 46-47) (Figure 6.9.B, right). 
Meanwhile, clones 3.90 (CRISPR WT) and 3.70 (G508S heterozygote mutant) were 
the only ones showing a statistically significant decrease in SORL1 expression when 
assessed with the probe detecting only the full-length SORL1 transcripts (SORL1 
exon 2-3) (Figure 6.9.B, left).  
I hypothesised that the approximately 50% reduction in SORL1 expression observed 
in the CRISPR WT clone 3.90 could be due to haploinsufficiency caused by a large 
deletion within the targeted locus. A recent paper reported the presence of large 
deletions and genomic re-arrangements around CRISPR/Cas9-targeted sites that 
had not been predicted as off-targets by any of the available CRISPR/Cas9 online 
tools 186. If occurring in one allele, such extensive genomic damage could lead to 
allele-specific loss of expression. Therefore, in order to investigate whether both 
SORL1 alleles were present in the CRISPR WT clone 3.90, I designed a PCR-based 
screening assay. Using the UCSC genome browser (https://genome.ucsc.edu/), I 
identified four SNPs within different SORL1 exons where the minor allele frequency 
was nearly 50%. In order to determine whether the LUHMES cell line was 
heterozygous for any of these four SNPs, I designed primers flanking them and ran 
RT-PCR using LUHMES WT cDNA as a template. Sequence analysis revealed that 
LUHMES were heterozygote for one of the four SNPs, which is located in SORL1 
exon 6. Subsequently, I used this primer pair to screen cDNA derived from the 
CRISPR WT (clone 3.90). Unlike the LUHMES WT line, clone 3.90 was homozygous 
for this SNP, indicating that this clone had lost one SORL1 allele as a result of the 
CRISPR process. Thus, it was concluded that clone 3.90 did not constitute a CRISPR 
WT (Figure 6.9.C).  
6.4.1.3. No difference in the SORLA protein levels was observed in the 
G508S heterozygote and compound heterozygote mutant lines 
Since incorporation of the G508S mutation led to decreased SORL1 mRNA levels in 
both heterozygote and compound heterozygote clones, I wanted to further investigate 
whether such reduction would also be observed at the protein level. I grew and 
differentiated the G508S clones (i.e. 3.90, 3.70, 3.44, 3.58 and 3.71), together with 
LUHMES WT controls of a similar passage number three independent times. Some 
of the clones (3.70, 3.44 and 3.71) died during one of the three growths. Following 14 
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days of differentiation, I collected protein lysates from these lines and performed 
western blot analysis. No significant difference in the SORLA protein levels was 
observed between either the G508S heterozygote clone, 3.70, or any of the three 
compound heterozygote clones (3.44, 3.58 and 3.71) when compared to WT 
LUHMES neurons. Additionally, clone 3.90, also showed SORLA levels similar to the 
WT controls (Figure 6.9.D).  
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Figure 6.9. Assessing SORL1 expression in the G508S heterozygous and compound 
heterozygous clones. [A] RT-PCR assessing the effect of the G508S mutation on splicing. 
1.7% agarose loaded with 1 Plus kb ladder (indicated as ‘M’) and stained with SYBER Safe. 
Lanes loaded with amplified cDNA products derived from human brain, LUHMES WT cells, 
CRISPR WT (3.90) and G508S heterozygous mutant (3.70) clones. Expected product size- 
397bp. [B] qRT-PCR assessing the SORL1 mRNA levels in the isolated clones. The x-axis 
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shows the clones, while the y-axis- SORL1 mRNA levels normalised to the geometric mean 
of UBE4 and TBP. WT LUHMES lines are shown in blue, clone 3.90 in bright blue, clone 3.70 
(G508S heterozygous mutant) in pink and clones 3.44, 3.58 and 3.71 (compound 
heterozygotes) in red. Graphs represent average of three growths with each dot indicating an 
independent growth [C] Sequencing traces showing the rs12364988 SNP located in SORL1 
exon 6 (marked with a red rectangular shape. ‘N’ at this position stands for any nucleotide and 
indicates that LUHMES are heterozygous for this SNPs. Meanwhile, clone 3.90 was identified 
as a homozygous for this SNP. [D] Western blot analysis, assessing SORLA protein levels in 
clone 3.90, the identified G508S heterozygote (3.70) and the three compound heterozygous 
mutants (3.44, 3.58 and 3.71), as well as in two LUHMES WT lines grown simultaneously. A 
representative western blot image is shown on the left, where a protein sample from IPSC-
derived neurons was included as a positive control (labelled as ‘Ctrl’). Membrane was probed 
for GAPDH to verify equal loading. The expected protein sizes (SORLA- 330kDA and GAPDH- 
37kDA) are marked on the left of the image. Quantification of the relative SORLA protein 
levels, normalised to GAPDH, in lysates collected from three independent growths (each dot 
on the graph represents an independent growth) is shown on the right. Error bars represent 
mean ± SD of three experimental replicates grown independently. 
 
6.4.1.4. Identifying SORL1 knockdown clones amongst the clones generated 
during the third attempt of introducing G508S  
As summarised in table 6.5, a large proportion of the clonal lines, generated during 
the process of introducing the G508S mutation, appeared from the PCR analysis to 
carry an indel in at least in one of their alleles. In order to investigate whether some 
of these constituted SORL1 KOs for the full-length SORL1 protein coding transcript, 
Divya Pandya (an honours student working under my supervision) thawed four clones 
that were identified as homozygous frameshift mutants, as well as twelve lines that 
carried an indel in at least one allele as identified by PCR. Only ten clones survived 
thawing. These lines were expanded, RNA was isolated from proliferating cells and 
qRT-PCR was performed to assess SORL1 mRNA levels. The cut site was located in 
exon 10, which is present only in the full-length SORL1 transcript. Given this, both 
probes, amplifying the 3’ (SORL1 exon 2-3) and the 5’ end (SORL1 exon 46-47) of 
the full-length SORL1 transcript were used to assess SORL1 expression levels. 
SORL1 expression was detected in all clonal lines with both probes (Figure 6.10.A). 
Five clones showed elevated SORL1 mRNA levels (Figure 6.10.A). Meanwhile, 
clones 3.1, 3.16 and 3.40 displayed lower SORL1 expression when compared to a 
Chapter 6 Assessing the effect of introducing the rare EOAD-associated mutation 
G508S on SORLA expression and Aβ production 166 
WT line of a similar passage number and grown at the same time (Figure 6.10.A). 
This decrease was detected using both probes (Figure 6.10.A). Subsequently, clones 
3.1, 3.16 and 3.40 which had the lowest mRNA levels were differentiated, together 
with one of the clones that showed increased SORL1 mRNA levels- 3.26, and two 
LUHMES WT lines of a similar passage number. Western blot analysis of protein 
lysates collected from these clones 14 days after differentiation identified clones 3.1 
and 3.16 as potential SORL1 knockdowns (Figure 6.10.B).  
 
 
Figure 6.10. Identifying SORL1 knockdown clones. [A] qRT-PCR assessing the SORL1 mRNA 
levels in RNA from proliferating cell for the selected mutant clones. The x-axis shows the 
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clones, while the y-axis- SORL1 mRNA levels normalised to the geometric mean of PRDM5 
and ENOX3. LUHMES WT is shown in blue and mutant clones in red. [B] Western blot 
analysis, assessing SORLA protein levels in LUHMES neurons (day 14) of the clones that 
showed the lowest SORL1 mRNA levels- 3.1, 3.16 and 3.40, as well as clone 3.26 and two 
LUHMES WT lines grown simultaneously. Western blot image is shown on the left with the 
expected protein sizes (SORLA- 330kDA and GAPDH- 37kDA) are marked on the left of the 
image. GAPDH was used to verify equal loading. Quantification of the relative SORLA protein 
levels normalised to GAPDH in the assessed clones is shown on the right. WT is shown in 
blue and mutant clones in red. Graphs represent the results from a single experiment.  
 
6.4.2. Assessing the effect of the Gly508Ser on APP processing 
SORLA plays a role in APP processing37 and Aβ metabolism41. Moreover, many rare 
variants in SORL1, found in EOAD and LOAD patients, have been associated with 
altered APP processing and Aβ accumulation41,76,173. Therefore, I decided to examine 
the effect of the introduced G508S mutation on Aβ production. I grew and 
differentiated the G508S heterozygote (3.70) and compound heterozygote (3.44, 3.58 
and 3.71) clones, alongside the identified SORL1 knockdown lines (3.1 and 3.16) and 
three WT controls of a similar passage number. Unfortunately, the G508S 
heterozygote clone (3.70) died before reaching day 14. At day 14 of differentiation, I 
collected media from these lines and performed Aβ42 sandwich ELISA. However, all 
of the results obtained were below the assay detection limit of 15.6pg/ml (Table 6.6) 
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Table 6.6. A table summarising the concentration of extracellular Aβ42 (pg/ml) obtained for 
each of the tested WT and SORL1 mutant cell lines using ELISA. All samples measured were 
below the assay lowest detection limit of 15.6pg/ml. 





Clone 3.1 3.16 
Clone 3.16  3.35 
Clone 3.44 2.86 
Clone 3.58 2.74 




The aims of the work described in this chapter were to:  
a) knock out the SORL1 gene and introduce the rare EOAD-associated SORL1 
missense mutation- G508S, in LUHMES cells using the CRISPR/Cas9 
genome engineering system; 
b) assess the effect of the introduced G508S missense mutation on SORL1 
expression; 
c) investigate the effect of both knocking out SORL1 and introducing the G508S 
missense mutation on Aβ production. 
First, I decided to knockout SORL1 by targeting exon 31, common to all SORL1 
transcripts found in LUHMES. Both attempts of knocking out SORL1 using this gRNA 
seemed to prove unsuccessful. However, the first transfection generated two clones 
(1.2 and 1.3) with SORL1 mRNA levels much lower than a LUHMES WT line grown 
simultaneously that may be useful in future analysis. Moreover, the second round of 
transfections resulted in many clones (eight out of 26 identified) that carried frameshift 
mutations in the targeted area. Unfortunately, due to time limitations, I screened only 
two of these clones further. Therefore, it is possible that some of these clones 
constitute SORL1 knockouts or at least knockdowns. However, since frameshift 
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mutations introduced close to the carboxy terminal are less likely to activate NMD 
pathways and thus to knock out the gene (as discussed in 4.4.), and due to time 
restraints, this was not investigated further. 
Introducing the G508S EOAD-associated missense mutation in SORL1 into LUHMES 
cells using CRISPR/Cas9 genome editing also proved to be challenging, with the first 
two rounds of transfections not generating a single G508S mutant clone. The third 
round, however, had a success rate for incorporation of the G508S mutation of around 
3%, which is within the range of knock-in efficiency previously reported for LUHMES 
cells (2%-8%)135. In comparison, the rate of incorporating the PAM site silent mutation 
was much higher (11%), suggesting that shorter cut-to-mutation distance might have 
resulted in better repair efficiency (the distance between the PAM site mutation and 
the cut site was 6bp, while that between the G508S mutation and the cut site- 11bp). 
All clones that carried the PAM site mutation, except for one, were homozygous. This 
is in agreement with the results of Paquet et al. (2016)180, according to which 
decreasing the cut-to-mutation distance results in a higher proportion of homozygous 
mutants compared to the number of heterozygous and CRISPR WT clones180.  
The third attempt of introducing the G508S mutation generated four G508S 
heterozygous mutants, three compound heterozygotes (carrying the G508S mutation 
on one SORL1 allele and an indel on the other), and four CRISPR WT clones. 
However, only one G508S heterozygous mutant and one CRISPR WT clone were 
revived following a short-term storage at -80oC. The high death rates following 
thawing could be explained either by incorrect freezing conditions or by the fact that 
around the time most of the clones were frozen down the freezer broke down.  
As mentioned above, the G508S missense mutation constitutes a single nucleotide 
substitution at the end of SORL1 exon 10, thus affecting a 5’ splice region. Therefore, 
it was hypothesised that the missense mutation might affect SORL1 splicing and thus 
expression and function. RT-PCR with primers flanking SORL1 exon 10 did not show 
any changes in splicing. Meanwhile, qRT-PCR detected lower SORL1 mRNA levels 
in both the G508S heterozygous (3.70) and compound heterozygous (3.44, 3.58 and 
3.71) clones. Surprisingly, clone 3.90, initially identified as a CRISPR WT, showed 
approximately 50% reduction in SORL1 mRNA levels compared to the WT levels. A 
SNP-based RT-PCR assay showed that this clone is homozygous for a SNP in this 
area, unlike the control LUHMES WT cell line. Since the SNP used in this assay is 
located in SORL1 exon 6, some distance from exon 10, the loss of heterozygosity 
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suggested the presence of a large deletion on one SORL1 allele as a result of the 
CRISPR editing process. Such events have been recently reported by others186 and 
have raised the question of the specificity of the CRISPR/Cas9 system. Given these 
results, clone 3.90 was excluded from any further analysis. Meanwhile, the decrease 
in SORL1 expression detected in the G508S heterozygote and compound 
heterozygote clones did not appear to translate into reduced protein levels.  
The location of the G508S mutation is at a splice site, which led to the hypothesis that 
indels in this region could potentially alter splicing and knockout the full-length SORL1 
protein transcript by activating NMD pathways. Thus, all clones that carried indels 
(identified either by sequencing analysis or based on the PCR results) and survived 
the thawing process were further screened to determine SORLA protein levels. 
Western blot analysis detected lower levels of SORLA protein in two of the clones that 
showed reduced SORL1 mRNA levels by qRT-PCR. These clones (3.1 and 3.16) 
were identified as SORL1 knockdowns.  
Many rare mutations in SORL1 have been linked to altered levels of APP processing 
and Aβ production41,76,173. In addition, the G508S mutation is located within close 
proximity of the SORLA binding site for Aβ178. Therefore, I hypothesised that 
introducing this missense variant will alter the levels of extracellular Aβ. Unfortunately, 
I was unable to detect Aβ42 in the media collected from the G508S mutant clones, as 
well as from the WT and SORL1 knockdown lines grown in parallel. These results 
suggest that a more sensitive Aβ42 assay would need to be used in the future if this 
experiment was to be repeated. Alternatively, both Aβ40 and sAPPβ have been 
previously detected in LUHMES neurons (day 12)134. Thus, it would be interesting to 
see whether introducing the G508S mutation has an effect on their production.  
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Chapter 7 Discussion 
Summary of thesis  
SORCS2 and SORLA are members of the Vps10p-domain receptor family, also 
known as the sortilins, which comprises a family of five receptors2. These receptors 
are predominantly expressed in the CNS, where they facilitate the sorting and 
trafficking of a diverse range of neurotrophic factors and their precursor forms, as well 
as of various transmembrane receptors and synaptic proteins2. All members of the 
receptor family have been implicated in multiple physiological process related to 
neuronal survival, differentiation and synaptic plasticity. Amongst these, the role of 
the receptor family in the sorting and processing of APP, and thus in Aβ generation 
was pivotal for the work described in this thesis. As discussed in chapter 1, genetic 
variation within the receptor family has been associated with many brain conditions, 
and knockout mice for these genes have provided further evidence for their 
involvement in neurodegenerative and psychiatric disorders, including AD.  
Increased DNA damage and compromised DNA repair have also been implicated in 
the aetiology of both psychiatric129 and neurodegenerative conditions169, AD in 
particular. However, the majority of studies report evidence for oxidative DNA damage 
occurring as a result of increased production of free radicals and reduced activity of 
relevant DNA repair pathways129,169. More recently, a specific type of DNA damage- 
DNA DSB formation, has been linked to both AD and physiological brain activity, i.e. 
learning and memory processes. Suberbielle et al. (2013)107 demonstrated that in 
mice, naturally occurring behaviour, such as exploration of a novel environment, leads 
to the transient formation of DSBs in the dentate gyrus (an area of the brain important 
for learning and memory), which are repaired within 24 hours. Similarly, Madabhushi 
et al. (2015)118 detected elevated levels of DNA DSBs in hippocampal lysates from 
WT mice subjected to a fear conditioning paradigm, as well as in WT mouse 
hippocampal primary neurons stimulated with NMDA. Moreover, they showed that the 
generation of these breaks depends on TopoIIβ activity and results in an increase in 
early-response genes expression118.  
Meanwhile, elevated levels of neuronal DSBs and defective DSB repair have been 
found in the dentate gyrus of hAPP mice (an AD mouse model). Further in vivo and 
in vitro experiments identified aberrant network activity and dysregulated NMDAR 
signalling as underlying mechanisms107. Subsequently, increased levels of DSBs 
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have been also detected in the hippocampus and the frontal cortex of MCI and AD 
patients compared to age-matched cognitively unimpaired controls128. 
The aim of my project was to investigate the link between two members of the 
Vps10p-domain receptor family- SORCS2 and SORLA, and DNA DSB formation, as 
a possible mechanism in neuropsychiatric illness. This aim stemmed from a few 
research findings. First, as briefly described above and more extensively in the 
previous chapters, both the Vps10-domain family, including SORCS2 and SORLA, 
and DNA DSB formation have been associated with neuropsychiatric conditions, as 
well as with processes related to learning and memory. Second, SORCS2 (evidence 
from in vitro studies), and particularly SORLA (in vitro and in vivo) play a role in APP 
processing and Aβ generation, and accumulation of the latter exacerbates DNA DSB 
formation in vivo and in vitro. Third, SorCS2 has been implicated in the trafficking of 
the NR2A-containing NMDARs, shown to be required for DNA DSB repair in vitro.  
In this chapter I will discuss my results, their limitations, as well as possible future 
directions towards examining further the relationship between SORCS2 and SORLA, 
DNA DSB formation and neuropsychiatric disorders.  
 
Aim 1: Examining the levels of DNA DSB formation in 
WT, Sorcs2-/- and Sorl1-/- mice, at baseline and 
following exploration of a novel environment 
To begin with, I replicated previous findings that naturally occurring behaviour, such 
as exploration of a novel environment, triggers transient increase in DSB formation in 
the hippocampus of adult WT mice. To do this, I utilised mouse brain samples 
obtained from our collaborator Assoc. Prof Simon Glerup (Aarhus University, 
Denmark), whose group had performed the behavioural experiments described 
below. I detected a significant increase in the percentage of nuclei positive for γH2A.X 
in the dentate gyrus, as well as in the CA2 and CA3 region of the hippocampus of WT 
mice, exposed to a novel environment compared to WT mice that remained in their 
home cages. Moreover, when the mice were left to recover for 24 hours after the 
exploratory activity in their home cages, the percentage of γH2A.X-positive neurons 
in the examined brain areas dropped back to baseline levels. However, the novel 
finding in this study was the effect of knocking out Sorcs2 on this process. Sorcs2-/- 
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mice in the home cage group showed significantly higher levels of baseline DNA 
DSBs in the dentate gyrus, but not in CA2 or the CA3 region of the hippocampus, 
compared to corresponding WTs. Further analysis revealed a difference in the way 
the Sorcs2-/- mice responded to the novel environment when compared to the WT 
mice, with the Sorcs2-/- mice failing to acquire addition DSBs on exposure to 
exploratory task. No interaction was identified between genotype and the extent of 
recovery from the novel environment.  
It is unlikely that the higher level of DSBs in the Sorcs2-/- mice reflect the hyperactivity 
phenotype in an open field test previously described for these mice6, as their 
behaviour and activity levels in the home cage did not differ from those of 
corresponding WT mice (Dr Ditte Olsen, personal correspondence). Meanwhile, the 
inability of the Sorcs2-/- mice to acquire additional breaks during the exploratory 
activity could be perhaps linked to the hippocampal LTP and LTD deficits previously 
reported for these mice5. However, it is surprising that there was no significant 
difference in the extent of DNA damage in the CA region of the hippocampus between 
the genotypes in the home cage. Sorcs2 is highly expressed in the CA2 region24, and 
recently published findings have implicated the receptor in protecting this region from 
epilepsy-induced neuronal loss22. In mice, SorCS2 was found to be strongly 
upregulated in the CA2 region following induction of status epilepticus, and loss of 
SorCS2 was associated with increased oxidative stress and neuronal death22. 
Despite the fact that results in the WT mice that matched the Sorcs2-/- mice replicated 
the findings previously reported by Suberbielle et al. (2013)107, the second batch of 
WT mice that matched the Sorl1-/- mice did not show the same pattern of transient 
γH2A.X foci formation following exploration of a novel environment. Moreover, these 
mice displayed higher levels of DSBs when compared to the WT mice from the 
Sorcs2-/- batch. Perhaps the most likely explanation for this surprising data is changes 
in the animal facility prior to the experiment, which were subsequently noted by our 
collaborators Dr Ditte Olsen and Mathias Kaas Ollendorff (personal communication).  
There are some caveats to the experiment performed on the Sorcs2-/- mice and 
matched WT controls, including the small sample size (n=3) and some differences in 
the way the novel environment protocol was conducted compared to Suberbielle et 
al. (2013)107. In the study described here, WT and Sorcs2-/- mice were exposed to the 
novel environment individually as opposed to together with their cage-mates. Thus, it 
might be speculated that the increased DSB formation observed in the WT mice 
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belonging to the ‘novel environment’ group occured as a result of a stress response 
to being exposed to novelty on their own, rather than the novel environment itself. 
However, these seems unlikely to be the case as adrenalectomised mice showed 
similar increase in the number of DSB-positive neurons following exploration of a 
novel environment compared to sham-operated controls107. Moreover, glucocorticoids 
have been recently shown to upregulated SORCS2 expression in vitro23. Thus, if the 
breaks detected in the ‘novel environment’ group were the result of corticosterone or 
the release of other stress response factors, it is highly likely that knocking out Sorcs2 
would have had an impact on this process.  
Despite the caveats described above, the increased levels of DNA DSB formation and 
the inability of Sorcs2-/- mice to acquire new breaks upon exploratory activity constitute 
interesting findings that would need to be further validated in a bigger sample set. Due 
to time limitations, I was not able to do this during my PhD. However, I was able to 
investigate the effect of knocking out SORCS2 on DNA DSB formation in vitro, as well 
as to explore possible mechanisms underlying this phenotype.  
 
Aim 2: Assessing the effect of knocking out SORCS2 
on DNA DSB formation and potential underlying 
mechanisms in vitro 
The second aim of my project comprised of three parts:  
1) Knocking out SORCS2 in the human neuronal cell line LUHMES, using 
CRISPR/Cas9 genome editing; 
2) Assessing the effect of knocking out SORCS2 on DNA DSB formation;  
3) Investigating possible mechanisms underlying this effect.  
 
Part 1: Knocking out SORCS2 in LUHMES cells 
Given their quick differentiation into a homogenous population of post-mitotic 
neurons, with spontaneous electric activity recorded after 10-12 days of 
differentiation133, LUHMES constituted a valid system for studying the role of SORCS2 
in DSB formation. Using qRT-PCR, I was able to show that all members of the sortilin 
receptor family, except for SORCS3, are expressed in the LUHMES cell line in what 
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appears to be a developmentally regulated manner, with their expression peaking up 
around day 10 and remaining stable from there on. Using CRISPR/Cas9 genome 
editing, I was able to knockout SORCS2 by independently targeting exon 1 and exon 
3 of its canonical, full-length isoform.  
 
Part 2: Assessing the effect of knocking out SORCS2 on DNA DSB 
formation 
There was no significant difference in the number of DSBs (identified as the foci where 
γH2A.X and 53BP1 signal co-localised) between untreated WT (n=9) and SORCS2 
KO (n=9) neurons (day 14). Conversely, when treated with etoposide, neurons (day 
14) derived from the same SORCS2 KO clones (n=9) displayed a significantly higher 
levels of γH2A.X/53BP1-positive foci per nucleus compared to the WT controls (n=9). 
There was no difference in the number of DNA DSBs per nucleus between the 
SORCS2 KO clones generated by targeting exon 1 (n=4) or exon 3 (n=5), both with 
and without etoposide treatment. This suggested that the increased DSB formation, 
observed in the SORCS2 KO lines following treatment with etoposide, is a 
consequence of the mutation introduced rather than a result of CRISPR off-target 
activity.  
The lack of significant difference in the number of DSBs per nucleus between 
untreated WT and SORCS2 KO clones, as opposed to the elevated levels of DSB 
formation detected in the latter, following treatment with etoposide, may be explained 
with the low and highly variable levels of DNA damage observed in the untreated cells. 
In post-mitotic neurons, etoposide acts by preventing the re-ligation of DNA DSBs 
induced by TopoIIβ activity162. Therefore, treatment with etoposide would lead to the 
accumulation of TopoIIβ-dependent DSBs, providing a more reliable measure of all 
events that took place over the course of the treatment. Bearing this in mind, the fact 
that I was able to detect significant difference in the number of DSBs after treatment 
with etoposide, but not in the untreated cells, might suggest that knocking out 
SORCS2 in vitro exacerbates the rate of TopoIIβ-dependent DNA DSB formation, but 
has no effect on their repair. Moreover, this observation supports the findings in the 
Sorcs2-/- mice, which showed increased DSB levels, but no recovery deficits following 
the exploratory task.  
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Knocking out SORCS2 was also associated with reduced neuronal viability at day 14, 
but not at day 6 of differentiation. This result is in line with the recently reported 
neuroprotective role of SORCS222, as well as with my early findings that in LUHMES 
neurons SORCS2 expression peaks after day 10 of differentiation. However, bearing 
in mind the results from the untreated cells that showed no difference in the number 
of DSBs per nucleus between the two genotypes, it is unlikely that the reduced viability 
detected in the SORCS2 KO clones is the result of accumulated DNA damage.  
Both the increase in DSB formation following etoposide treatment (n=9), as well as 
the reduced viability observed in SORCS2 KO day 14 neurons (n=7) constitute 
preliminary results from single experiments, which, due to technical problems and 
time constraints, I was unable to repeat. Thus, further experiments are required for 
these findings to be confirmed.  
 
Part 3: Investigating possible mechanisms underlying the effect of 
knocking out SORCS2 on DNA DSB formation 
Stimulating WT LUHMES neurons (day 14) with NMDA led to a significant increase 
in the number of DSBs per nucleus, in line with previous work reporting increased 
γH2A.X foci formation upon NMDA application in mouse primary neurons115,118. I did 
not, however, observe any difference in the extent of γH2A.X/53BP1-positive foci 
formation in NMDA-treated SORCS2 KO clones compared to WT controls. This 
experiment also suffers from the caveats of small sample size (n=3). Unfortunately, 
due to time limitations and technical issues with cell culture plasticware, I was not able 
to repeat it on a larger number of clones.  
Given that NMDA-induced DSBs occur within the same regions of the genome as the 
ones triggered by etoposide118, if the lack of difference between NMDA-treated 
SORCS2 KO and WT clones was confirmed in subsequent experiments, this would 
suggest that the observed increase in etoposide-induced DSBs is unlikely to be due 
to dysregulated NMDAR signalling. Such a result would be surprising given the role 
of SorCS2 in the trafficking of the NMDAR subunit NR2A51, shown to be required for 
DSB repair107. A possible explanation for such a discrepancy would be that the role of 
SorCS2 in the trafficking of the NR2A subunit was demonstrated in medium spiny 
neurons (MSNs) of the mouse striatum51. MSNs constitute a specific type of 
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GABAergic inhibitory neurons, while LUHMES are a homogenous population of 
human dopaminergic neurons.  
Unfortunately, I was unable to measure Aβ42 reliably in LUHMES as the levels 
detected were below the assay lower limit. Increased Aβ levels have been linked to 
increased DSB formation both in vivo and in vitro107, and knockdown of SORCS2 in 
HEK293 cells has been associated with increased APP amyloidogenic processing46. 
Therefore, elevated Aβ levels could constitute a possible explanation of the increased 
number of etoposide-induced DNA breaks observed in the knockout lines. Thus, 
future analysis could include using a more sensitive ELISA assay and/or measuring 
Aβ40 and sAPPβ levels, as both metabolites of amyloidogenic APP processing have 
been previously detected in LUHMES neurons134.  
Surprisingly, there was no difference in the number of etoposide-induced DNA DSBs 
in Sorcs2-/- mouse primary hippocampal neurons (DIV12) compared to control WT 
cultures. In fact, looking at the absolute number of DNA breaks per nucleus, I 
observed a decrease in the number of DSBs both in untreated and etoposide-treated 
Sorcs2-/- neurons. Due to problems with mice breeding, neuronal culture and the short 
nature of my visit to Aarhus University, Denmark, I was able to perform this 
experiment only on three independent mouse cultures. It is thus possible that the 
small sample size led to insufficient power to detect a difference. Therefore, further 
experiments would be required to assess if the observed decrease represents a true 
result.  
If the findings of decreased DSBs in the Sorcs2-/- mouse primary neurons were 
confirmed with subsequent experiments, there are a few possible explanations for the 
discrepancy with the findings of increased DSB formation detected in the dentate 
gyrus of SorCS2-deficient mice. One explanation could be that the primary cultures 
are less mature than the hippocampal neurons of an adult mouse and the observed 
discrepancy is a reflection of differences in experience of the adult animal versus 
neurons taken from a P0 pup. Alternatively, this discrepancy might suggest that the 
elevated levels of DSBs in the Sorcs2-/- mice are the result of altered input to the 
hippocampus, rather than being specific to hippocampal neurons. This possibility is 
supported by the increased number of DNA breaks detected in the etoposide-treated 
SORCS2 KO LUHMES neurons. Therefore, it would be interesting to examine how 
SorCS2 deficiency affects the extent of DSB formation in brain areas receiving 
dopaminergic input. One such area could be the frontal cortex, which receives 
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dopaminergic input from the VTA and has been shown to be hyperinnervated in 
Sorcs2-/- mice6. Having said that, I did not detect a significant difference in the 
extracellular levels of dopamine, secreted by the SORCS2 KO LUHMES cells. Thus, 
despite the high levels of variation observed in the KO clones, it is perhaps unlikely 
that altered dopamine levels underlie the increase in DSB formation. However, future 
experiments assessing aspects of dopamine metabolism and turnover might 
constitute an area of interest.   
 
Aim 3: Introducing the EOAD-associated rare SORL1 
missense mutation G508S and examining its 
effect on SORL1 expression and Aβ production 
In addition to examining the effect of knocking out SORCS2 on DSB formation, in the 
beginning of my PhD I was also planning to investigate this phenotype in SorLA-
deficient mice and SORL1 KO LUHMES neurons. Unfortunately, as discussed above 
and more extensively in chapter 3, I was unable to assess DSB formation in Sorl1-/- 
mice before and after exploratory activity, as well as following recovery from it. 
Subsequently, during my visit to Aarhus University, Denmark, I also aimed at 
investigating the levels of DNA DSB formation in primary hippocampal neurons 
derived from Sorl1-/- pups (P0). However, due to problems with breeding the Sorl1-/- 
mice, I was unable to perform these experiments. 
Knocking out SORL1 in LUHMES cells using CRISPR/Cas9 genome editing also 
proved to be difficult to achieve. SORL1 encodes for a large number of transcripts, 
the majority of which start after exon 25 of the full-length SORL1 transcript. Previous 
work in the lab performed by Susan Anderson has shown that in addition to the 
canonical full-length isoform, LUHMES express several shorter isoforms whose 5’ 
ends lie within the second half of the 48 exons. Based on this, I decided to knockout 
the gene by targeting the first exon common for all SORL1 transcripts- exon 31. No 
SORL1 KO clones were identified following two attempts of knocking out the gene 
using a gRNA targeting this region. With hindsight, these results were not surprising 
given that exon 31 is located far away from the beginning of the full-length transcript. 
Thus, frameshift mutations introduced at this region were more likely to generate 
truncated versions of the long SORL1 isoform, rather than activate NMD pathways. A 
more efficient approach of knocking out SORL1 would have been generating a whole 
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gene deletion by introducing two gRNAs, targeting either ends of the gene. This would 
result in the formation of two DSBs at the targeted locus, which would be repaired via 
NHEJ pathway, deleting the intervening DNA segment. 
In parallel to my attempts to knock out the SORL1 gene, I aimed to introduce one of 
the many rare EOAD-associated SORL1 variants- G508S, in LUHMES cells using 
CRISPR/Cas9 genome editing. This specific variant was chosen for many reasons 
(discussed in chapter 6), amongst which was its location. G508S constitutes a 
missense mutation occurring at the last nucleotide of exon 10 and thus affecting a 5’ 
splice region. Therefore, it was highly likely that it might affect SORL1 splicing. 
Additionally, any indels in this region could have potentially altered splicing and 
knocked out the full-length SORL1 transcript.  
I was unable to identify any SORL1 KO clones amongst the clones that were 
homozygous for a frameshift mutation within the targeted region. However, two of 
these clones showed reduced SORLA protein levels and were identified as 
knockdowns. I also generated four G508S heterozygous mutants and three 
compound heterozygotes, carrying the G508S mutation on one allele and an indel on 
the other. However, only one G508S heterozygous mutant was revived successfully.  
RT-PCR performed on cDNA derived from the G508S heterozygous clone showed no 
changes in SORL1 splicing. However, I detected lower SORL1 mRNA levels in both 
the G508S heterozygous and the three compound heterozygous clones, which did 
not translate into an alteration at the protein level.  
As mentioned above, these experiments were performed on only one clone. Thus, if 
I was to continue this project, first I would create more mutant lines to ensure that any 
phenotypes identified are the result of the mutation itself. Provided more lines carrying 
the G508S mutation were generated, I would continue by repeating the experiments 
described above, but given that I had shown that the mutation does not impact 
splicing, I would assess whether it affects APP processing and Aβ production. This 
could be achieved by either measuring the amounts of sAPPα, sAPPβ and Aβ 
produced by the mutant clones using ELISA, or, alternatively, by measuring levels of 
secretase activity as described by Reitz et al. (2013)46. Unfortunately, I was unable to 
measure reliably the levels of extracellular Aβ42 produced by both WT and SORL1 
mutant clones. This suggests that a more sensitive system than the one used in this 
study would be required if this experiment is to be repeated in the future. Moreover, 
since the G508S variant is in a close proximity to the SORLA binding site for Aβ, 
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assessing how the mutation affects the receptor’s ability to direct Aβ molecules for 
lysosomal degradation might also be of interest. Finally, if the G508S mutation was 
found to promote Aβ accumulation, investigating its effect on DSB formation might 
also be of interest.  
Regardless of all caveats of this part of my project, I was successful in introducing the 
rare EOAD-associated SORL1 missense mutation- G508S. I also showed, based on 
the one cloned examined, that there is no evidence that the G508S mutation affects 
SORL1 splicing. Although I was unable to further analyse the effect of this mutation 
on SORLA function, the optimisation of the CRISPR process for knocking in mutations 
at this position can be used to create more independently-derived G508S mutant lines 
or adapted to introduce other EOAD-associated variants in the future. 
 
Other Future Directions 
As discussed in chapter 1, SORCS2 has been recently shown to play a role in the 
neuronal defence against oxidative stress22. It does so by facilitating the trafficking of 
EAAT3 to the cell surface and thus the import of cysteine, required for the synthesis 
of the ROS scavenger glutathione. Loss of SorCS2 in mice has been associated with 
elevated levels of the oxidative stress DNA marker 8-OHdG and cell death in the 
dentate gyrus and the CA2/3 region of the hippocampus following PTZ kindling22. 
Despite the disagreement in the literature regarding the link between oxidative stress 
and γH2A.X foci formation, it would be interesting to investigate whether the Sorcs2-
/- mice in our study, as well as the SORCS2 KO LUHMES clones, exhibit higher 8-
OHdG levels. If so, future work may also involve co-staining for γH2A.X and 8-OHdG 
and establishing the levels of overlap between the two markers of DNA damage in 
WT and SorCS2-deficient mice and/or cells. Examining the response of SORCS2 KO 
LUHMES neurons to oxidative stress could also constitute an area of interest. 
Stressing the cells with hydrogen peroxide and then measuring 8-OHdG levels and/or 
expression of genes involved in oxidative stress defence pathways might be one way 
of approaching this. It would also be interesting to test whether inducing oxidative 
stress would exacerbate the difference in neuronal viability I detected in day 14 
SORCS2 KO LUHMES neurons. In addition, given the recently identified role of 
SORCS2 in the cellular response to alcohol23, following experiments looking at the 
consequences of treating SORCS2 KO neurons with alcohol might prove to be 
illuminating, as well. 
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Madabushi et al. (2015)118 showed that TopoIIβ-dependent DSBs promote the 
expression of early response genes, including Fos, FosB, Npas and Egr1. If knocking 
out SORCS2 exacerbates DNA DSB formation in vivo and in vitro, this poses the 
question how such an increase in DSBs affects the expression levels of these genes 
and what the downstream consequences are, in terms of neuronal function and 
survival. In rat ganglion neurons, accumulation of unrepaired DSBs has been 
associated with transcriptional silencing, potentially as a mechanism of preventing 
aberrant mRNA synthesis and protein production187. Thus, it would be interesting to 
investigate whether the increased DSB formation in the SORCS2 KO clones leads to 
a reduced expression of early-response genes.  
In conclusion, both increased DNA damage and members of the sortilin gene family 
have been implicated in the aetiology of many brain disorders. The work completed 
in this project constitutes the first evidence for a potential role of the sortilins in the 
generation of correct, physiological DSBs and protection against aberrant DSB 
formation. Future work investigating this link further might provide us with valuable 
knowledge on the cellular mechanisms underlying neurodegenerative and psychiatric 
conditions. 
Appendices  182 
 Appendices 
 
Appendix A- Summary of the actual count number per 
group/ experiment and the results of the 
statistical analyses described in Chapter 3 
 
Table A1 Counts obtained per mouse per experimental group from the preliminary experiment 
described in 3.4.1. Mean percentage of γH2A.X-positive neurons in the dentate gyrus and the 
CA3 region of the hippocampus of WT and Sorcs2-/- mice belonging to one of the three 
experimental groups- home cage, Novel E and recovery. 
Condition Dentate gyrus CA3 region 
WT Sorcs2-/- WT Sorcs2-/- 
Home cage  24.439 32.374 33.444 36.807 
22.870 26.864 30.358 35.966 
22.646 29.107 31.524 35.087 
Novel E 37.276 35.535 36.763 42.089 
33.242 28.459 38.215 36.374 
38.680 39.636 46.870 39.252 
Recovery 25.395 27.890 27.927 40.070 
25.156 26.504 33.674 44.237 
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Table A2 Assessing the effect of the environment on the formation of DSBs in the beginning 
of the hippocampus of WT and Sorcs2-/- mice. Summary of the results obtained from post-hoc 
tests as part of the parametric One-way ANOVA analysis performed in 3.4.1. ‘E’ stands for 
environment, ‘HC’- home cage, ‘NE’- novel environment and ‘R’- recovery.   
 
 
Table A3 Counts obtained per experimental group per mouse from the preliminary experiment 
described in 3.4.2. Mean percentage of γH2A.X-positive neurons in the dentate gyrus and the 
CA3 region of the hippocampus of WT and Sorl1-/- mice belonging to one of the three 
experimental groups- home cage, Novel E and recovery. 
Condition Dentate gyrus CA3 region 
WT Sorl1-/- WT Sorl1/- 
Home cage  29.073 48.225 67.192 63.553 
47.4908 32.427 65.989 71.743 
51.928 15.058 59.661 53.879 
Novel E 51.260 27.098 48.109 11.030 
35.891 32.332 41.942 65.862 
19.551 11.513 65.352 61.598 
4.231  70.866 64.409 
Recovery 55.201 29.702 56.192 52.608 
22.174 62.687 69.061 49.016 
45.022 32.625 52.257 68.358 








E1 E2 E1 E2 
Wild type mice 
Dentate 
gyrus 
HC NE 23.32 36.4 -13.08 10.54 0.0007
 
HC R 23.32 26.56 -3.237 2.609 0.2344 
NE R 36.4 26.56 9.843 7.932 0.0033
 
CA3 HC NE 31.78 40.62 -8.84 4.035 0.0653 
HC R 31.78 31.74 0.03232 0.01475 >0.9999 




HC NE 29.45 34.54 -5.095 2.406 0.2796 
HC R 29.45 26.92 2.523 1.192 0.6925 
NE R 34.54 26.92 7.618 3.598 0.0965 
CA3 HC NE 35.95 39.24 -3.285 1.588 0.5358 
HC R 35.95 39.25 -3.299 1.595 0.5333 
NE R 39.24 39.25 -0.01404 0.00679 >0.9999 
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Table A4 Assessing the effect of the environment on the formation of DSBs in the beginning 
of the hippocampus of WT and Sorl1-/- mice. Summary of the results obtained from post-hoc 
tests as part of the parametric One-way ANOVA analysis performed in 3.4.2. ‘E’ stands for 
environment, ‘HC’- home cage, ‘NE’- novel environment and ‘R’- recovery.   
 
Table A5 Counts obtained per experimental group per mouse from the experiment described 
in 3.5. Mean percentage of γH2A.X-positive neurons in the dentate gyrus, the CA2 and CA3 
region of the hippocampus of WT and Sorcs2-/- mice belonging to one of the three experimental 
groups- home cage, Novel E and recovery. 
Condition Dentate gyrus CA2 region CA3 region 
WT Sorcs2-/- WT Sorcs2-/- WT Sorcs2-/- 
Home 
cage  
31.428 46.045 25.897 57.113 28.139 57.732 
31.503 42.373 38.609 34.846 40.152 45.332 
39.848 50.542 38.472 42.416 53.748 53.585 
Novel E 59.427 57.852 57.033 54.084 54.013 53.965 
59.682 45.817 53.763 49.346 56.323 51.092 
55.031 52.367 62.204 55.350 63.779 50.958 
Recovery 43.440 45.977 23.859 35.745 29.263 39.485 
42.683 45.603 49.860 47.797 49.092 56.438 












E1 E2 E1 E2 
Wild type mice 
Dentate 
gyrus 
HC NE 42.83 27.73 15.1 1.612 0.5221
 
HC R 42.83 40.8 2.032 0.2029 0.9887 
NE R 27.73 40.8 -13.07 1.395 0.6077
 
CA3 HC NE 64.28 56.57 7.713 1.376 0.6155 
HC R 64.28 59.17 5.11 0.8527 0.8231 




HC NE 31.9 23.65 8.255 0.9526 0.7856 
HC R 31.9 44.9 -13 1.604 0.5253 
NE R 23.65 44.9 -21.26 2.622 0.2215 
CA3 HC NE 63.06 50.72 12.33 1.282 0.6515 
HC R 63.06 58.83 4.227 0.4394 0.9485 
NE R 50.72 58.83 -8.107 0.9102 0.8010 
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Table A6 Assessing the effect of the environment on the formation of DSBs in the 
hippocampus of WT and Sorcs2-/- mice. Summary of the results obtained from the non-
parametric ANOVA-type analysis performed in 3.4.3. ‘E’ stands for environment, ‘HC’- home 











Environment Rank means Rank Mean 
Difference 
t-value p-value 
E1 E2 E1 E2 
Wild type mice 
Dentate 
gyrus 
HC NE 5.44 13.56 -8.12 34.38 4.53x10-9 
HC R 7.78 11.22 -3.44 3.65 0.056 
NE R 12.33 6.67 5.66 22.82 1.78x10-6 
CA2 HC NE 3.50 9.50 -6 18.78 1.46x10-5 
HC R 6.17 6.83 -0.66 0.08 0.774 
NE R 9.00 4.00 5 6.52 0.011 
CA3 HC NE 4.17 8.83 -4.66 4.45 0.035 
HC R 7.00 6.00 1 0.12 0.734 




HC NE 8.11 10.89 -2.78 1.52 0.218 
HC R 9.56 9.44 0.12 0.04 0.835 
NE R 11.56 7.44 4.12 2.91 0.088 
CA2 HC NE 5.83 7.17 -1.34 0.32 0.574 
HC R 7.17 5.83 1.34 0.44 0.508 
NE R 7.83 5.17 2.66 3.20 0.074 
CA3 HC NE 6.67 6.33 0.34 0.02 0.889 
HC R 7.67 5.33 2.34 1.08 0.299 
NE R 8.17 4.83 3.34 2.86 0.091 
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Table A7 Assessing the effect of the genotype-environment interaction on the formation of 
DSBs. Summary of the results obtained from the non-parametric ANOVA-type analysis 
performed in 3.4.3. fitting in the genotype by interaction. ‘E’ stands for environment, ‘HC’- 
home cage, ‘NE’- novel environment and ‘R’- recovery. 
 
 
Table A8 Assessing the effect of the environment on the formation of DSBs. Summary of the 
results obtained from the non-parametric ANOVA-type analysis performed in 3.4.3. fitting in 
the genotype by interaction. ‘E’ stands for environment, ‘HC’- home cage, ‘NE’- novel 












 E1 E2 WTxE1 WTxE2 KOxE1 KOxE2 
Dentate 
gyrus 
HC NE 8.22 26.44 16.89 22.44 10.50 0.001 
NE R 25.67 12.56 21.22 14.56 1.66 0.198 
CA2  
HC NE 19.00 11.67 14.17 12.33 5.35 0.021 
NE R 7.50 14.00 9.50 14.50 1.99 0.158 
CA3  
HC NE 17.83 13.00 12.50 14.17 3.87 0.049 
NE R 6.67 14.50 10.00 15.17 2.19 0.139 
Brain 
region 
Environment Rank means t-value p-value 
E1 E2 E1 E2 
Dentate 
gyrus 
HC NE 12.56 24.44 37.00 1.18x10-9 
HC R 16.50 20.50 5.97 0.015 
NE R 23.44 13.56 15.63 7.71x10-5 
CA2 HC NE 8.42 16.58 11.12 0.001 
HC R 12.50 12.50 0.00 1.000 
NE R 16.50 8.50 10.41 0.001 
CA3 HC NE 9.83 15.17 3.24 0.072 
HC R 13.75 11.25 0.54 0.462 
NE R 16.67 8.33 10.33 0.001 
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Table A9 Assessing the effect of the genotype on the formation of DSBs. Summary of the 
results obtained from the non-parametric ANOVA-type analysis performed in 3.4.3. fitting in 
the genotype by interaction. ‘E’ stands for environment, ‘HC’- home cage, ‘NE’- novel 

















Environment Rank means t-value p-value 
E1 E2 Wild type Sorcs2-/- 
Dentate 
gyrus 
HC NE 17.33 19.67 1.43 0.233 
HC R 15.39 21.61 14.45 1.44x10-4 
NE R 19.11 17.89 0.24 0.625 
CA2 HC NE 12.08 12.92 0.12 0.734 
HC R 10.50 14.50 1.68 0.195 
NE R 13.25 11.75 0.37 0.545 
CA3 HC NE 12.25 12.75 0.03 0.866 
HC R 9.42 15.58 3.29 0.070 
NE R 12.75 12.25 0.04 0.847 
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Figure B1 Comparison of the percentage of γH2A.X-positive nuclei detected in the dentate 
gyrus [A] and the CA3 region of the hippocampus [B] of Sorcs2-/- and Sorl1-/- mice. Error bars 
represent means ± SD; unpaired t-test; ‘**’ indicates p<0.01. 
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Figure B2 Comparison of the rate of DSB formation (left) and repair (right) in the CA2 [A] and CA3 [B] regions in WT and Sorcs2-/- mice. n=3, non‐
parametric ANOVA‐type statistic.
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